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CHAPTER I 
 
BACKGROUND AND OBJECTIVES 
 
Background 
 
Drug Discovery and Development 
The driving force behind drug discovery and development is to connect the 
process of understanding a disease with bringing a safe and effective new treatment to 
patients. Scientists work to piece together the basic causes and biological intricacies of 
disease at the level of genes, proteins and cells. Out of this knowledge “targets” emerge 
which potential new drugs might be able to affect.  Researchers work to validate these 
targets, discover a potential drug to interact with the chosen target, submit the compound 
through a series of clinical tests for safety and efficacy and gain approval so that the new 
drug can get into the hands of doctors and patients. The discovery and development of 
new medicines is a long, complicated process and takes an average of 10-15 years.
1, 2
 The 
average cost to research and develop each successful drug is estimated to be $800 million 
to $1 billion.
3
 This accounts for the thousands of failures that a company must go through 
before successfully producing a viable drug compound.  For every 5,000- 10,000 
compounds that enter the research and development (R&D) pipeline, ultimately only one 
receives approval.  These numbers seem astronomical, but by developing a better 
understanding of the R&D process which is outlined in Figure 1, one can see why so 
many compounds don‟t make it through the process and why it takes immense resources, 
2 
 
the best scientific minds, highly sophisticated technology, interdisciplinary collaboration 
and complex project management to get one successful drug to patients. 
Before any potential new medicine can be investigated, scientists must be able to 
understand the disease being treated.  It is necessary to elucidate the underlying cause of 
the condition as well as how the genes are altered, how that affects the proteins they 
encode and how those proteins interact with each other in living cells.  These changes 
directly relate to how the disease affects the patient. This knowledge is the basis for 
treating the problem and guides research for the discovery of new therapeutic 
compounds. Researchers from government, academia and industry all contribute to this 
knowledge base.
4
  However, even with new tools and insights, this research takes many 
years of work and, too often, leads to frustrating dead ends.  Thus, there is an ever present 
need for new technologies and methods to assist in understanding the underlying cause of 
a disease.  Even if the research is successful, it will take many more years of work to turn 
this basic understanding of what causes a disease into a new treatment.   
Once there is enough understanding of a disease, pharmaceutical researchers 
select a “target” for a potential new medicine. This “target” is usually a gene or protein 
involved with the disease that can interact with a drug compound.  It is then, that large 
screening processes begin to look for a lead compound. Once a potential compound is 
identified initial Absorption, Distribution, Metabolism, Excretion and Toxicological 
(ADME/TOX) studies are performed.  The pharmacokinetic and pharmacodynamic 
(PK/PD) tests are performed both in-vitro and in-vivo in what are known as the pre-
clinical trials.  The results for these analyses help scientists to understand what the drug 
does, how it works, as well as any side effects or safety issues.
5
 
3 
 
 
 
Figure 1:  Overview of the drug discovery and development process.  It can take upwards 
of 15 years and over 800 million dollars to develop just one FDA approved drug out of 
about 10,000 candidates.  At all stages of the pre-clinical and clinical trials, advanced 
technologies, interdisciplinary interactions and cutting edge science are utilized.  
 
 
After years of work, one to five molecules out of 5,000-10,000 will survive the 
pre-clinical trial and will be considered for clinical trials.  Before a clinical trial can 
begin, an Investigational New Drug (IND) application is filed with the Food and Drug 
Administration (FDA).  This report describes all the results of the pre-clinical trials, the 
drug‟s structure, mechanisms of action in the body and any known side effects.  In 
addition to the IND application, the clinical trials must be approved by the Institutional 
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Review Board (IRB) and throughout the trials regular reports are monitored and 
submitted to both the FDA and IRB. 
6
 
The clinical trials consist of three phases.  Phase I is a small initial test performed 
in 20-100 healthy volunteers to see if the compound is safe for use in humans.  The 
ADME of the drug is studied as well as any side effects that result.  Phase II trials focus 
on testing the effectiveness of the compound on the indicated disease.  The trial includes 
100-500 patients and evaluates if the drug is targeting the disease as well as establishes 
both dosing strength and dosing schedule.  Phase III trials test a large group of patients to 
show efficacy and safety.  At hundreds of sites across the United States and worldwide, 
1,000-5,000 patients are administered the drug and monitored. 
3, 7
 
After clinical trials, a New Drug Application (NDA), which can be over 100,000 
pages long, is filed with the FDA.  The document contains all of the PK/PD results from 
the trials.  After approval the drug goes into manufacturing and distribution and ongoing 
studies are maintained to continue monitoring the drug‟s performance.8 
Throughout this long and complex process, one can identify numerous areas 
where cutting edge technologies, new methods and interdisciplinary collaborations can 
help to advance the understanding of human biology and disease.  This can lead to 
numerous breakthroughs for developing new medications.  Researchers face great 
challenges in understanding and applying these advances to the treatment of disease, but 
these possibilities continue to grow as our scientific knowledge expands and becomes 
increasingly more complete. 
Mass Spectrometry (MS) has played a large role in these processes of developing 
new drugs in all aspects of the drug development process.  MS has been used to 
5 
 
characterize small molecule compounds, evaluate biomolecules for targets, protein 
identification, analytical detection and quantitation.  It has been used in all stages of pre-
clinical and clinical trials and there is room for growth of the technology‟s use in new and 
innovative ways. 
 
Current Methods for Drug Quantitation  
 Before modern day MS, small molecule quantitation was achieved using high 
pressure liquid chromatography (HPLC) and ultraviolet (UV) detection.  UV detectors 
measure the ability of chromaphores in compounds within a sample to absorb UV light.  
This can be accomplished at one or multiple wavelengths within the range or 190-400 
nm.  Most organic compounds can be measured by UV detectors.
9
  However, this 
methodology suffered from lack of specificity and sensitivity.  There are instances when 
a drug metabolizes but the metabolites retention time and detection are the same as the 
parent compound.  Mass spectrometry has filled this need for both specificity and 
sensitivity in the quantitation of small molecules along with the ability to distinguish 
parent drug compound from its metabolites.  Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) is now the de facto technique for providing quantitation data 
for drug evaluation and submission for drug approval.
10
 
 The accepted way of performing MS quantitation is by using a mass spectrometer 
capable of MS/MS fragmentation.  MS/MS used in conjunction with quantitation is 
commonly accomplished with a triple quadrupole or ion trap mass spectrometer.  The 
reason MS/MS is required is because many compounds have the same intact mass.  
While many researchers use the first dimension of MS to perform quantitation, that 
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technique again suffers from lack of specificity especially in very complex matrices.  The 
second dimension of MS fragmentation in the majority of cases provides a unique 
fragment.  The combination of the specific parent mass and the unique fragment ion is 
used to selectively monitor for the compound to be quantified. 
11-14
  However, while this 
technique offers specificity and sensitivity the protocols required for the analysis cause 
the loss of spatial information. 
 
MALDI Imaging Mass Spectrometry 
New advances in MS now provide the opportunity for investigative studies of 
molecular interactions in intact tissue, much like studies conducted decades ago with 
intact tissue for metabolic studies, but now with exquisite molecular specificity.  In 
particular, matrix-assisted laser desorption/ionization (MALDI) imaging mass 
spectrometry (IMS) provides the investigator with the ability to analyze the spatial 
distribution of molecules directly in tissue specimens. 
IMS can be used to localize specific molecules such as drugs, lipids, peptides and 
proteins directly from fresh frozen tissue sections with lateral image resolution down to 
10 µm.  Thin frozen sections (10-15 µm thick) are cut, thaw-mounted on target plates and 
subsequently an energy absorbing matrix is applied.  Areas are ablated with an UV laser, 
typically having a target spot size of about 50 µm diameter, and give rise to ionic 
molecular species that are recorded according to their mass-to-charge (m/z) values.  Thus, 
a single mass spectrum is acquired from each ablated spot in the array.  Signal intensities 
at specific m/z values can be exported from this array to give a two-dimensional ion 
density map, or image, constructed from the specific coordinate location of that signal, 
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and its corresponding relative abundance.  For high resolution images, matrix is deposited 
in a homogeneous manner to the surface of the tissue in such a way as to minimize the 
lateral dispersion of molecules of interest.  This can be achieved by either automatically 
printing arrays of small droplets or by robotically spraying a continuous coating.  Each 
micro spot or pixel coordinate is then automatically analyzed by MALDI MS (Figure 2). 
From the analysis of a single section, images at virtually any molecular weight may be 
obtained provided there is sufficient signal intensity to record. 
 
 
 
Figure 2: Cartoon schematic of a typical direct tissue imaging experiment.  The figure 
demonstrates three types of matrix application; spray coating, high density droplet array, 
and mist coating.  Subsequent image acquisition is shown for each technique. 
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One of the most compelling aspects of IMS is the ability to simultaneously 
visualize the spatial arrangement of hundreds of analytes directly from tissue without any 
prior knowledge or need for target specific reagents such as antibodies.  IMS provides the 
ability to visualize post translational modifications and proteolytic processing while 
retaining spatial localization.  Other MS techniques, such as secondary ionization mass 
spectrometry (SIMS), have also seen use for a variety of imaging applications.
15-17
  One 
of the major advantages of SIMS is that it is capable of high resolution imaging (50-100 
nm) for elements and small molecules (m/z <1000 Da).  However, thus far, it has not 
been shown to be effective for the analysis of proteins and large peptides. 
 
Instrumentation and Experimental Process 
The mass spectrometry instrumentation best suited for the analysis of peptides 
and proteins directly from tissues is MALDI time-of-flight (TOF) technology.  The 
ablation process directed by the focused laser beam together with the high frequency of 
the laser pulse renders this the favored ionization method for imaging.  The duty cycle of 
a modern TOF analyzer is an ideal match for the pulsed laser process and also has the 
advantage of a theoretically unlimited mass range, high ion transmission efficiency, 
multiplex detection capability and simplicity in instrument design and maintenance.
18
 
A typical analysis of proteins directly from tissue is described for illustrative 
purposes.  Additional descriptions of a MALDI TOF MS can be found in other works. 
19, 
20
  Two main experimental approaches may be used: profiling and imaging. Profiling 
involves analyzing discrete areas of the tissue sections and subjecting the resulting 
protein profiles to computational analysis. Typically, this uses 5–20 spots, each 
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approximately 0.2–1 mm in diameter. These experiments are designed to make 
comparisons between representative areas on a single piece of tissue, such as normal 
healthy area and diseased area, or between two different specimens.  Thus, in the 
„profiling‟ mode, fine spatial resolution is not required.  A sufficient number of areas 
must be sampled to gain statistical confidence in the results and this will vary depending 
on the specific experiment.  On the other hand, high resolution imaging of a tissue 
requires that the entire tissue section is analyzed through an ordered array of spots, or 
raster, in which spectra are acquired at intervals that define the image resolution (e.g. 
every 50 μm in both the x and the y direction). 2D ion intensity maps, or images, can then 
be created by plotting the intensities of any signal obtained as a function of its x, y  
coordinates. The resulting images allow protein localization differences between and 
among samples to be rapidly assessed. 
Tissues used for analysis should be frozen in liquid nitrogen immediately after 
resection to preserve the morphology and minimize protein degradation through 
proteolysis.  The tissue is usually sectioned in a cryostat to give 10-12 μm thick sections 
and thaw-mounted onto an electrically conductive sample plate.
19
  Sample plates include 
gold-coated or stainless steel metal plates and glass slides that have a conductive coating.  
The tissue may be gently rinsed with ethanol as a fixative and wash to remove lipids and 
salts.  Alternatively, IMS compatible tissue staining protocols can be used in conjunction 
with the optically transparent glass slides, allowing correlation of IMS data with 
histological features of the same section by optical microscopy.
21
 
MALDI IMS requires the application of energy absorbing matrix.  This is 
typically a small organic molecule that co-crystallizes with the analytes of interest on the 
10 
 
tissue surface.  The matrix is capable of absorbing laser energy causing the analyte to 
desorb from the sample surface and ionize.  The most commonly used matrices include 
3,5-dimethoxy-4-hydroxy-cinnamic acid (SA), 2,5-dihydodroxybenzoic acid (DHB) and 
α-cyano-4-hydroxycinnamic acid (CHCA). (Figure 3)  Solvent combinations and the 
matrix used will vary depending on the type of molecule and tissue being investigated.
19
  
A 50:50 (v/v) acetonitrile/water or ethanol/water mixture is generally recommended for 
use in tissue analysis.  SA is an excellent matrix for the analysis of protein
19
 and DHB 
and CHCA are primarily used for the analysis of peptides and lower molecular weight 
analytes. 
 
 
 
 
Figure 3:  Structures of the common matrices used in MALDI MS analyses. A) 3,5-
dimethyoxy-4-hydroxycinnamic acid (sinapinic acid, SA), 
B) α-cyano-4-hydroxycinnamic acid (CHCA), and C) 2,5-dihydroxybenzoic acid (DHB). 
11 
 
For high resolution imaging, the matrix solution should be homogenously 
deposited across the tissue section in such a manner to avoid significant lateral migration 
of analytes.  Currently, this is achieved by applying matrix solution to the tissue in either 
a spotted array or a homogenous spray coating.
19
  A continuous and homogenous spray 
coating allows the highest spatial resolution, but densely spotted arrays show higher 
reproducibility and generally better spectra quality.  A number of robotic spotting devices 
are commercially available and utilize acoustic,
22
 piezoelectric,
23
 inkjet printer,
24
 and 
capillary deposition techniques
25
.  Several robotic spray coating devices are also 
commercially available and utilize a mist nebulizing method
26
 or a thermally-assisted 
spray method.
27
 
Protein analysis is usually performed on a linear TOF instrument to achieve 
highest sensitivity.  Ions formed and desorbed during the laser pulse are extracted and 
accelerated into the field free region of the TOF analyzer.  Ions are usually detected by a 
multi-channel plate detector and the time of flight of the various ions is inversely 
proportional to their m/z values.  This time measurement is then converted to m/z through 
appropriate calibration procedures.  For the analysis of low molecular weight species, an 
ion mirror or reflectron can be used in the ion flight path to compensate for the initial 
velocity/energy distribution and improve resolution.
28
 
Other analyzer combinations have been used with MALDI IMS including TOF-
TOF,
23
 orthogonal TOF and orthogonal Quadrapole-TOF (Q-TOF),
29, 30
 ion mobility,
31
 
fourier transform ion cyclotron resonance (FTICR) 
32, 33
 and ion trap technologies.
34, 35
  
These additional tools have provided capabilities for protein identification, high mass 
12 
 
resolution acquisition and the ability to detect small molecules such as drugs and 
metabolites.
23, 29-32, 34
 
 
Applications of MALDI IMS 
To date, considerable effort has been focused on finding molecular markers as 
early indicators of disease.  MALDI IMS provides a means to visualize molecularly 
specific information while maintaining spatial integrity.  For example, cancer progression 
is dependent on essential characteristics such as the presence of growth factors, 
insensitivity to growth-inhibitory signals, evasion of apoptosis, high replicate potential, 
sustained angiogenesis, and tissue invasion and metastasis.
36
  Alterations in protein 
expression, proteolytic processing and post-translational modifications all contribute to 
this cellular transformation.  IMS analyses of tissue sections reflect the overall status of 
the tissue, therefore, analyses of tissues in different states can reveal differences in the 
expression of proteins which otherwise could not be predicted.  Thus, IMS has been used 
to image protein distributions in multiple types of cancer.  Imaging analysis has been 
used to probe proteome changes in mouse breast and brain tumor.
37, 38
 glioblastoma 
biopsies,
39
 human lung metastasis to the brain,
40
 and prostate.
37, 41
  Identifying features 
that display differential expression patterns between cancerous and normal tissue can 
provide valuable insight into the molecular mechanisms, provide molecular diagnostic 
and prognostic signatures, and identify possible drug targets in implicated pathways. 
In addition to the ability to assist in disease differentiation/diagnosis, the 
proteome signature of a tissue can also be used for determining the effects of drug/small 
molecule administration to an animal model or patient.  Over the past decade, proteins 
13 
 
have become principle targets for drug discovery and proteomics-oriented drug research 
has come to the forefront of activity in this area. Proteomics can play a major role in drug 
development including target identification, target validation, drug design, lead 
optimization, and pre-clinical and clinical development.
42
  Due to the lengthy and 
complex drug discovery process,
43
 it is essential to find ways to speed-up and streamline 
this process.  With the early assessment of the distribution of a drug candidate in targeted 
tissues, IMS can greatly assist in the discovery and validation of processes related to drug 
ADME.
44, 45
  For example, IMS can individually detect the presence and location of a 
drug and its metabolites in a label-free protocol, a significant advantage over other small 
molecule imaging techniques which typically require the addition of a radioactive tag to 
the molecule of interest such as in autoradiography.  Another advantage of IMS is that it 
is capable of providing information on both the pharmacological and biological effects of 
a drug in that it can detect molecular features that may be markers of drug efficacy or 
toxicity.  Other imaging techniques give little information on the molecular identity of 
these biological endpoints.  Thus, IMS can monitor the analyte of interest and also the 
corresponding proteome response.  An example of this is work performed in the 
discovery of transthyretin as a marker for Gentamicin-induced nephrotoxicity in rat.
46
 
Gentamicin-induced nephrotoxicity is seldom fatal and is usually reversible but often 
results in long hospital stays. Thus, there is great interest for finding potential markers of 
early toxicity and also to help elucidate the molecular mechanism.  Investigators utilized 
MALDI IMS to determine differential protein expression within the rat kidney (cortex, 
medulla, and papilla), identified features of interest between dosed and control rat, and 
then applied downstream protein identification procedures.  Transthyretin was 
14 
 
significantly increased in the treated mouse kidney over control and these finding were 
validated with western blot and immunohistrochemistry.
46
 
These same procedures can also be applied to whole-body animal tissue sections 
for a system wide analysis in a single experiment.
29
  For whole-body sagittal tissue 
sections, using the same sample preparation and analysis conditions described for IMS 
experiments of tissues, exogenous small molecule signals found in various organs were 
detected and used to produce images of dosed rat sections (Figure 4).  By expanding the 
capabilities of MALDI IMS to investigate multiple tissue types simultaneously across a 
whole-body tissue section distinct protein patterns as well as small molecule distribution 
can be identified and used to monitor whole-body system dynamics. 
The molecular complexity of biological systems obviates the need for molecularly 
specific tools to elucidate proteomic events in both spatial and temporal distributions.   
One of the most effective ways to present such information is in the form of images, as 
demonstrated through Magnetic Resonance Imaging (MRI), Positron Emission 
Tomography (PET), and confocal microscopy.  Similarly, images of the molecular 
composition of living systems will allow us to gain a more comprehensive view of 
biological processes and reveal complex molecular interactions.  This approach will be 
vital in elucidating molecular aspects of disease, such as primary brain tumors, and also 
drug effectiveness by providing spatial and relevant time-based information. 
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Figure 4: MALDI images of Olanzapine and it major metabolites in whole body rat 
tissues.  A) Optical image of rat sagittal section across four gold MALDI target plates. B) 
Ion image of Olanzapine MS/MS ion 256. C) Ion image of N-desmethyl metabolite 
MS/MS ion 256. D) Ion image of 2-hydroxymethyl metabolite MS/MS ion 272. (Images 
courtesy of Dr. Sheerin K. Shahidi)  
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Primary Brain Tumors 
In this study the above technology will be applied to primary brain tumors.  
Primary malignant brain tumors, which are tumors that start in the brain, account for 2 
percent of all cancers in adults living in the United States (U.S.).
47
  There are many types 
and subtypes of primary brain tumors. They include gliomas (which include 
astrocytomas, oligodendrogliomas, and ependydomas), meningomas, medullablastomas, 
pituitary adenomas, and central nervous system lymphomas.
47, 48
  Figure 5A shows a 
photograph of an excised patient brain with a glial tumor.  The upper left portion of the 
brain is consumed with the tumor mass.  More recently the  World Health Organization 
(WHO) classification has been expanded to include additional types of primary tumors 
such as angiocentric glioma, glialneuronal tumors, and atypical choroid plexus 
papillomas.
49
   Brain tumors produce a variety of symptoms, including headache, seizure, 
and neurological changes, whose onset could progress gradually or could occur at a very 
rapid rate.  
Diagnosis of brain tumors involves a neurological exam and various types of 
imaging tests. Imaging techniques include MRI, computed tomography (CT), and PET 
scan. Typically biopsies are performed as part of surgery to remove a tumor, but there are 
cases where it is performed as a separate diagnostic procedure.
47, 48
  The standard 
approach for treating brain tumors is to reduce the tumor as much as possible using 
surgery, radiation treatment, or chemotherapy.  Typically, such treatments are used in 
various combinations with each other.  Survival rates in primary brain tumors depend on 
the type of tumor, patient age, functional status of the patient, and the extent of surgical 
tumor removal.  Figure 5B displays some typical glial tumor diagnoses along with the 
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average survival time for patients post surgery.  In recent years, survival of the treatment 
of a (solid) neoplasm of the brain has dramatically increased. Survival for the higher 
graded tumors, as well as long term survival of younger patients, is also on the rise.  
Patients with benign gliomas may survive for many years,
50, 51
 while survival in most 
cases of glioblastoma multiforme is limited to a few months after diagnosis if treatment is 
ignored.  New molecularly targeted therapies are now coming to the forefront of research 
with the hopes of increasing survival and quality of life for patients at even a much better 
rate.  Two of those therapies will be investigated in this study and are discussed in later 
chapters. 
 
 
Figure 5:  Human glioma tumors.  A) Photograph of an excised patient brain with a 
glioma.  B) The WHO naming classification for types of gliomas along with patient 
survival post-surgery.  The upper left portion of the brain is consumed with a tumor mass.  
   
Biomarker Discovery 
In recent years, clinical practice has shifted focus to the concepts of personalized 
medicine which includes the use of targeted molecular therapy.  Toward this goal, 
biomarkers are providing early diagnosis of diseases and are helping physicians 
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determine safe and effective medication dosages as well as new possible drug targets.
52
 
The National Institutes of Health (NIH) defined biomarkers as characteristics that are 
objectively measured and evaluated as indicators of normal biological processes, 
pathogenic processes, or pharmacologic responses to therapeutic interventions.
53
  In a 
disease such as cancer the identification of a molecule or molecular signature that is 
accurately indicative of these processes will be of extraordinary benefit to clinicians and 
patients.
54
  For these biomarkers to be put into clinical practice for the goal of 
personalized medicine, extensive research, testing and validation needs to be performed. 
The main hypothesis driving the search for cancer biomarkers is the concept that 
organs secrete a specific set of proteins representing a molecular signature indicative of 
its physiological state.
55
  Genetic mutation and other altered biological processes will 
affect the proteins that are secreted and expressed becoming a unique signature to a 
disease phenotype.
55
  Detection and characterization of these molecular fingerprints 
provides a unique view into the biology associated with various disease states.  The 
potential use of biomarkers for the early detection of cancer has compelled significant 
research in this field.
54, 56
 
Another advantage of biomarkers is the potential to aid clinicians in selecting 
patients to undergo certain treatments.  This research is conducted based on previous 
evaluations of treatment efficacy and safety from patients exhibiting a specific biomarker 
or group of markers.  These markers may also be used to monitor response to treatment 
and disease progression.
57
 
Numerous studies have been published describing the discovery of putative 
biomarkers using mass spectrometry. 
25, 43, 58, 59
 Although these studies established a 
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trend-setting basis for mass spectrometry in biomarker research, they also initiated a 
controversial debate questioning the clinical validity of the obtained results. It needs to be 
noted that new potential biomarkers discovered through the proteomics process need to 
undergo a chain of discovery and identification, validation in clinical trials, and approval 
by regulatory agencies before they are implemented in clinical practice (Figure 6).
60
 
 
 
 
 
 Figure 6:  Developmental phases and estimated timeline for the discovery and validation 
of biomarkers.  
  
 
Summary and Objectives 
Drug discovery and development is a long and complex process and there is an 
ever present need for new technologies and methods to aid in making the procedures 
more efficient and cost effective. MS is already involved in almost every stage of the 
drug development process, from new chemical entities to formula determination to target 
profiling and preclinical work.  It is even used in end stages of manufacturing and quality 
assurance and much research is focused on using MS for diagnostics.  One can identify 
numerous areas where MALDI IMS could be implemented to assist in the monitoring of 
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an administered drug and its metabolites, discover potential drug targets, assist in 
diagnosis and evaluate the effects of a treatment.  
 The goal of the research presented here is to implement MALDI IMS for the 
purpose of demonstrating its effectiveness and usefulness in the drug discovery and 
validation processes.  Drug distribution can be evaluated as well as quantitative 
information obtained at localized points without losing spatial integrity due to 
homogenization processes.  Pharmacodynamic effects will also be studied toward 
identifying possible features for biomarker validation that represent not only disease 
state, but which can be used as indicators of targeted molecular therapy treatment 
responses in glioma primary brain tumors. 
 Chapter II will address how with MALDI IMS it is possible to achieve small 
molecule quantitation directly from tissue sections without the need for additional sample 
treatment or separation techniques. Current methodologies do not have the capability of 
retaining spatial information related to the drug concentration and require laborious 
protocols involving homogenization and extraction techniques.  The MALDI IMS 
quantitation methodology developed will provide a solution to the issues presented by 
LC-MS/MS methods.  In addition, small molecule images will be obtained along with 
protein images to allow for the correlation of drug tissue distribution and therapeutic 
response within the same sample   
The quantitation protocol has been applied to the investigation of two therapies 
under investigation for the treatment of Glioblastomas (brain tumors of glial cell origin) 
to determine the quantities of compound that reach the brain and tumor areas in mouse 
models.  In addition to drug quantitation, the treatment effects on the proteome of the 
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brain were investigated in relation to the amount of drug present.  Chapter III focuses on 
the investigation of the molecularly specific therapy imatinib and Chapter IV explores the 
effects of the plant alkaloid cyclopamine on the gliomas.  Future work will be discussed 
in Chapter V that demonstrates how the affected protein signals found in the mouse 
models can be related back to human tumor biopsies, demonstrating the feasibility of 
utilizing mouse models to discover protein signatures that can be used as indicators of 
therapy response.  All of this work demonstrates the value that MALDI IMS has in the 
drug development process and the advantages that it can provide. 
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CHAPTER II 
 
DRUG QUANTITATION PROTOCOL DEVELOPMENT 
 
Overview 
Typically analysis of small molecules by MS has relied on the use of liquid 
chromatography tandem mass spectrometry.
11-14
  Information ranging from structural 
characterization to pharmacokinetic extraction studies can be obtained. These analytical 
evaluations provide vital information regarding the preclinical ADME properties of 
potential therapeutic compounds.  In the pharmaceutical industry, distribution studies of 
drug candidates are performed to gain knowledge about the localization and 
accumulation of drugs in various tissues throughout an animal.  While the LC-MS/MS 
technique proved invaluable for drug quantities in tissues, there is a loss of spatial 
information regarding drug distribution due to the necessity of homogenization 
methodologies prior to analysis.  MALDI mass spectrometry can fill this information gap 
by providing drug distribution information with relatively easy sample preparation.  
Typically in the past, MALDI MS has been overlooked as a viable option for small 
molecule quantitative studies.  Analysts have usually assumed that potential differences 
in ionization efficiency between analyte and internal standards and an inherent 
heterogeneity of the sample spot would limit MALDI MS as a quantitative technique.
61
  
However, with the introduction of automated spotters and newly developed protocols, the 
use of MALDI mass spectrometry for small organic molecule quantitation can become a 
reproducible and reliable analytical procedure. The protocol developed here involving 
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robotic sample preparation combined with automated MALDI mass spectrometry 
provides a viable method for quantitation of small molecules.  
 
Introduction 
 
Issues with Quantitation  
 LC-MS/MS quantitation for tissue samples, while effective, still faces many 
issues that complicate the methodology.  The first step of any quantitative tissue analysis 
usually involves that the tissue must be homogenized which causes the loss of any spatial 
information within the tissue.  The next part of the process involves the extraction of the 
small molecule to be analyzed using a series of centrifugation steps, solvent washes and 
shaking, inversion or sonication.  These processes can result in incomplete extraction, 
loss of the compound due to sticking or leeching into tube walls of the equipment used or 
ineffective sample transfer which would also affect the quantitation results. The LC 
process could also create inconsistencies in the results.  Shifts or convoluted retention 
times due to changes in instrument parameters, interferences from other compounds and 
loss of the small molecule due to sticking on the column are all issues that could create 
fluctuations or inaccurate results.  MALDI IMS can alleviate these issues while also 
performing the analysis with minimal sample preparation steps and an analysis time on 
the order of micro-seconds (µs) as opposed to minutes or even hours. 
In the past, MALDI mass spectrometry was frequently not used for small 
molecule analysis because of chemical interference from the MALDI matrix in the mass 
range of a typical analysis (less than 1 kDa).  However, the accepted way of performing 
24 
 
mass spectral quantitation is by using a mass spectrometer capable of MS/MS 
fragmentation.  MS/MS used in conjunction with quantitation is commonly accomplished 
with a triple quadrupole or ion trap mass spectrometer.  The reason MS/MS is required is 
because many compounds have the same intact mass.  Tandem mass spectrometry 
involves analyzing the product ions of a particular precursor ion.  In the MALDI MS/MS 
instrument, the first mass analyzer acts as a mass filter by selectively allowing a narrow 
mass window (0.2 Da to 5 Da depending on the instrument), usually centered on the 
small molecule of interest, to continue on into the instrument, while preventing matrix 
molecules from entering, helping to eliminate the matrix interference that has stifled 
MALDI MS as a practical tool for small molecule analysis.  The second process analyzes 
the specific product ions of the molecules of interest which serves as a specific 
fingerprint.  Figure 7 shows the schematics of both a Q-TOF and a LTQ, two instruments 
used for MALDI MS/MS. 
 To assess changes in drug concentrations in a given tissue, pixel to pixel 
reproducibility must be high, that is, two pixels close together having the same drug 
concentrations should give the same spectra within acceptable standards.  Although, this 
will vary from experiment to experiment, typically variations of ±30% or less are deemed 
acceptable.  Factors that have a direct bearing on this aspect of the analysis include 
ionization efficiency of a given molecule, ion suppression effects, extraction efficiency of 
the matrix deposition process and the robustness and effectiveness of post acquisition 
processing.   High pixel to pixel reproducibility can be achieved by careful attention to 
sample preparation and the matrix application steps.  In addition, instrument parameters 
such as voltage settings and laser power must be kept constant within a given experiment. 
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A robotic matrix application device is invaluable in removing operator to operator 
variations.
29
   
 
 
 
 
 
Figure 7: MALDI MS/MS instrument schematics.  A) Schematic of the QStar XL (MDS 
Sciex, Concord, Canada) equipped with an oMALDI source (20 Hz 337 nm nitrogen 
laser) and a hybrid QqTOF mass analyzer  B)  Schematic of the MALDI LTQ XL 
(Thermo Scientific Inc.)  
 
 
Importance of Internal Standards 
An internal standard (i.s.) should be used when performing MS quantitation.  An 
appropriate internal standard will control for extraction, sample introduction and 
ionization variability.  An internal standard should be added at the beginning of the 
sample work-up and should be added at the same level in every sample including the 
standards and should also give a reliable MS response.  The amount of the internal 
standard added needs to be well above the limit of detection but not so high as to 
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suppress the ionization of the analyte.  The best internal standard is an isotopically 
labeled version of the molecule you want to quantify.  An isotopically labeled internal 
standard will have a similar extraction recovery, ionization response, and separation 
behavior as the analyte of interest.
62
 
 
Results 
 
Signal Depth  
 When acquiring small molecule data there a number of parameters that 
must be considered in order to accurately represent the amount of drug that is in 
the tissue.  How many laser shots need to be acquired, how much of the matrix 
spot needs to be sampled spatially and how should the internal standard and the 
analyte desired be acquired from the same location. To begin investigating this, 
Olanzapine (OLZ) dosed tissue sections were cut and spotted with DHB matrix in 
50% methanol spiked with 2 µM of d4-OLZ internal standard.  Various positions 
across the matrix spots were analyzed collecting a spectrum every 45 laser shots.  
The data was then plotted comparing the area under the curve (AUC) for the 
MS/MS fragment (m/z 256) of the small molecule parent compound OLZ (m/z 
313) versus the number of laser shots.  As can be seen in Figure 8, the majority of 
the OLZ signal from the dosed tissue is acquired in the first 90 laser shots and 
then tapers off quite drastically with most signal for each position being entirely 
gone after 600 laser shots.  Similarly, the d4-OLZ internal standard signal showed  
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Figure 8:  Major OLZ fragment (m/z 256) area under the curve plotted against the 
number of laser shots taken for each position across a DHB spot (approximately 
250 µm diameter).  
 
 
similar behaviors as displayed in Figure 9A.  When looking at the major fragment of d4-
OLZ (m/z 256) AUC again it is shown that the majority of the signal is acquired in the 
first 100 laser shots when spectra were taken every 45 laser shots.  Looking at the data 
from spectra acquired every 15 laser shots (Figure 9B) it is seen that even within the 45 
laser shot packet, the majority of signal is obtained in the first 15 laser shots and then 
decreases from there.  This indicates that the first initial shots taken from a sample in 
small molecule analysis are critical if one wants to get an accurate representation of the  
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Figure 9:  Major fragment (m/z 259) area under the curve for d4-OLZ plotted against the 
number of laser shots taken for each position across a DHB spot.  A) Spectra acquired 
every 45 laser shots.  B) Spectra acquired every 15 laser shots.  
 
 
amount of drug present in a tissue. However, it is also necessary to collect beyond these 
first initial shots to obtain all the signal given by the drug. 
 
Area Ablated Calculation  
Looking at the spectra acquired from the various locations within the matrix spot, 
it is clearly seen that the crystallization of the matrix affects the drug signal.  There are 
variances in drug signal across the matrix spots.  This leads to the conclusion that one 
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position within the matrix spot is not an accurate representation of the amount of drug 
present.  It is necessary to evaluate multiple positions within a matrix spot.  In order to 
determine how many positions need to be analyzed to represent the amount of drug in a 
given matrix spot, it must first be determined what area of the matrix spot is being 
sampled by the laser.  By evaluating laser burn patterns in a thin layer of DHB (sublimed 
onto the target pate) the laser spot size dimensions can be determined.  Laser spot size is 
dependent on the number of laser shots being taken in a particular location and the laser 
power used.  For these experiments the laser power was kept constant at 20 µJ, which 
was found to be the laser power necessary to obtain small molecule signal from the DHB 
matrix spots.  However, the number of laser shots taken at a particular location was 
varied.  The previous experiments showed that a bulk of signal was acquired in the first 
90 laser shots, thus a burn pattern was achieved by shooting at a laser power of 20 µJ for 
a total of 90 laser shots in the same spatial position (Figure 10A).  This resulted in an 
elliptical burn pattern size of 136 x 16 µm giving a total ablated area of 1709 µm
 2
, while 
a burn pattern achieved by shooting for a total of 600 laser shots, which is the number of 
laser shots needed to ensure all the signal has been detected, was 153 x 31 µm giving a 
total ablated area of 3725 µm
2 
(Figure 10B).  Note that all laser burn pattern 
measurements were taken from no less than a total of ten spots and resulted in percent 
relative standard deviation (%RSD) values of less than 12%.   
Looking at the laser burn areas from a micro-raster pattern it can be determined 
what spatial resolution will be required to ablate all of the matrix in a given area.  Laser 
burn patterns were generated from a micro-raster of 50 µm x 4 positions within a spot 
and an overall spatial array of 300 x 300 µm using both 90 laser shots per position and 
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600 laser shots per position (Figure 10 C and D respectively).  It is seen that the 90 laser 
shots per position in this micro-raster pattern does not ablate all of the matrix within the 
entire encompassed area, while the 600 laser shots per position condition does indeed 
ablate all of the matrix within the given area of the micro-raster.  The total ablated area 
within the 600 laser shots per position condition is approximately 16650 µm
2
.  The area 
ablated by the laser needs to be taken into consideration when evaluating the quantity of a 
small molecule within a tissue so that the amount of sample that is analyzed can be 
known.  In order to ensure that all of the signal is being obtained from a given area it is 
necessary to use 600 laser shots per position with a micro-raster of 50 µm across the 
matrix spot being analyzed.  For a 250 µm matrix spot, a total of 14 micro-rasters at 50 
µm need to be analyzed to ablate the whole spot.  The sum of the intensities at each 
location can be taken and then added together to give the total intensity sum over the 
entire matrix spot.  Thus, the investigator will know the total area sampled and the total 
intensity of the small molecule being investigated from any given evaluated area. 
 
 
Tissue Dimension Calculations 
 In addition to knowing the total area that is being sampled the amount of tissue 
under that area needs to be known.  This can be done by obtaining the mass of a brain 
section along with its total area so that the mass of the tissue under the matrix spot can be 
calculated.  To do this, a total of ten sections of brain tissue at 12 µm thickness were cut 
and then immediately weighed on a microbalance.  The total mass of the ten sections was 
then divided to obtain the mass of one thin tissue section.  This experiment was repeated  
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 Figure 10: Laser burn patterns on a thin layer of DHB photographed at 10x 
magnification.  All burn patterns were created with a laser power of 20µJ. A)  90 laser 
shots per position in a 300 x 300 µm array.  B) 600 laser shots per position in a 300 x 300 
µm array.  C) 90 laser shots per position in a 50 µm micro-raster pattern (x4) in a 300 x 
300 µm array.   D) 600 laser shots per position in a 50 µm micro-raster pattern (x4) in a 
300 x 300 µm array. 
 
 
 
five times for each tissue type analyzed.  A 12 µm rat brain section had an average mass 
of 1.02 mg with a RSD of 8%.  To get the total tissue area, 12 µm brain sections were 
cut, thaw mounted onto microscope slides, stained with cresyl violet and then scanned on 
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a flat bed scanner at 3200 dpi.  The scanned images were imported into Adobe Photoshop 
so that the area could be calculated. The area of the rat brain section was 250 mm
2
 with a 
RSD of 0.3%.  Using these dimensional measurements it is possible to calculate the 
amount of tissue being sampled under any one given matrix spot.   
 
Acquisition Methods 
 When using an internal standard it is important to evaluate the best way to acquire 
both signal for the analyte of interest to be quantified and the signal given by the internal 
standard to be used for normalization.  Ideally, both signals will be acquired from the 
same spatial location within the tissue section to give the most accurate results.  As can 
be seen by the signal depth experiments, the first shots of an acquisition are critical to 
obtain all of the drug signal within a location.  When alternating acquisition of analyte of 
interest and internal standard this needs to be taken into consideration.  Thus matrix spots 
with known concentrations of OLZ standard and d4-OLZ standard were analyzed using 
two methods.  One method acquired internal standard (d4-OLZ) in the first 15 laser shots 
and then the analyte of interest (OLZ) in the next 15 laser shots alternating from there 
until 600 laser shots had been acquired at each location.  The second method acquired 
OLZ spectra for the first 15 laser shots and then d4-OLZ spectra in the next 15 laser shots 
alternating until 600 laser shots had been acquired at each location.  For each spot the 
total intensity sum was calculated for the OLZ and d4-OLZ standards and then the ratio 
of analyte/internal standard was calculated.  Figure 11 shows the ratio results for the 
matrix spots revealing that there is no significant difference between the two acquisition  
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Figure 11:  Effects of acquisition method on signal ratios detected from a dilution series 
of OLZ spiked matrix with 2 µM of d4-OLZ.  The OLZ first series indicates that the first 
15 laser shots were acquired for the OLZ major fragment then the next 15 laser shots 
were acquired for d4-OLZ major fragment, alternating until 600 laser shots were 
acquired.  The d4-OLZ first series is d4-OLZ for the first 15 laser shots and then OLZ, 
alternating.  The ratios collected by either method show no significant difference from 
each other.  
 
 
methods.  The ratios fit within the standard deviations of both acquisition methods and 
the percent difference was no higher than 15%. 
 
Limits of Detection and Calibration Curves 
 The limit of detection (LOD) is usually defined as the lowest quantity or 
concentration of a component that can be reliably detected with a given analytical 
method. Intuitively, the LOD would be the lowest concentration obtained from the 
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measurement of a sample (containing the component) that would be able to be 
discriminated from the concentration obtained from the measurement of a blank sample 
(a sample not containing the component).
63
 
64
  The parameters used here to determine the 
LOD are 3 standard deviations above the blank standard value. 
A calibration curve is a method for determining the concentration of a substance 
in an unknown sample by comparing the unknown to a set of standard samples of known 
concentration.  It is a plot of how the analyte signal changes with the concentration of the 
analyte.  A line or curve is fit to the data and the resulting equation is used to convert 
readings of the unknown sample into concentration.  In the instance of a linear fit :  
Signal= slope x concentration + intercept 
 Calibration curve standards of OLZ were added to matrix solutions to yield final 
concentrations of 100, 10, 1, and 0.1 ng/ml. A 2 µM concentration of d4-OLZ was also 
added to the matrix as an internal standard in each solution.  For the analysis of OLZ, 
DHB in 50% methanol (MeOH) was used as the matrix.  Using the Portrait™ 630, matrix 
spots were deposited onto tissue sections in known volumes.  Knowing the volume of 
matrix standard deposited it is possible to calculate the amount of drug compound that 
was deposited onto the tissue within the matrix spot.  For the standard curve the amount 
of drug within the matrix spots was 680, 68, 6.8 and 0.68 fg and a blank standard 
containing matrix only.  As can be seen in Figure 12, the top panel shows a spectra taken 
from a blank matrix spot and shows no signal at m/z 256 where the OLZ MS/MS 
fragment would be, indicated by the red arrow.  The bottom panel is a spectra taken from 
a matrix spot containing 680 fg of OLZ and shows a clear signal at m/z 256. 
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Figure 12: SRM spectra of olanzapine acquired on a MALDI LTQ A) Spectra taken from 
a matrix spot with no OLZ spike B) Spectra taken from a matrix spot containing 680 fg 
OLZ.  
 
 
Using the acquisition methods described above, a total of ten matrix spots (140 
positions) for each point on the OLZ calibration curve were analyzed and then the 
intensity ratios were averaged providing a RSD no higher than 20% and excellent 
linearity with an R
2
 value of 0.9982 (Figure 13). From this analysis the LOD is above the 
analyte/internal standard ratio of 0.14 which equates to approximately 0.20 fg of OLZ 
within a 250 µm matrix spot. 
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Figure 13:  Calibration curve for OLZ showing ratios of OLZ/d4-OLZ signals against fg 
of drug in the matrix spots.   
 
 
 
Discussion 
Taking all of the information from the above experiments into consideration; it is 
now possible to outline a methodology for direct quantitation of small molecules from 
tissue using MALDI MS/MS.  First dosed tissues need to be sectioned at a known 
thickness and the area of the section along with the section mass must be determined.  
The area ablated by the laser using experiment specific acquisition methods must also be 
determined.  Using this information a simple ratio calculation can be performed to find 
y = 0.0083x + 0.2583
R² = 0.9982
0
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the amount of tissue that is sampled within a specific location.  For OLZ dosed rat brain 
the tissue section area was found to be 250 mm
2
 and the tissue section mass was found to 
be 1.02 mg.  The area sampled by the laser in one position acquiring a total of 600 laser 
shots at a laser power of 20 µJ is approximately 0.0035 mm
2
. To find the amount of 
tissue sampled under one laser position the following equation was used:  250mm
2
/1.02 
mg = 0.0035 mm
2
/X mg.  From this calculation it was determined that 1.42x10
-5
 mg of 
tissue was sampled.  A similar calculation was performed to determine the amount of 
tissue sampled under a 250 µm matrix spot.  The matrix spot has an area of 49087 µm
2
 
which results in 5 x 10
-4 
mg of tissue sampled.   
A calibration curve for the small molecule of interest must be acquired to provide 
an equation for determining how much of the small molecule substance is in the sample 
by comparing the unknown to a set of standard samples of known amounts.  The dosed 
tissue sections were then cut at 12 µm and spotted with matrix (DHB, 40 mg/ml in 50% 
MeOH) spiked with an internal standard (d4-OLZ) and analyzed on the MALDI LTQ.   
For each matrix spot a total of 14 locations were analyzed to completely ablate all of the 
small molecule signal, taking 600 laser shots per location.  A total of ten matrix spots 
were analyzed for each dosed tissue.  Using in-house software (developed by Surendra 
Dasari) the total intensity sums were calculated for the OLZ signal and the d4-OLZ signal 
at each location.  These totals were then used to get the ratio of OLZ signal over d4-OLZ 
signal within a matrix spot.  The ratio values were plugged into the calibration curve‟s 
linear equation to result in the amount of drug present in each spot.  Dosed tissue sections 
collected 2 hour (2h), 6 hour (6h) and 12 hour (12h) after a single dose of OLZ were 
analyzed and resulted in an average of 790 fg, 70 fg, and 15 fg respectively of OLZ 
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compound.  Dividing these values by the mass of the area sampled gave the average OLZ 
concentration taken from the analyzed matrix spots for each of the dosed tissues with an 
average RSD of 33%.  At 2h post dose the OLZ concentration was 55.65 ng/mg, 6h post 
dose was 4.89 ng/mg and 12h post dose was 1.84 ng/mg. 
 To compare the OLZ concentration results, an LC-MS/MS extraction protocol 
was performed.  The dosed tissues were homogenized, extracted and then analyzed on an 
ESI TSQ Quantum triple-quadrupole system.  Using this methodology for the 2h, 6h, and 
12h samples, the concentrations of OLZ were found to be 57.30 ng/mg, 3.74 ng/mg and 
2.64 ng/mg respectively with an average RSD of 33%.  Figure 14 displays the results for 
both the MALDI MS/MS analysis and the LC MS/MS analysis.  It can be seen that the 
methodologies result in very similar concentrations for each of the dosed tissues.  The 2h 
sample has a percent difference of 3, the 6h sample has a percent difference of 24 and the 
12h sample has a percent difference of 13 (Table 1).  This demonstrates that the MALDI 
MS/MS methodology developed here can be used to provide an accurate drug 
quantitation for dosed tissue sections with excellent reproducibility and low standard 
deviations. 
 In addition to the experiment descriptions provided in the material and methods 
section of this chapter a detailed step by step protocol is included in Appendix A that 
outlines the methodology developed to obtain absolute drug concentration directly from 
tissue sections using MALDI IMS. 
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 Figure 14: Comparison of MALDI IMS and LC-MS/MS quantitation methods for OLZ. 
Olanzapine concentration in ng of OLZ per mg of tissue as determined by LC-MS/MS 
and MALDI IMS experiments for each tissue sampled.  
 
  
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Comparison of OLZ concentration values calculated with LC-MS/MS and 
MALDI-IMS methods 
 
OLZ 
   
ng/mg 2h 6h 12h 
LC* 57.30 3.74 2.64 
MALDI* 55.65 4.89 2.30 
% difference 3 24 13 
 
*Average RSD=33%  
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Materials and Methods 
 
Materials  
The MALDI matrices, 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid, 
SA), α-cyano-4-hydroxycinnamic acid (CHCA), and 2,5-dihydroxybenzoic acid (DHB), 
were purchased from Sigma Chemical Co. (St. Louis, MO) along with sodium hydroxide 
and ammonium acetate.  HPLC grade acetonitrile, methanol, and hexane were purchased 
from Fisher Scientific (Suwanee, GA). HPLC grade cyclohexane was purchased from 
Acros Organics (Geel, Belgium).  Fischer 344 rats were purchased from Charles River 
Laboratory, Inc. (Wilmington, MA).  Zyprexa tablets (OLZ) were obtained from the 
Vanderbilt University Hospital Pharmacy (Nashville, TN).  All animal studies were 
approved by the Institutional Animal Care and Use Committee at Vanderbilt University. 
 
Animal Dosing Methods 
OLZ was administered per oral (p.o.) at pharmacologically relevant doses of 8 
mg/kg to 10 week-old male Fischer 344 rats, which had fasted overnight prior to start of 
study.  Animals were euthanized at 2h, 6h and 12h post-dose by isoflurane anesthesia 
followed by exsanguination via decapitation.  Control and dosed brain, liver, and kidney 
were harvested and frozen in powdered dry ice. 
 
Signal Depth Methods 
 Fresh frozen tissue sections at 12 µm thickness were collected at -20 ºC using a 
Leica CM3050s cryomicrotome (Leica Microsystems, Inc., Germany) and thaw-mounted 
42 
 
to gold-coated MALDI target plates.  Sections were acquired for Olanzapine dosed rat 
brain.  Target plates were stored in a dessicator until analysis.  Matrix solution was made 
fresh at 40 mg/ml DHB in a 50% methanol solution and spiked with 2 µM of d4-
olanzapine.  The matrix solution was spotted onto the tissue sections on the Portrait™ 
630 (Labcyte Inc.) depositing a total of 6.8 nl (40 passes, 1 drop/pass, 170 pl/drop) in a 
300 µm x 300 µm spatial resolution array.  Photos were acquired for the spotted tissue 
sections using an Olympus BX50 microscope (Olympus Optical Co, LTD. Tokyo, 
Japan,) fitted with a Micropublisher 3.3 camera (QImaging, Canada) at 10x 
magnification.  Once spotting was completed the plates were allowed to dry in the dark 
for a minimum of 15 minutes before being introduced into the MALDI LTQ XL (Thermo 
Scientific Inc.).  Spectra were acquired across the array in a total of 7-14 locations per 
matrix spot to get an accurate representation of the signal distribution across the entire 
area.  At each position spectra were acquired at 45 laser shot intervals (3 µscans/step, 15 
laser shots/µscan) or at 15 laser shot intervals (3 µscans/step, 5 laser shots/µscan) with a 
20 µJ laser energy.  Spectra were acquired at the same absolute x and y coordinate 
location until no signal was detected.  Spectra were introduced to in-house software 
designed by Surendra Dasari (Frappienator) to export the absolute x and y coordinates 
along with the total signal intensity for a specific m/z for each spectra acquired and the 
information was put into an excel spreadsheet for further statistical analysis. 
 
Area Ablation Calculation Methods 
 A gold coated MALDI target was covered with a thin layer of DHB matrix by 
sublimation using an in-house built sublimination chamber.  Once coated the plate was 
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introduced into the MALDI LTQ XL (Thermo Scientific Inc.) for laser spot size analysis.  
The laser was positioned over an area of the plate with the DHB matrix and then fired at 
specified laser powers and raster patterns typically used for acquiring data. The plates 
were then taken to an Olympus BX50 microscope (Olympus Optical Co, LTD. Tokyo, 
Japan,) fitted with a Micropublisher 3.3 camera (QImaging, Canada) at 10x magnification 
and pictures were acquired at 10x magnification.  Using the microscope software, Image-
Pro Plus, the dimensions of the laser spot burn patterns were measured to determine the 
size of the laser spots.  
 
Tissue Dimension Calculation Methods 
 Fresh frozen tissue sections at 12 µm thickness were collected at -20 ºC using a 
Leica CM3050s cryomicrotome (Leica Microsystems, Inc., Germany).  One section was 
thaw mounted to a glass slide while ten subsequent sections were collected on a 
previously weighed piece of wax coated weigh paper.  The ten sections were immediately 
weighed on a micro balance to get their mass.  The weight of the weigh paper was 
subtracted from the total mass.  This process was repeated five times for each tissue 
evaluated and the average mass of a tissue section was calculated.  The sections on the 
slides were stained with cresyl violet and cover slipped.  The stained slides were allowed 
to dry and then images were acquired on a flat bed scanner at 3200dpi next to a 
measurement slide.  The images were imported into Adobe Photoshop software. Using 
the marquee tool make a rough selection of the area of interest.  Open the color range 
tool.  Using the Select Drop Down Menu and select Color Range.  Once the dialogue box 
is open, make sure the radio dial box is checked selection and the selection preview is set 
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to Black Matte. Hold down the shift button and select the various color regions needed 
for area calculation.  Use the Fuzziness toolbar by sliding to the right to adjust until all 
areas to be used for the calculation are selected without any unwanted areas showing in 
the preview window.  Finalize the selection by clicking OK.  Now that the area has been 
selected it is necessary to find the number of pixels within the selection.  This can be 
done using the Histograms, located in the palates toolbar on the right hand side of the 
screen.  Make sure the view is in expanded mode and the show statistics button is also 
selected. Number of pixels can be found in the lower left hand corner of the statistics 
display.  Occasionally the histrogram will show an error icon indicating that it needs to be 
refreshed to calculate the pixels with uncached data.  Do this by clicking the refresh 
button in the upper right hand corner of the histogram dialogue box.  This must be done 
to ensure that an accurate pixel count is obtained. Take note of the number of pixels 
selected.  In order to convert the number of pixels into actual units, it is necessary to find 
the number of pixels within an object in the image for which the actual real life 
dimensions are known.   Using the marquee tool, select the area of known dimensions as 
accurately as possible.  Go back to the Histograms box and obtain the number of pixels.  
Now you can use the information to convert the number of pixels to physical units.  
Divide the number of pixels within the unknown area of interest by the number of pixels 
within the area of known dimensions.  Multiply by the known dimension.  This results in 
the exact physical measurement for the area of interest. 
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Limits of Detection and Calibration Curve Methods 
 A dilution series of OLZ stock solutions was made in 100% methanol and stored 
at -20
o
C until use.  The series spanned six orders of magnitude (1 ng/ml, 10 ng/ml,       
100 ng/ml, 1000 ng/ml, 10,000 ng/ml, 100,000 ng/ml) to allow for accurate limit of 
detection determination.  From these stock solutions a standard series was made by 
adding known amounts into already prepared matrix (DHB 40 mg/ml, 50 % methanol: 
50% water). One hundred µl of the appropriate stock was added to 900 µl of matrix to 
make the following dilution series: 0.1 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml, 1,000 ng/ml 
and 10,000 ng/ml.  To each solution the appropriate internal standard was added to a 2 
µM concentration.   
 Fresh frozen tissue sections at 12 µm thickness were collected at -20 ºC using a 
Leica CM3050s cryomicrotome (Leica Microsystems, Inc., Germany) and thaw-mounted 
to gold-coated MALDI target plates.  Sections were acquired for Fisher 344 rat brain.  
Plates were put into a dessicator to dry for a minimum of 60 minutes.  After drying, the 
plates were spotted with the standard spiked matrix dilution series on the acoustic reagent 
multi-spotter (Portrait™ 630, Labcyte Inc.) 6.8 nl per spot (40 passes, 1 drop/pass, 170 
pl/drop) in a 300 µm x 300 µm spatial array resulting in a 20 x 10 spot array for each 
standard solution.  The plates were allowed to dry in the dark for 15 minutes before being 
introduced into the MALDI LTQ XL (Thermo Scientific Inc.) where spectra were 
acquired.  The acquisition method used a 50 µm raster at 14 different positions across the 
matrix spot, 2 scan events (one for the analyte, one for the internal standard) alternated 
for a total of 40 scan events per position, 3 µscans per scan event, 5 laser shots per µscan 
at a laser power of 20 µJ. 
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Dosed Tissue Analysis 
 Fresh frozen tissue sections at 12 µm thickness were collected at -20 ºC using a 
Leica CM3050s cryomicrotome (Leica Microsystems, Inc., Germany) for each OLZ 
dosed brain. Plates were put into a dessicator to dry for a minimum of 60 minutes.  After 
drying, the plates were spotted with DHB matrix (40 mg/ml, 50% MeOH) spiked with 2 
µM of d4-OLZ as an internal standard on the acoustic reagent multi-spotter (Portrait™ 
630, Labcyte Inc.) 6.8 nl per spot (40 passes, 1 drop/pass, 170 pl/drop) in a 300 µm x 300 
µm spatial array resulting in a 20 x 10 spot array.  The plates were allowed to dry in the 
dark for 15 minutes before being introduced into the MALDI LTQ XL (Thermo 
Scientific Inc.) where spectra were acquired.  The acquisition method used a 50 µm raster 
at 14 different positions across each matrix spot, 2 scan events (one for the analyte, one 
for the internal standard) alternated for a total of 40 scan events per position, 3 µscans per 
scan event, 5 laser shots per µscan at a laser power of 20 µJ.   
 
Drug Quantitation Using LC-MS/MS 
The extraction protocols used here were modeled after published protocols of 
OLZ quantitation from dosed tissues.
65-67
  For each tissue being evaluated a piece of the 
tissue was cut and then weighed with a minimum of 100 mg used, this was done in 
triplicate.  Once the tissue was weighed it was homogenized with water, 1 ml for every 
100 mg of tissue used, and 3 µg of the internal standard being used.  The tissue was 
homogenized thoroughly until uniform by visual inspection and then the liquid was 
transferred to a test tube using a Pasteur pipet.  A 1:1 dilution of sodium hydroxide was 
added to the tube and the solution was vortexed to pH the solution.  For the extraction, 
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ten ml of cyclohexane was added to the test tube and then mixed by inversion for two 
hours.  The mixture was then centrifuged for 30 minutes at 3500 rpm.  The organic layer 
was removed and transferred into a scintillation vial which was then dried under Nitrogen 
gas at 37 °C.  Samples were reconstituted in 300 µl of 10mM ammonium acetate  in 50% 
acetonitrile and then transferred to autosampler vials.  Standard curves were prepared by 
spiking a control homogenate with the OLZ standard, which covered a concentration 
range of 1-1000 ng/g. 
Samples were analyzed on an ESI TSQ Quantum triple-quadrupole system 
(Thermo Scientific, Waltham, MA) equipped with an autosampler (set at 4 ºC) and HPLC 
system. A C12 Synergi MAX-RP 150 x 2 mm column (Phenomenex, Torrance, CA) was 
used with a fast gradient run of mobile phase A (5:95 acetonitrile:0.5% acetic acid in 
water, 10 mM ammonium acetate) to mobile phase B (95:5 acetonitrile:0.5% acetic acid 
in water, 10 mM ammonium acetate).    
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CHAPTER III 
 
ANALYSIS OF IMATINIB TREATED GL26 MURINE CELL XENOGRAFTS 
 
Overview 
Glioblastoma multiforme (GBM) is the most common type of malignant primary 
brain tumor with over 10,000 new cases diagnosed each year in the United States.
68
  
Glioblastomas account for approximately 60 to 70% of malignant gliomas, anaplastic 
astrocytomas for 10 to 15%, and anaplastic oligodendrogliomas and anaplastic 
oligoastrocytomas for 10%; less common tumors such as anaplastic ependymomas and 
anaplastic gangliogliomas account for the rest.
68
  Despite current methods of therapy 
including surgery, radiation and chemotherapy the median survival for GBM is only 12-
18 months.  However, with recent progress in understanding the molecular pathways of 
this disease it is becoming possible to generate new and better therapies for treatment of 
GBM.  Malignant transformation in gliomas is the result of sequential accumulation of 
genetic aberrations and deregulation of growth factor signaling pathways.  Targeted 
therapies have been developed against these pathways.
69
  Targeted therapy may provide 
greater specificity toward tumor cells with potentially less toxicity than conventional 
chemotherapy.  The success of these agents in other systemic cancers demonstrates their 
potential in tumors with well-defined molecular targets.
70, 71
 Even though the complexity 
of the molecular abnormalities in GBMs and the redundancy of the signaling pathways 
make it unlikely that single agents will achieve great success, there has been significant 
interest in this approach.   
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Inhibition of deregulated protein kinases by small molecule drugs has evolved 
into a major therapeutic strategy for the treatment of human malignancies. Knowledge 
about direct cellular targets of kinase-selective drugs and the identification of druggable 
downstream mediators of oncogenic signaling are relevant for both initial therapy 
selection and the nomination of alternative targets in the event that molecular resistance 
emerges. Protein kinases are critical regulators in human cancer and play major roles in 
tumor cell proliferation, migration and survival. Aberrant kinase activity has been 
identified as a major factor contributing to disease progression in various human 
malignancies. The targeted inhibition of protein kinases has therefore emerged as a major 
therapeutic approach and fueled the development of various kinase-selective drugs, such 
as cell-permeable small molecule inhibitors, with the potential to address currently unmet 
medical needs in cancer therapy. 
In this project, we now seek to detect the quantitative distribution of the targeted 
molecular therapy Imatinib (IMAT) and to define the biological mechanisms that govern 
the ability of molecular targeted therapies to induce death of tumor cells in the brain.  
The results of these studies will assist us in improving and validating future molecular 
targeted therapies for malignant brain tumors. 
 
Introduction 
 
PDGF in Gliomas 
 Tyrosine kinases are a group of protein kinases critical to signal transduction 
pathways involved in cell proliferation, growth, survival, adhesion, motility and 
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differentiation.  The group includes receptor tyrosine kinases (RTKs) which are 
transmembrane proteins containing an extracellular binding domain that binds ligands 
and an intracellular kinase domain that activates intracellular signaling pathways.  
Platelet derived growth factor (PDGF) is a member of this family and induces cellular 
growth, proliferation and differentiation by activating intracellular signaling mechanisms 
via platelet derived growth factor receptor (PDGFR).
72
  PDGF consists of a dimer of two 
polypeptide chains, A and B with a 60% homology.  They can assemble as a heterodimer 
(PDGF-AB) or homodimers (PDGF-AA or PDGF-BB).  The receptors are membrane 
glycoproteins expressed in several tissue cells and consist of two subunits α and β 
encoded by two different genes.
73, 74
  There are also more rare forms of PDGF being C 
and D.
75
 All forms of PDGF and PDGFR have been found to be overexpressed in human 
brain tumors such as menigiomas, astrocytomas, oligodendrogliomas, medulloblastomas, 
and ependymomas and are associated with the more malignant tumors.
72, 74, 75
  Because of 
the numerous genetic and physiological alterations observed in human glioma the 
importance of PDGF signaling is still not fully understood.  But PDGF autocrine loops 
are thought to both initiate and sustain the transformed phenotype of glioblastoma cells.
76
  
This notion has experimental support. Glioma-like tumors can be induced in mice after 
overproduction of PDGF in mouse brain. Also, some glioma-derived cell lines have been 
blocked by interference with PDGF receptor signaling.
77
 
 
Imatinib 
Imatinib is a small molecule drug used for the treatment of some cancers.  It is 
known to inhibit PDGFR-α, PDGFR-β, Bcr-Abl, c-Fms, and c-kit tyrosine kinases.78  As 
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described in the previous section dysregulated PDGFR kinase activity has been linked to 
a variety of cancers, including glioblastoma. 
72, 74, 75
   IMAT has been shown, in animal 
models, to enhance the antitumor effects of chemotherapeutic agents due to inhibition of 
PDGFR phosphorylation and therefore may have potential efficacy as an adjuvant 
therapy.
79
 The mechanism of action is thought to be growth delay through growth arrest 
in the G0-G1 phase rather than inducing apoptosis.  IMAT inhibits the autocrine PDGFR 
stimulation which leads to decreased cell population.
76, 79
 
 
Use of Animal Models 
In order for scientists to fully understand how cancers develop, spread through the 
body and discover new and effective ways of diagnosis and treatment, it is necessary to 
carry out research on live animals.  Animal studies are essential to understand the 
complexities of the biological processes that are involved in cancer within living 
organisms.  They are also required before any trials for new drugs can begin in humans. 
While the use of nonhuman animal models is a common component of biomedical 
research, the role of animal models in research, its scientific and ethical justification and 
legal regulations and policies need to be considered before any project can begin.
80, 81
  
Approval and animal protocols must be submitted and approved by the Institutional 
Animal Care and Use Committee (IACUC).
82
  Careful consideration also needs to be 
taken to ensure that the animal model selected will biologically represent the disease or 
condition that you are investigating.   
When designing a MALDI IMS experiment it is important to select the proper 
small animal model. In the early phases of drug discovery and development, therapeutic 
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candidates cannot be administered to humans, and therefore, predictions about the PK/PD 
properties have to be made from an in vivo animal model. The two most common species 
include rats and mice, which have different metabolic rates and pathways; hence 
providing vastly different metabolite and distribution information. In general, rats are 
used for PK/PD studies due to their similarity to human pathways to determine the 
ADME of an administered pharmaceutical.  In other cases, mice may be preferred, since 
many more models of disease are available in mice rather than rats.
83
 Taking all of this 
into consideration a syngenic mouse GL26 glioma model was chosen.  It has been shown 
that GL26 experimental murine gliomas share most characteristic histological features 
with human gliomas.
84
 
 
Results 
 
Animal Implantation and Drug Dosing 
To start the study two sets of mouse implantations and drug dosing were done.    
One set was used to evaluate the effects of chronic dosing of the imatinib.  For this set of 
experiments 25 mice were implanted with GL26 cultured tumor cells and tumor growth 
was allowed to occur for 12 days.  (Extra mice were implanted to take into account any 
casualties.)  On day 12 the IMAT treatments began and continued for six days.  Group 
one was the control group dosed once a day for six days with saline solution (p.o.).  
Groups two through five were dosed once a day with 100 mg/kg IMAT (p.o.) for 1 day 
(1d), 2 days (2d), 4 days (4d) and 6 days (6d) respectively.  Twenty-four hours after the 
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final dose the mice were sacrificed, the brains were excised, immediately flash frozen in 
liquid nitrogen and stored at -80 °C.  
The second set of mice was to evaluate the effects of a single imatinib dose over 
time.  Five groups of five mice each were evaluated for a treatment response. 30 mice 
were implanted with GL26 murine tumor cells and tumor growth was allowed to occur 
for 12 days.  (Extra mice were implanted to take into account any casualties.)    On the 
12th day mice were given a single dose of 100 mg/kg IMAT (p.o.) and then sacrificed in 
groups according to the time point they would represent.  Groups were sacrificed 2 hours 
(2h), 6 hours (6h), 12 hours (12h) or 24 hours (24h) after the administration of the IMAT 
dose.  Control mice were sacrificed 24 hours after a dose of saline solution (p.o.). The 
brains were excised and immediately flash frozen in liquid nitrogen and stored at -80 °C. 
  
Drug Detection and Quantitation 
 When deciding to use a treatment for a particular disease, one of the most 
important things to investigate is whether or not the compound is getting to the area that 
needs to be treated.  To this end, the distribution of IMAT was determined in tumor 
bearing mouse brain tissues to elucidate if the drug was penetrating through the Blood 
Brian Barrier (BBB) or the Blood Tumor Barrier (BTB). The BBB is the bottleneck in 
brain drug development and is the single most important factor limiting the future growth 
of neurotherapeutics.
85
   
 Sections for analysis were cut on a cryostat at 12 µm and then prepared for 
MALDI IMS accordingly by applying DHB matrix with d8-IMAT internal standard 
using a Portrait™ 630 (Labcyte Inc).  All sections were analyzed on a MALDI LTQ XL 
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(Thermo Scientific, Inc.) monitoring the major collision induced fragment of IMAT at 
m/z 394.1.  To display the images, the data was input into Biomap and then normalized to 
the d8-IMAT internal standard by taking the ratio of the IMAT signal over the d8-IMAT 
signal at each location.  IMAT signal was detected very strongly from the tumor area of 
the mouse brain with much less signal coming from the normal brain tissue (Figure 15).  
The MALDI images are shown in the grey boxes and below are the scanned images of 
Hemotoxylin and Eosin (H&E) stained serial sections of mouse brain tissue.  These 
images show that the IMAT is penetrating into the brain mainly in the tumor region. 
Various tissue types can have different ionization effects, so to determine if the 
image results were an effect of differing ionization efficiencies standard solutions were 
analyzed on both the normal and tumor tissue types. DHB matrix was made in 50% 
methanol with 2 µM of d8-IMAT as an internal standard. IMAT standard was then spiked 
into aliquots of the matrix resulting in concentrations of 10000 ng/ml and 1000 ng/ml.  
The spiked matrix was spotted on both the tumor bearing portion of a non-dosed brain 
and also the non-tumor bearing areas of the tissue resulting in matrix spots that contained 
68000 fg of IMAT and matrix spots with 6800 fg of IMAT.  Spectra were acquired from 
each of the spots and the intensities were recorded.  There was not a significant increase 
or decrease in the control or tumor regions intensities for the IMAT or d8-IMAT signals 
and no significant differences of the IMAT/d8-IMAT ratios.  The percent difference 
between standard intensity ratios from the tumor and normal regions was below 5%. 
Table 2 shows the IMAT/d8-IMAT ratio averages taken from the matrix spots containing 
either 68000 or 6800 fg of IMAT.  Both the tumor and normal regions show the same 
ionization efficiency for the IMAT signal.  These results indicate that the signal 
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differences seen between the tumor and normal areas of the dosed brain images are not 
due to a difference in ionization effects of the tissue but are true differences in the amount 
of IMAT present in the tissues.   
  
 
 Figure 15:  IMAT images taken on a MALDI LTQ XL monitoring for CID fragment  
m/z 394.1.  A) A tumor bearing mouse brain dosed with a saline solution.  The grey box 
contains the MALDI image and below is an H&E stained section of the mouse brain.  B)  
A tumor bearing mouse brain dosed with IMAT.  The grey box contains the MALDI 
image and below is an H&E stained serial section of the mouse brain.  
 
 
MALDI images were acquired for each of the brains within the respective dosing 
groups.  For the acutely dosed mice it can be seen that the IMAT signal is strong at 2h 
post dose in the tumor regions and is at its highest concentration 6h post dose.  From 
there the amount of detected IMAT decreases at the 12h and 24h post dose time-points as    
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Table 2: IMAT/d8-IMAT signal ratios taken from standards spotted on tumor and normal 
tissues within a mouse brain 
 
 68,000 fg of IMAT 6,800 fg of IMAT 
Normal 22.29 ± 0.69     %RSD=3.12 2.69 ± 0.07  
%RSD=2.64 
Tumor 21.19 ± 0.91 %RSD=4.32 2.66 ± 0.10 
%RSD=3.78 
% Difference 4.9 1.1 
 
 
seen in Figure 16. For the chronically dosed samples the amount of detected IMAT is 
relatively constant in the normal regions of the brain tissue but there is an increase of 
IMAT signal in the tumor region after 4d and 6d of continued treatment shown in Figure 
17. 
With the images providing a qualitative assessment for the amount of IMAT 
present in each of the dosing groups, experiments needed to be performed to 
quantitatively assess the absolute IMAT concentration in the brain tissues.  This was 
accomplished by following the MALDI quantitation protocol developed in Chapter II and 
outlined in Appendix A.  First 12 µm sections were collected from each brain and 
weighed on a microbalance immediately following sectioning.  A 12 µm GL26 implanted 
brain section had an average mass of 0.64 mg with an 8% RSD.  Brain sections were then 
stained and scanned using a flatbed scanner at 3200 dpi to provide images for tissue area  
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Figure 16:  Imatinib images for the acutely dosed mouse brain samples.  The top-most 
row shows the imatinib distribution for a representative brain at each acute time-point 
(images acquired on the Thermo MALDI LTQ). The bottom row displays the H&E 
stained section for the representative brains.  
 
 
 
 
 
 
Figure 17:  Imatinib images for the chronically dosed mouse brain samples.  The top-
most row shows the imatinib distribution for a representative brain at each chronic time-
point (images acquired on the Thermo MALDI LTQ). The bottom row displays the H&E 
stained section for the representative brains.  
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calculation.  The images were imported into Adobe Photoshop and the area of a 12 µm 
GL26 implanted brain section was determined to be 62.37 mm
2
 with a 0.6% RSD.  The 
area of the laser to be used for spectra acquisition was determined to be 0.0035 mm
2
 
(Chapter II) and using this information the amount of tissue sampled within one laser 
position can be calculated: 62.37 mm
2
/0.64 mg = 0.0035 mm
2
/ X mg.  The amount of 
tissue sampled is 3.59x10
-5
 mg.  Next, a calibration curve of IMAT was constructed.  
Matrix solutions were spiked with IMAT to yield final concentrations of 100, 10, 1, 0.1 
ng/ml along with 2 µM of d8-imatinib as the internal standard.  Using the Portrait™ 630, 
matrix was deposited onto non-dosed brain tissue sections in known volumes resulting in 
680, 68, 6.8 and 0.68 fg of IMAT along with a blank standard of matrix only with 
internal standard.  Spectra were acquired from each of the spots, using 600 laser shots per 
position and 14 positions per matrix spot.  This totaled 140 different laser positions for 
each standard due to the fact that ten matrix spots per calibration standard were analyzed.  
For each matrix spot the total signal of the IMAT and the d8-IMAT was summed using 
in-house software (Frappienator) and the ratio of IMAT/d8-IMAT was taken. The ratios 
for each calibration standard were plotted and a linear fit was calculated.   Each point on 
the curve had a RSD no higher than 25% and the curve had excellent linearity with an R
2
 
value of 0.9996 as shown in Figure 18.  From this curve, the LOD of imatinib with this 
acquisition method by MALDI, was determined to be approximately 20 ng/g of tissue. 
 IMAT dosed tissue sections were cut for each brain and spotted with DHB in 50% 
methanol spiked with 2 µM of d8-IMAT as an internal standard.  From each dosed 
section 140 positions were analyzed totaling 5600 spectra for each brain.  The average 
ratio of IMAT/d8-IMAT signal was taken for each time-point and plugged into the  
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Figure 18:  Imatinib Calibration Curve obtained using MALDI IMS Methods  
 
calibration curve equation to calculate the average amount of IMAT present in fg. 
Dividing this value by the amount of tissue sampled gives the IMAT concentration for 
each of the dosed tissues in ng of IMAT within 1 g of tissue.  Table 3 shows the 
concentration values calculated for the 2h, 6h, 12h, 24h, 2d, 4d and 6d mice in both the 
tumor and normal regions of the brain.  Results show good reproducibility with a RSD no 
higher than 15% for the normal tissue samples analyzed.  The tumor tissue region showed 
a bit more variability with an RSD no higher than 30%.  This is most likely due to the  
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Table 3:  Imatinib concentrations calculated by MALDI-IMS Methods 
ng/g 2h 6h 12h 24h 2d 4d 6d 
Normal 595.35 773.90 546.84 496.72 499.42 514.27 496.38 
% RSD  6 8 3 2 9 15 6 
Tumor 12255.82 53826.45 6936.43 546.59 572.20 1940.11 1651.40 
 % RSD  32 27 36 9 6 27 4 
 
 
fact that the tumor bearing area of the brain is much more heterogeneous than the normal 
area.  Gliomas are known to be heterogeneous both phenotypically and genotypically.
86-88
 
 Traditional drug quantitation techniques requiring homogenization and extraction 
followed by analysis on a LC-triple quadrapole system were also performed on the 
tissues.  The calibration curve for this experiment was constructed using an IMAT 
concentration range from 10 to 3000 ng/ml and the response curve was generated using a 
weighted (1/x) least-squares linear regression model.  The measurement of IMAT was 
linear with respect to concentration across a minimum of three orders of magnitude with 
an R
2
= 0.9992.  The LOD for imatinib was 1 ng/ml of tissue homogenate.  The recovery 
of imatinib extraction was estimated to be around 80% as demonstrated in previous 
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studies.
89, 90
  Samples of tissue from both tumor and normal tissues of the brain for each 
dosing group were prepared and then analyzed.  Using the response curve, average 
imatinib concentrations were found for each dosing group and are shown in Table 4.  As 
with the MALDI results, the RSD for the normal samples was around 15% and the tumor 
samples around 30%, again speaking to the higher heterogeneity of the tumor tissue.   
 
Table 4:  Imatinib concentrations calculated by LS-MS/MS Methods 
ng/g 2h 6h 12h 24h 2d 4d 6d 
Normal 542.31 710.48 401.92 355.26 240.54 357.12 361.32 
% RSD  11 6 14 16 8 16 16 
Tumor 6099.49 11632.86 1492.48 243.34 377.72 733.95 570.20 
 % RSD  33 5 9 35 15 6 11 
 
 
The quantitation results for both the MALDI and the LC methods were plotted on 
a line graph for comparison.  Figure 19 shows the IMAT concentrations in ng/g (ng of 
IMAT per g of tissue) for the acutely dosed mouse groups, 2h, 6h, 12h and 24h.  The blue 
trace represents the results obtained by LC-MS/MS and the red trace represents the 
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results obtained by MALDI-IMS.  The tumor tissue results are plotted on a graph 
separately (top graph) from the normal tissue results (bottom graph). The values 
calculated using the MALDI method are higher in all instances than the values calculated 
using the LC method with a percent difference between the two methods as low as 30% 
for the tumor samples and 8% for the normal samples.  Figure 20 shows the IMAT 
concentrations in ng/g (ng of IMAT per g of tissue) for the mice dosed chronically, 1d, 
2d, 4d, and 6d.  The tumor (top graph) and normal (bottom graph) results are plotted 
separately with the blue trace representing the LC-MS/MS results and the red trace 
representing the MALDI-IMS results.  Here again the MALDI results are all higher than 
those of the LC results.  Across all of the samples the average percent difference between 
the two methods is 40% with the results from the MALDI being higher in all instances.  
Looking at the plotted data, the MALDI and LC results follow the same trends of drug 
concentration across the different dosing groups. 
 
Proteome Response Study 
 
In order to evaluate for a pharmacodynamic response to the imatinib presence in 
the tumor bearing portion of the brains, each brain was imaged by MALDI-TOF MS.  
Standard MALDI imaging preparation steps were employed to get the samples ready for 
analysis. Samples were cut on a cryostat, thaw mounted onto target slides, dried and then 
matrix application was performed on a Portrait™ 630 spotter before imaging on a Bruker 
Autoflex TOF MS.  Three sections were analyzed for each brain and sample acquisition 
was randomized to eliminate bias.  Serial sections were cut for each brain and stained 
according to a standard cresyl violet staining protocol. These stained sections were 
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Figure 19: Imatinib quantitation results in ng/g for the acutely dosed mice.  The blue trace 
represents the results obtained by LC-MS/MS methods.  The red trace represents the 
results obtained by MALDI-IMS methods.  The graph on top shows results for the tumor 
tissue and the graph on the bottom shows results for the normal tissue.  
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Figure 20: Imatinib quantitation results in ng/g for the chronically dosed mice.  The blue 
trace represents the results obtained by LC-MS/MS methods.  The red trace represents the 
results obtained by MALDI-IMS methods. The graph on the top shows results for the 
tumor tissue and the graph on the bottom shows results for the normal tissue.  
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scanned on a Mirax Scanner (Carl Zeiss MicroImaging) and the images were saved.  
After acquisition of the MALDI images it was possible to import, co-register and overlay 
the stained image with the MALDI image and optical image of the spotted section using 
Flex Imaging software (Bruker Daltonics, Germany).  This allowed for the visualization 
of all the MALDI images and for spectra from specific regions in the brain to be selected 
and saved into separate folders for further processing and statistical analysis.  With the 
assistance of a neuro-oncologist, the tumor bearing areas of the brain tissue were 
identified and spectra from these areas were extracted.  Figure 21 shows the co-
registration and spectra selection process. 
 
 
 
Figure 21:  Workflow for extracting regions of spectra from an image data set.  A) 
Optical image of a matrix spotted brain section B) Scanned image of a cresyl violet 
stained serial brain section C) Co-registrated overlay of the optical and stained image.  
Red outlined areas indicate where spectra were selected from the tumor region of the 
brain and put into a folder.  Black outlined areas indicate where spectra were selected 
from the normal region of the brain and put into a folder.  These folders of spectra then 
underwent spectral processing procedures and statistical analysis. 
 
 
MALDI IMS analysis was performed on a total of 40 brains, with three sections 
being imaged for each brain.  This resulted in 120 sections analyzed and approximately 
10,000 spectra acquired.  From each brain section 15 or more spectra were selected from 
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the tumor region so that there were a minimum of 45 spectra representing each brain and 
225 spectra representing each dosing group. 
All spectra were processed using ClinPro Tools, commercially available software 
from Bruker Daltonics (Germany).  Once the spectra had undergone baseline subtraction, 
smoothing, normalization, realignment and peak picking the data for each spectrum was 
exported collectively into a feature table (a list of each m/z value and its corresponding 
intensity value for each spectrum).  Using these feature tables, various analyses and 
statistical tests were performed to evaluate the protein changes that occurred with respect 
to amount of IMAT present.   
The feature tables generated from ClinPro Tools were put into the program 
MiniTab® (MiniTab Inc., State College, Pennsylvania) to create interval plot of each m/z 
value as its analyte signal progressed from the dosing group with low drug concentration 
to the dosing group with the most IMAT presence. Figure 22 shows example interval 
plots for m/z 4195 and 14422.  These plots provided a visual inspection of the m/z trends 
as a result of drug concentration.  Once imported into MiniTab® and interval plots had 
been reviewed, one-way analysis of variance (ANOVA) statistical analysis was computed 
for each m/z.  An ANOVA algorithm tests the hypothesis that the means of several 
populations are equal.  A one-way ANOVA can be used to tell you if there are 
statistically significant differences among the level means. The null hypothesis for the 
test is that all population means (level means) are the same. The alternative hypothesis is 
that one or more population means differ from the others.  ANOVA measures two 
sources of variation in the data and compares their relative sizes using the F-statistic 
finding the variance between the groups in relation to the variation within the groups.  A  
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Figure 22: Example Interval Plots created in the MiniTab® software program.  A)  
Interval Plot of m/z 4195 demonstrating an increase in signal intensity going from no 
IMAT presence in the samples to a high concentration of IMAT in the samples.  B) 
Interval plot of m/z 14422 demonstrating a decrease in signal intensity going from low to 
high IMAT concentrations. 
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large F-value is evidence against the null hypothesis and means more difference between 
groups that within.  The p-value computed denotes the probability that the variation for 
that group is random.  For all experiments a p-value less than 0.05 is considered 
statistically significant. 
Since the ANOVA output only verifies that differences are present between the 
dosing groups, it does not indicate how these differences are occurring.  Differences 
could be randomized among the dosing groups, or there could be patterns showing a 
significant increase or decrease associated with IMAT concentration presence.  To verify 
in what order the changes were occurring, the software program Significance Analysis of 
Microarrays (SAM, Stanford University, California) was used. Two by two comparisons 
were made between each of the dosing groups in order of least IMAT concentration to 
most IMAT concentration using a simple t-test for all of the m/z values that showed a 
validated significant ANOVA score.   
SAM is a statistical technique for finding significant features proposed by Tusher, 
Tibshirani and Chu.
91
  It uses repeated permutations of the data to determine if the 
expression of any features is significantly related to the response. The cutoff for 
significance is determined by a tuning parameter delta, chosen by the user based on the 
false positive rate. One can also choose a fold change parameter, to ensure that the 
identified feature change meets a pre-specified amount.  The results of these comparisons 
were used to show which features demonstrated a consistent significant increase in signal 
in response to IMAT concentration or a significant decrease in signal in response to 
IMAT concentration.  These results were again visually confirmed with the interval plots 
for each m/z value as well as individual spectral analysis from the average traces for each 
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dosing group.  Figure 23 shows an overlay of average spectra representing each IMAT 
treatment group.  Inset zoom plots of the spectra show examples of features that either 
increase or decrease as a result of the IMAT concentration in the tissue. 
 
 
 
 
Figure 23: Overlay of average protein spectra from each treatment group at varying 
concentrations of IMAT.  Examples of statistically significant features across the mass 
range are displayed in the zoom plots with trends indicated by the red arrows next to the 
m/z values. 
 
The statistical methodologies resulted in 99 m/z values being found to have either 
a positive or negative correlation with the IMAT concentration in the brains and 43 of 
these features showed a significant difference as early as 2h after drug administration 
across the mass range of (4-30 kDa) as shown in Table 5.  
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Table 5:  Statistically significant features affected by IMAT presence 
m/z Trend Fold 
Change 
SAM 
score 
ANOVA 
p-value 
ANOVA 
F Score 
ANOVA 
R-Sq 
AUC 
4195 up 1.7 9.8 < 0.005 48.67 16.54 0.90 
4445 up 1.4 3.8 < 0.005 6.09 2.42 0.70 
4606 up 2 7.5 < 0.005 17.54 6.67 0.76 
4682 up 1.4 7.7 < 0.005 30.07 10.91 0.85 
4710 up 1.5 4.6 < 0.005 17.17 6.54 0.85 
4768 up 2.1 6.4 < 0.005 14.29 5.5 0.69 
4901 up 1.4 4.5 < 0.005 13.41 5.18 0.76 
4965 up 1.8 7.7 < 0.005 22.81 8.5 0.73 
5143 up 1.6 5.5 < 0.005 16.09 6.15 0.72 
5172 up 2.2 6 < 0.005 18.77 7.1 0.71 
5445 up 1.4 8 < 0.005 25.71 9.48 0.83 
6345 down 1.2 -2.9 < 0.005 41.20 14.37 0.78 
6547 up 1.5 7.6 < 0.005 31.99 11.53 0.84 
6574 up 1.5 10.7 < 0.005 39.98 10.92 0.91 
7108 down 1.3 -7.2 < 0.005 47.15 16.11 0.78 
7750 down 1.2 -7.5 < 0.005 64.87 20.9 0.63 
7793 up 1.2 6.1 < 0.005 22.18 8.28 0.85 
7829 up 1.4 4.1 < 0.005 10.78 4.31 0.75 
7858 up 1.3 4.2 < 0.005 18.88 6.76 0.74 
7891 up 1.4 5.2 < 0.005 21.26 7.97 0.73 
7933 up 1.9 5.9 < 0.005 28.,23 10.31 0.80 
8602 down 1.2 -5.3 < 0.005 38.48 13.55 0.66 
9071 up 1.3 3.1 < 0.005 18.24 6.92 0.68 
9203 up 1.2 3.1 < 0.005 4.40 1.62 0.70 
9534 up 1.4 3.2 < 0.005 7.26 2.87 0.73 
9638 up 1.2 3.3 < 0.005 17.60 6.69 0.71 
9701 up 1.5 5.5 < 0.005 18.38 6.97 0.79 
9740 up 1.8 11.9 < 0.005 23.32 8.68 0.92 
9777 up 1.2 3.8 < 0.005 32.36 11.65 0.68 
9912 up 1.3 7.2 < 0.005 28.20 9.94 0.77 
10256 down 1.3 -6.5 < 0.005 19.27 6.9 0.60 
10640 up 1.3 3.5 < 0.005 17.06 6.5 0.70 
10953 up 1.6 5.7 < 0.005 37.72 13.32 0.74 
11309 down 1.2 -7.6 < 0.005 36.72 13.01 0.50 
11337 down 1.2 -8.6 < 0.005 56.83 18.47 0.57 
11517 down 1.7 -21.7 < 0.005 107.82 30.52 0.96 
11841 down 1.3 -5.7 < 0.005 27.19 9.97 0.62 
12203 down 1.3 -7.9 < 0.005 69.88 22.16 0.66 
12285 down 1.4 -7.7 < 0.005 50.20 16.98 0.75 
13897 down 1.3 -8.7 < 0.005 42.31 14.07 0.83 
14053 down 1.1 -4.1 < 0.005 8.75 3.44 0.57 
14422 down 1.4 -10.8 < 0.005 47.17 16.12 0.73 
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For the table the first column lists the m/z values that were found to be significant 
followed by the trend up or down relative to the increasing amount of IMAT presence in 
the second column. The third column lists the fold change which represents the maximum 
change found between the two group extremes in the data set; between the samples with 
no IMAT presence and the samples with the maximum amount of IMAT presence in the 
tissues.  This value was calculated by the SAM analysis along with a SAM score which is 
shown in column four.  The score assigned to each m/z value was based on the change in 
expression relative to the standard deviation of repeated measurements. It is the 
standardized change in expression.  A positive SAM score means that there is an increase 
of the signal going from group one to group two, the opposite is true for a negative SAM 
score.   
The next three columns list the results from the ANOVA test.  The p-value 
computed denotes the probability that the variation for that group is random.  For all 
experiments a p-value less than 0.05 was considered statistically significant.  The F-Score 
represents the results from the F-statistic stating that there was more difference between 
groups that within the groups.  A larger F-Score indicates a stronger confidence.  The 
ANOVA R-sq is often referred to as the coefficient of determination and is a measure of 
the „goodness of fit‟ of the regression model. If R-sq equals zero, then there is no linear 
relationship between the dependent and independent variables; if R-sq equals 1, the 
relationship is perfect and all values of the dependent and independent variables lie on a 
straight line.   
The AUC values listed in the final column were obtained from a Receiver 
Operating Characteristic (ROC) curve for each peak.  It is an evaluation of the 
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discrimination quality of a peak.  The area under the ROC curve (AUC), measures 
discrimination, which is the ability of the test to correctly classify two groups.  In this 
instance the AUC is the score between the samples with the least IMAT concentration 
and the samples with the most IMAT concentration.  Thus, the AUC measures the ability 
of a particular m/z to discriminate the two groups. The closer the area is to 0.5, the less 
useful the test is, and the closer it is to 1.0, the better the test is.  This test was performed 
in the ClinProTools (Bruker) software. 
MALDI IMS produces mass specific data of the intact protein species; however, 
the m/z alone is often not sufficient to positively identify the protein, as the biologically 
active protein may have undergone post-translational modifications.  Robust protein 
identification is routinely achieved through protein separation/isolation, proteolytic 
digestion, sequencing of peptides by LC MS/MS, and matching the peptides to genome-
based protein databases.  The MALDI peaks confidently identified using these strategies 
are shown in Table 6.  The molecular weight (MW) and corresponding protein 
identifications are listed along with the percent coverage, modifications, SwissProt 
Identification number, the number of peptides identified, peptide residues sequenced, and 
the protein trend as affected by the concentration of IMAT present. 
 
Discussion 
From the image data it can be determined that the IMAT is getting to the tumor, 
crossing the BTB, but there is substantially less IMAT penetrating into the normal, non-
invaded, parts of the brain through the BBB.  In previous studies it has been shown that 
the permeability of the BTB is greater than that of the BBB.
92, 93
  BBB and BTB  
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Table 6:  Protein Identifications for tumor implanted mouse brains treated with imatinib 
 
 
 
 
 Protein Name 
% coverage 
of 
unprocessed 
precursor 
Modifications 
(amino acid 
chain) 
Swissprot 
Primary 
Accession 
Number 
Number 
of 
Peptides 
Peptide 
Residues 
covered Trend 
4964 Thymosin beta-4 38 *(8-50) P20065 1 27-45 up 
6546 
40S ribosomal protein 
S29 19 (2-56) P62274 5 34-40, 49-56 up 
7829 
cAMP-dependent 
protein kinase inhibitor 
alpha 48 (2-76) P63248 2 21-58 up 
7890 
Guanine nucleotide 
binding protein 
G(1)/G(S)/G(0) subunit 
gamma-13 13 *(2-67) Q9JMF3 2 45-54 up 
9202 
Cytochrome c oxidase 
subunit 7A2 25 *(2-83) P48771 2 34-56 up 
9637 
Cytochrome b-c1 
complex subunit 8 54 (2-82) Q9CQ69 3 
11-25, 49-71, 
74-82 up 
9911 
Acyl-CoA-binding 
protein 34 *(2-87) P31786 5 34-53, 73-83 up 
10255 ATP synthase subunit f 24 *(2-88) P56135 2 17-39 down 
10639 Protein S100-B 15 *(2-92) P50114 2 7-21, down 
10952 
Protein S100-A111 
(Calgizzarin) 16 (2-98) P50543 2 8-18, 51-57 up 
11336 ATP synthase subunit g 36 *(2-103) QPCPQ8 3 
12-24, 36-54, 
96-103 down 
11516 cytochrome c, somatic 32 *(2-105) P62897 5 
29-39, 40-56, 
93-100 down 
11840 
FK506-binding protein 
1B 23 *(1-108) Q9Z212 2 2-14, 59-72 down 
12202 Snrpf protein 17 (1-112) Q6NZQ3 2 92-99, 100-112 down 
13896 
Small nuclear 
ribonucleoprotein D3 13 *(2-126) Q91VM2 3 55-64, 70-78 down 
14052 Beta-synuclein 37 (1-133) Q91ZZ3 5 33-84 down 
14421 Bol A like protein 1 26 *(1-137) Q9D8S9 3 
22-37, 40-52, 
77-85 down 
*acetylated N-terminus (+42 Da) 
       
 
 
permeability measured by quantitative autoradiography (QAR) shows that the BTB has a 
Ki value of 12 while the Ki value of the BBB averages at 3. (The Ki value is the 
unidirectional transfer constant (µl/g/min) of a  [
14
C] labeled tracer.)
92
  In another study 
brain metastasis uptake of 
14
C-paclitaxel and 
14
C-doxorubicin was generally greater than 
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normal brain.
93
  There is general agreement that most chemotherapy agents achieve only 
relatively low concentrations in the normal central nervous system, that the blood-brain 
barrier is variably disrupted in malignant brain tumors, and that the concentration of 
chemotherapy drugs in the brain adjacent to tumor is intermediate between 
concentrations achieved in brain tumors versus normal brain.  Average drug 
concentrations in brain adjacent to tumor are lower than those within brain tumors
94
  This 
difference in BTB and BBB permeability would explain why the IMAT signal is much 
stronger in the tumor region of the brain.  This is also supported by a study that shows the 
IMAT can reach significant intratumoral concentrations in patients  with glioblastoma 
multiforme and a disrupted BBB.
95
   
The IMAT shows no signal in the control tissues, very high signal at 2h and then 
reaches its most intense at 6h.  Following that at 12h and 24h the signal decreases.  It has 
been shown that IMAT is rapidly absorbed after oral administration with peak plasma 
concentrations between 2h-6h having maximum plasma concentrations of 0.921 ± 0.095 
μg/ml (mean ± S.D., n = 4).96  Following that the terminal elimination half life was 
determined to be 13.5 ± 0.9 h.
96
  IMAT is extensively distributed into tissues and highly 
protein bound, predominantly to albumin and α1-glycoprotein (AGP).97  The image 
results correspond to the previous studies of IMAT absorption with highest signal 
intensities between 2h and 6h then drastically decreasing at 12h and 24h.  In the chronic 
dosed tissues there is little signal in the 1d, 2d, and then increased signal in the 4d and 6d 
samples indicating there is an additive effect of the IMAT with chronic treatment.  By 
continually taking a drug a steady-state of the drugs concentration can be reached and this 
is optimal for maximum efficiency of the treatment.  It takes somewhere between 5 and 6 
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half-lives for a drug to reach steady state.
98
 With the half-life of IMAT being around 12h 
it would be expected that by day 6 the IMAT presence in the brain has reached its steady 
state concentration. 
Using the newly developed MALDI-MS/MS methods (Chapter II), the absolute 
concentration of the IMAT in the brain tissues was able to be calculated.  When 
compared to the results obtained with the LC-MS/MS results there is an average percent 
difference of 40% with the MALDI results consistently higher in every instance.  Part of 
the difference is most likely due to the fact that the recovery of the LC IMAT extraction 
was around 80%, so there is drug lost through the extraction process.  There could have 
also been drug lost as a result of the IMAT sticking to the HPLC column during analysis.  
Another explanation could be that for the LC method, the entire tissue section analyzed is 
homogenized thereby averaging the entire tissue‟s drug concentration for the sample.  For 
the MALDI, the spatial integrity is maintained, and the spots selected for analysis each 
receive their own IMAT concentration calculation and thus could represent areas of 
higher concentration locally than the average of the entire tissues concentration.  Despite 
the higher concentrations calculated by the MALDI-IMS method, the trends of 
concentration from dosing group to group remains the same for both the MALDI and LC 
results.    
  Detection and identification of changes in the proteome of glioma as a result of 
targeted molecular therapies provides invaluable insights into the drug‟s activity.  
Typically, the proteins affected by IMAT administration are not extensively known. 
Many drug effects occur primarily when the blood level of the drug is either going up or 
down.  When the drug reaches a steady state, these effects can be attenuated or 
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completely absent.  Therefore the most drastic changes will be seen in the samples with 
most varied levels of IMAT present as within the acutely dosed sample set. 
A number of protein signals were found to have either increased or decreased 
signal intensities as a result of the IMAT presence.  A group of these proteins are found 
to be involved in the mitochondrial electron transport chain (ETC).  Cytochrome c 
oxidase subunit 7a2 (part of complex IV) and cytochrome b-c1 complex subunit 8 (part 
of complex III) were found to have an increase in intensity as the concentration of IMAT 
increased, while cytochrome c and ATP synthase subunits f and g (parts of complex V) 
had a decrease in intensity. Adaptive response to agents that challenge cellular 
homeostasis involves important changes in mitochondrial function. Given their crucial 
role in cell physiology, mitochondria are among the first responders to various stressors.
99
   
 The ETC or respiratory system occurs in the cristae of the mitochondria, where a 
series of membrane associated complexes, cytochromes and coenzymes, mediate 
biochemical reactions to produce ATP.  These cytochromes and coenzymes remove 
electrons from the donor, NADH, and pass them to a terminal electron acceptor, O2 via a 
series of redox reactions. The reactions create a proton gradient across the mitochondrial 
inner membrane, resulting in the transmembrane proton gradient used to make ATP via 
ATP synthase in oxidative phosphorylation.
100
  The process of electron transport consists 
of four complexes. Complex I, which consists of NADH dehydrogenase (synonym: 
NADH-ubiquinone oxidoreductase), removes two electrons from NADH and transfers 
them to the carrier, ubiquinone.  Simultaneously, Complex I moves four protons across 
the membrane to produce a proton gradient later used to generate ATP through oxidative 
phosphorylation. Complex II, which consists of succinate dehydrogenase, funnels 
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electrons into the quinone group by removing electrons from succinate and transferring 
them via FAD to the quinone.  Complex III (cytochrome bc1 complex) removes two 
electrons from the quinone and transfers them to two molecules of cytochrome c, a water-
soluble electron transporter located on the outer surface of the membrane. 
Simultaneously, Complex III moves two protons across the membrane, producing a 
proton gradient consisting of four total protons. When electron transfer is somehow 
hindered in Complexes I and III, there is a tendency for premature electron leakage to 
oxygen, resulting in the formation of superoxide. Complex IV, consists of cytochrome c 
oxidase. It is responsible for removing four electrons from the four molecules of 
cytochrome c and transferring them to O2, producing two molecules of water. 
Simultaneously, it also moves four protons across the membrane, producing a proton 
gradient. Finally, this proton gradient is utilized by the ATP synthase complex, also 
known as complex V to make ATP via oxidative phosphorylation. 
The changed intensities of the proteins associated with the ETC can possibly be 
explained by evaluating the mechanisms of resistance to RTK inhibition such as 
antiapoptotic mechanisms.  The mechanisms of resistance to RTK inhibition have not 
been fully elucidated, but is has been shown that tumor cells unresponsive to EGFR 
inhibitors are characterized by reduced induction of apoptosis. 
101
   Furthermore, while 
IMAT dramatically increases apoptosis in BCR-ABL–positive chronic myelogenous 
leukemia and in gastrointestinal stromal tumors, it does not induce apoptosis when 
administered to glioblastoma cells either in vitro or in vivo, even at high 
concentrations.
76, 102
 Antiapoptotic mechanisms that render glioma cells resistant to 
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cytotoxic agents (chemotherapy and radiotherapy) may also modulate their response to 
targeted therapies such as RTK inhibitors.
103
   
A recent study into the chemoresistance of temozolamide (TMZ) showed that 
there were changes involving ETC.  They explored changes in paired patient samples 
both before and after TMZ treatment.  They found that complex II, III, and IV activities 
increased significantly (p = 0.0005) along with a significant decrease in complex I and V 
activity.
104
 Considering that the cytochrome c/complex III molar ratio is the minimum 
needed for complex III activity
105, 106
 an increase in complex III activity will likely 
decrease the pool of cytochrome c available for release from the mitochondrion to initiate 
apoptosis.  This would explain why after the administration of IMAT there is an increase 
in the subunits associated with complexes III and IV of the ETC and a decrease in the 
cytochrome c and ATP synthase subunits (complex V) intensity in the tumor samples 
shown here.  With this information, targeted experiments to elucidate the exact function 
of these proteins and how they could possibly be linked to treatment resistance and anti-
apoptotic functions after administration of IMAT in gliomas can be investigated. 
S100B is another protein that is affected by IMAT presence.  There is a decrease 
in S100B protein intensity as the IMAT concentration increases in the tumor areas.  
S100B is a Ca
2+
-binding protein of the EF-hand type that is abundantly expressed in 
astrocytes and has been implicated in the regulation of several intracellular activities, 
including proliferation and differentiation.  S100B might contribute to reduce the 
differentiation potential of cells of the astrocytic lineage and participate in the astrocyte 
activation process in the case of brain insult and in invasive properties of glioma cells. 
Astrocytes represent the brain cell type with the highest expression of S100B.  Levels of 
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S100B also increase in gliomas, raising the possibility that the protein might have a role 
in glioma pathophysiology.
107, 108
  Studies have demonstrated that inhibition of S100B 
production in glial cells is correlated with at least three phenotypic changes: (a) a more 
flattened cellular morphology; (b) an alteration in cytoskeletal organization at the level of 
the microfilament network; and (c) a decrease in cellular growth rate.
109
 Results obtained 
with two distinct antisense methods support the conclusion that S100B has important 
roles in regulation of glial cell morphology, cytoskeletal structure, and cell proliferation.  
Thus, a decrease in S100B intensity could indicate that IMAT mechanisms inhibit S100B 
and therefore create a decrease in the tumors cellular growth rate.  
Another affect of increased IMAT concentration in the tumor tissue was a 
decrease in beta-synuclein intensities.  β-synuclein is a synuclein protein found primarily 
in brain tissue and is seen mainly in presynaptic terminals. β-synuclein is predominantly 
expressed in the neocortex, hippocampus, striatum, thalamus, and cerebellum.
110
  The γ-
synuclein protein has been found to be abnormally expressed in a high percentage of 
tumor tissues of cancer types, including liver, gastric, lung, prostate, cervical etc.
111
 and 
α-synuclein has been implemented in a number of neurodegenerative disorders.112 
Synucleins have also been found to be expressed highly in glial tumors
113
 and although 
their exact function is not yet known they are known to be involved in cellular functions 
including synaptic plasticity, neurofilament organization, control of dopamine 
homeostasis and vesicular transport.
114
 
Many other identified proteins were also affected by the IMAT concentrations 
although not all of the functions in glioma tissues have been completely elucidated.  
Small nuclear ribonucleoprotein D3 intensities are decreased at high concentrations of 
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IMAT in tissue.  Small nuclear ribonucleoprotein particles have been shown to have an 
integral role in pre-mRNA splicing.
115
  Global aberrant alternative pre-mRNA splicing 
has been indicated as an epigenetic phenomenon in cancer and specifically independent. 
In silico genome-wide assessments have identified genes expressing particular splice 
isoforms more frequently in glioma than in normal brain.
116
  BolA like protein 1 has a 
decreasing intensity at high concentrations of IMAT.  The BolA-like proteins seem to be 
involved in cell proliferation or cell-cycle regulation, but the molecular function is still 
unknown.
117
  Acyl CoA binding protein shows an increase in intensity and is known to 
bind medium- and long-chain acyl-CoA esters with very high affinity and may function 
as an intracellular carrier of acyl-CoA esters.  In vitro and in vivo experiments suggest 
that it is involved in multiple cellular tasks including modulation of fatty acid 
biosynthesis, enzyme regulation, regulation of the intracellular acyl-CoA pool size, 
donation of acyl-CoA esters for β-oxidation, vesicular trafficking, complex lipid 
synthesis and gene regulation.
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In summary, the MALDI MS data obtained in this study were able to provide 43 
molecular features associated with IMAT concentration in the brain tumors.  Correlating 
IMAT distribution to proteome response in the brain MALDI MS analyses provided a 
means to directly correlate drug distribution with pharmacological response and provided 
insight into the concentration-effect relationship. Further work needs to be performed to 
determine the identity of all the molecular features altered in order to rationalize the 
biological significance of these proteins.  Evaluating some of the proteins already 
identified, many molecular processes including ETC, proliferation, cell cycle regulation 
and pre-mRNA splicing have been found to be affected by the administration of IMAT.  
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Additional experiments can delve further into these functions and provide more 
information on the efficacy of IMAT, reveal additional drug targets, and help elucidate 
the mechanisms of the drug action on the brain tumors.  Additionally, the MALDI-IMS 
techniques provide a rapid, reproducible method to find the IMAT drug concentrations in 
tissue while maintaining spatial integrity. 
 
Materials and Methods  
  
Materials 
The MALDI matrices, sinapinic acid and 2,5-dihydroxybenzoic acid, tissue 
staining chemicals cresyl violet acetate, hemotoxylin and eosin, and ammonium acetate 
were purchased from Sigma Chemical Co. (St. Louis, MO). Acetic acid, HPLC grade 
acetonitrile, ethanol, methyl-tert-butyl ether (MTBE) and MeOH were purchased from 
Fisher Scientific (Suwanee, GA). Trifluoroacetic acid (TFA) and hydrochloric acid (HCl) 
was purchased from Burdick and Jackson (Muskegon, MI).  Dulbecco‟s Phosphate-
Buffered Saline (D-PBS), Dulbecco‟s modified eagle medium (DMEM), fetal calf serum, 
penicillin-streptoycin, Tissue Protein Extraction reagent (TPER), phosphate buffer 
solution (PBS), tricine gels, reducing agent, See Blue, Novex Tricine SDS Running 
Buffer, trypsin, 0.05% with EDTA and Colloidal Blue Staining kit were purchased from 
Invitrogen (Carlsbad, CA).  Trypsin gold was purchased from Promega (Madison, WI).  
Imatinib was acquired from the Vanderbilt Research Pharmacy in 100 mg tablets 
(Nashville, TN).  Imatinib and d8-imatinib were provided as their mesylate salts by Dr. 
Jeremy Norris (Protein Discovery, Knoxville, TN).  GL26 murine glioma cells were 
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acquired from Vanderbilt University (Dr. Moneeb Etesham‟s laboratory, Nashville, TN).  
C57BL/6NCr female mice were purchased from Charles River Laboratories 
(Wilmington, MA).  Animal sedatives xylazine, ketamine, and buprenorphine were 
purchased from Lloyd laboratories (Shenandoah, Iowa). 
 
Cell Culturing 
Cryogenically frozen GL26 murine glioma cells were obtained from the 
Neurology Department Brain Tumor Bank at Vanderbilt University.  The cells were 
thawed and then placed in DMEM containing 10% fetal calf serum, and 1% penicillin-
streptomycin.  Aseptic cell culturing technique as described
119
 was employed to continue 
the cell line growth and cells were maintained in humidified incubators gassed with 5% 
carbon dioxide.  Prior to injection, GL26 cells were harvested, washed twice in PBS, 
counted, and adjusted to 100,000 cells per µl of DPBS in an eppendorf tube. 
 
Tumor Implantation 
From their time of arrival at the animal facility, each animal was housed 
undisturbed to acclimate to the new environment for a period ranging from 1-3 days.  
Food, Purina 5001 rodent diet, and water were provided ad libitum to animals upon 
arrival and throughout the study.  After the acclimation period, animals were taken to the 
procedure room for survival surgery to implant the GL26 murine tumor cells 
intracranially.  The survival surgery involved the establishment of intracerebral brain 
tumors in the mice. To achieve this, animals were first anesthetized.  For administration 
of the anesthesia the animals were held by hand while the brief injection was made 
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directly above the hind limb on the underbelly of the animal (intraperitoneal injection) of 
200 µl (0.019 ml/g of weight) of a mixture of xylazine (2.2%) and ketamine (6.5%).  
After administration the animals were immobilized in a stereotactic frame, and received 
an intracranial injection (2 µl, approximately 200,000 cells) of the GL26 brain tumor 
cells (resuspended in DPBS) into the brain. This necessitated the placement of a midline 
incision in the scalp followed by creation of a burr hole (using a high-speed dental drill) 
in the skull at the site 2.5 mm lateral to bregma where the tumor injection was to take 
place. Tumor cells were injected at a depth of approximately 2.5 mm below the surface of 
the skull. The injection was done very slowly (1 µl/min), and then the needle was left in 
place for 2 min before removal to avoid liquid reflux.  The syringe was removed and the 
scalp incision was closed with wound clips.  All techniques were performed using 
sterilized instruments and the wound was created and closed using aseptic procedure. In 
the postoperative period it was expected that these techniques impart pain on the animal. 
To address this, animals received a subcutaneous injection of buprenorphine (0.05 - 1.0 
mg/kg) prior to the animal waking up from anesthesia.  They then received an additional 
injection of buprenorphine 8-12 hours after the first injection due to the possibility of 
further postoperative pain.  Animals were placed on a thermal blanket during surgery to 
ensure maintenance of body temperature and were kept under a physiological heat lamp 
after surgery while they were recovering from anesthesia. Following recovery, animals 
were placed back in their cages, returned to the vivarium, and monitored daily for signs 
of infection or distress.  After ten days, once the scalp incision had healed, the wound 
clips were removed. 
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Animals were monitored daily for a period ranging from 15-20 days to allow for 
tumor growth to occur.  After this period select animals that had been designated for drug 
dosing were handled and received a non-toxic and physiologically relevant dose of drug 
as determined by the experiment being performed. 
Operative mortality will likely occur within 48-72 hours of surgery; these animals 
will be removed from the analysis. As a 10-12.5% mortality has been reported using this 
procedure, one additional animal per treatment group per experimental replicate was 
implanted. 
 
Drug Dosing 
Imatinib was obtained from the Vanderbilt Research Pharmacy in the form of a 
100 mg tablet.  These are the same tablets that patients would receive if prescribed 
IMAT.  Tablets were dissolved in water at a pH=4 (water made acidic with the addition 
of HCl) resulting in a 10 mg/ml drug solution.  IMAT is readily soluble at acidic pH 
values (≤ 5).  The solution was vortexed for five minutes to ensure that the entire quantity 
of IMAT was dissolved.  The IMAT solution was stored at -4 °C for no longer than 48 
hours before fresh solution was made.  The drug placebo administered was water at pH=4 
(made acidic with the addition of HCl). 
For oral gavage the animal was held by hand while tipping the head up to allow 
the insertion of the oral gavage blunt tipped needle into the mouth and down toward the 
stomach.  Once the needle was in place approximately 300 µl of the drug solution 
(resulting in a 100 mg/kg dose) were administered to the animal.  After administration the 
needle was slowly removed from the mouth and the animal was immediately released. 
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Tissue Preparation and MALDI Imaging 
 After all dosing had been completed the animals were taken to be sacrificed.  
Each animal was put under anesthesia, (110 mg/kg Ketamine and 10 mg/kg Xylazine) 
through intraperitoneal injection as a single dose followed by spine dislocation and 
immediate decapitation.  Brain tissues were excised from the C57/BL/6 mice using sterile 
dissection techniques and immediately flash frozen in liquid nitrogen.  All tissues were 
kept at -80 °C until further use. 
Frozen brain tissues were mounted onto a cryostat chuck with OTC.  Tissue was 
trimmed until an even sagittal section was acquired at Interaural 10.6 mm, Bregma 1.6 
mm, where the corpus callosum has started to join at the mid-line of the brain.  From this 
position tissue sections (12 µm) were collected, one for protein analysis, a serial section 
for IMAT analysis and a serial section for H&E staining.  Sections for protein and IMAT 
analysis were mounted onto gold-coated MALDI targets while the sections for staining 
were thaw mounted onto charged glass microscope slides.   
For cresyl violet staining, 0.5% cresyl violet was made by adding 2.5 g of cresyl 
violet acetate to 250 ml of distilled water and 1.5 ml of acetic acid.  The solution was 
stirred for 20 minutes and then filtered.  After sections had been mounted onto the 
charged glass slides, they were dipped briefly, approximately 5 seconds, into water.  The 
slides were then dipped into the 0.5% cresyl violet for 45 seconds, rinsed briefly with 
water and rinsed with 100% ethanol for 20 seconds.  Slides were then placed into Xylene 
for 5 minutes followed by cover-slipping with cytoseal. 
For H&E staining, slides were dipped in a series of solutions to re-hydrate, 
dehydrate and stain the tissue sections.  30 seconds in 95% ethanol. 30 seconds in 70% 
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ethanol.  30 seconds in Milli-Q water.  2 minutes in hematoxylin solution (deep purple; 
stains nuclear contents).  20 seconds in Milli-Q water.  30 seconds in 70% ethanol.  30 
seconds in 95% ethanol.  1 minute in eosin solution (pink; stains cytoplasm).  30 seconds 
in 95% ethanol.  30 seconds in 100% ethanol.  2-2.5 minutes in Xylene.  To cover-slip, 
dry the back of the microscope slide and around the tissue section with a Kimwipe to get 
rid of excess xylene.  Put 1-3 drops of cytoseal on the tissue section and then place a 
coverslip over area.  Make sure to get rid of air bubbles and let the cytoseal dry until 
hardened.   
MALDI targets were placed into a desiccator for at least an hour to dry.  To 
prepare sections for imatinib imaging a matrix solution of DHB (40 mg/ml, 50% MeOH) 
was prepared with 2 µM d8-imatinib as the internal standard.  Sections were spotted on 
the Portrait (Flyby 1 drop 40 repeats) at 300 µm x 300 µm spatial resolution.  All  
IMAT images were acquired on a MALDI-LTQ XL.  The MALDI target with sections 
designated for protein analysis was reagent washed (70% reagent alcohol for 30 seconds, 
70% reagent alcohol for 30 seconds, 100% reagent alcohol for 15 seconds, air dried).  
The surface of the sections were then seeded with finely ground SA.  Fresh SA matrix 
solution was made in 60% acetonitrile 40% water 0.02% TFA.  The sections were spotted 
using the Portrait (Flyby 1 drop 30 repeats) in a 300 µm x 300 µm array.  The MALDI 
target was scanned and sections were imaged on an Autoflex (Bruker Daltoniks). 
 
Data Pre-Processing 
Data analysis generally lies in two categories; pre-processing and statistical 
analysis.  It is important to assess reproducibility of the mass spectra so that variations in 
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peak intensities can be correlated to biological endpoints.  The pre-processing step 
reduces the experimental variance between spectra through the removal of background, 
normalization of the peak intensity to the total ion current, and peak alignment 
algorithms.  Normalization of the spectra minimizes variation arising from day to day 
instrument fluctuations, differences in matrix crystallization across tissue sections, and 
changes in sample preparation and chemical properties of the underlying tissue 
120
.  
Various algorithms are employed for all of the spectra processing steps; baseline 
subtraction, smoothing, peak alignment, normalization and peak picking.  Ion images are 
generated directly from these processed data sets. 
For each image acquired, the corresponding stained serial section was co-
registered and with the assistance of a neuro-oncologist the spectra from the tumor 
bearing regions were exported.  Spectra from each section were kept together in separate 
folders.  These folders were then input into ClinPro Tools where the imported spectra 
were processed with the following parameters; 1200 Resolution,  data reduction factor of 
5, Top Hat baselining with 10% Minimal Baseline Width, Savitsky Golay Smoothing 
enabled at 2 width 10 cycles, recalibration 2000 ppm max peak shift with 20% match to 
calibrate peaks excluded not recalibratable spectra, from m/z range 4000-20,000, and null 
spectra exclusion. Once spectra were imported into ClinPro Tools and processed, peak 
selection was performed (peak picking on total avg spectrum, SN=2, 0% relative 
threshold to the base peak) and peak list feature tables were output.   
 
Protein Identification 
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Tissues were homogenized in TPER supplemented with protease inhibitors. For 
each extract, a Vydac C8 polymeric reversed-phase column (3.2 x 150mm) fractionated 
300 g of protein solution (96 min linear gradient from 2-90 plate). During separation, a 
liquid handling robot moves the transfer capillary sequentially into each of the 96 wells at 
1 min intervals. To identify wells containing proteins of interest in an automated process, 
0.2 L was removed from each well, mixed with SA matrix, and analyzed by MALDI-MS 
(Bruker Autoflex). Fractions containing m/z values of interest were run on a gel (10-
20tricine) and bands of interest were excised and digested with trypsin gold (Promega; 
Madison, WI). In solution trypsin digest was also performed on fractions which contained 
m/z values of interest. A non-linear quadrupole high capacity trap (Bruker HCT Plus) 
was used to analyze digested proteins. The peptides were separated on a packed capillary 
column, with C18 resin (Monitor C18, 5 m; Column Engineering, Ontario, CA), using a 
linear gradient (5MS/MS spectra were initially analyzed by searching the mouse 
International Protein Index database using Sequest software).  Protein IDPicker software 
(David Tabb and Bing Zhang laboratories in the Vanderbilt University Medical Center 
department of Biomedical Informatics) was then used to determine the probability that a 
protein had been correctly identified, based on the available peptide sequence evidence. 
 
Drug Quantitation Using LC-MS/MS 
 Standards of IMAT and d8-IMAT were prepared as stock solutions in methanol.  
Calibration standards were made by adding the stock solutions to control brain tissue 
homogenate to yield final concentrations of 3000, 1000, 500, 100, 25, 10, 1 ng/ml. 
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Tissue specimens were homogenized with PBS in a ratio of 1:4 (mg/µl) using a glass 
homogenizer until uniform by visual inspection.  A minimum of 30 mg of tissue was used 
to prepare the homogenate, which was then transferred to eppendorf tubes before being 
centrifuged at 3000 g for ten minutes.  Fifty microliters of the supernatant was combined 
with 25 µl of internal standard (d8-imatinib, 1000 ng/ml) and then the protein was 
precipitated by adding 250 µl of acetonitrile/ethanol/acetic acid (90/10/0.1) with mixing 
by inversion for 20 minutes.  Samples were then centrifuged at 4000 g for ten minutes to 
remove the precipitant.  After centrifugation, the supernatant was transferred to glass 
autosampler tubes and dried in a vacuum centrifuge for two hours at 40 °C and then 
reconstituted in 75 µl of 50% methanol containing 0.05% ammonium acetate. 
 Chromatographic separation was performed using a Waters XTerra RP® C18 
reverse phase column (2.1 x 100 mm, 5 µm particle) with a column heater (50 °C) and 
autosampler (4 °C) on an HPLC system.  The system was held at 90% MeOH for two 
minutes then a linear gradient of MeOH and water, both with 0.5% ammonium acetate 
was increased from 20% to 90% MeOH over two minutes and held at 90% MeOH for 
two minutes before the column was then washed with a solution containing 70% 
acetonitrile, 20% MTBE and 10% water of the course of five minutes, going from 0 to 
100% over two minutes and maintaining at 100% for three minutes.  The system was then 
returned to initial conditions over two minutes and equilibrated for two minutes before 
beginning the next run.  The total run time was 14 minutes per sample at a flow rate of 
0.5 ml/min.  Ten microliters of sample were injected using a 10 µl PEEK loop and 
subsequently analyzed on an ESI TSQ Quantum triple-quadrupole system (Thermo 
Scientific, Waltham, MA).  
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CHAPTER IV 
 
ANALYSIS OF CYCLOPAMINE TREATED DIRECT HUMAN GLIOMA CELL 
IMPLANTED MOUSE XENOGRAFTS 
 
Overview 
 
Despite recent advances in therapeutic techniques, the prognosis for patients with 
malignant brain tumors remains grim. The lethality of this disease process stems in part 
from the highly invasive nature of these tumors. Microscopic nests of tumor cells 
intersperse themselves with normal brain tissue, often at significant distance from the 
main tumor mass. Due to their large number and varied location, current treatment 
strategies are unable to specifically eliminate these tumor reservoirs in their entirety, 
leading to eventual tumor recurrence.  
One possible means of targeting disseminated tumor within the brain is the use of 
targeted molecular therapies. It has previously been demonstrated that targeted molecular 
therapies are capable of directly or indirectly inducing tumor-cell death in various cancer 
models.  The previous chapter investigated one of these therapies (IMAT).  These 
findings point to the potential that MALDI IMS technologies are useful in evaluating 
treatment of malignant brain tumors. 
Little is currently understood regarding the biological pathways and mechanisms that 
govern the effects of these molecular compounds on tumor cells. The elucidation of these 
pathways will be critical in order to better understand and optimize this highly promising 
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therapeutic strategy for brain cancer. In this project, we now seek to detect the 
quantitative distribution of the targeted molecular therapy cyclopamine and to define the 
biological mechanisms that govern the ability of molecular targeted therapies to induce 
death of tumor cells in the brain.  
 
Introduction 
 
Sonic Hedgehog Pathway in Gliomas 
 Sonic Hedgehog (Shh) is a member of the Hedgehog (Hh) family of secreted 
glycoproteins, which affect the development of many organs and cell groups. In 
mammals, there are three known Hh family members; Sonic, Desert and Indian Hh.  
They are involved in the development of many tissues and organs, including skin, lung, 
brain, bone and blood. Shh is the most widely expressed.
121, 122
  In the central nervous 
system, Hh  signaling is critical for early ventral patterning of the neural tube along the 
entire neuroaxis and later on for the development of the dorsal brain, including that of the 
cerebellum and neocortex.
123, 124
   Hh acts by inhibiting a 12-pass transmembrane protein 
called Patched1 (Ptc1) which normally inhibits a 7-pass transmembrane protein called 
Smoothened (Smo).  Activating Smo sends a signal intracellularly through intricate 
mechanisms by a complex of proteins, to ultimately lead to the action of the zinc finger 
Gli transcription factors.
125
  When this pathway is activated or maintained 
inappropriately, various tumors can develop, including those in skin, muscle and brain.  
Numerous studies have now shown that Shh signaling is essential for glioma cancer stem 
cell self-renewal and cancer stem cell-initiated brain tumor growth.
121, 125-127
  Inhibition of 
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the hedgehog pathway however, kills these cancer stem cells and can prevent cancer from 
growing and developing which could lead to a very effective stem cell targeted therapy 
for gliomas. 
 
Cyclopamine 
Cyclopamine (CYC) is a teratogen that has been isolated from the lily Veratrum  
californicum.  It is a member of the steroidal jerveratrum alkaloids.  CYC was originally 
given its name due to the birth defects it caused in sheep giving them one eye.  Much 
interest in CYC has developed, owing to its ability to inhibit the Shh pathway resulting in 
the inhibition of tumor growth and tumor progression.
128-131
  CYC acts by targeting Smo, 
which inhibits its activity in the absence of Ptc1, thereby turning off the Hh pathway and 
stopping the malignancy growth source.  
 
Direct Human Cell Xenograft Animal Models 
Typically animal models used in the investigation of cancer involve the 
transplantation of mouse or rat tumor cells into a host of the same species and strain.
132, 
133
 Growth of human (xenogeneic) tumor cells can be achieved using immunodeficient 
(nude or SCID) mice to prevent rejection.
134, 135
 Most transplantable tumors are 
established subcutaneously but more complex models may involve orthotopic 
transplantation at appropriate primary sites.
136
  There is an increasing trend to establish 
xenograft tumors directly from human cancer stem cells, to avoid artificial selection of 
cells in tissue culture and changes in gene expression and phenotype, which this may 
induce.
137-139
  These transplants may better model the principal cancer under 
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investigation, by more accurately representing the tumor architecture, heterogeneity, 
expression of certain targets and response to therapy.
140
  Glioma cells are known to 
undergo phenotypic and genotypic transformation in culture, however tumor stem cells 
derived directly from primary glioblastomas have extensive similarities to normal neural 
stem cells and recapitulate the genotype, gene expression patterns, and in vivo biology of 
human glioblastomas.
141
 
 
Results 
 
Animal Implantation and Drug Dosing 
To begin the study, a series of mouse implantations with human tumor cells and 
sub sequential drug dosing was performed.  Nod-scid immunodeficient mice were used 
and orthotopically implanted with glioma tumor stem cells derived directly from human 
biopsy tissue.  The cells were never subjected to culture and were obtained by 
homogenizing the tumor samples directly, dissociating with papain, and passing the 
homogenate through a 40 μm filter. Cells were labeled with a CD133/1 antibody cross-
linked to magnetic nanoparticles and subjected to immunomagnetic cell separation using 
the EasySep Magnetic Selection Kit.
130
    Three primary tumor specimens were used to 
result in the following xenografts, an anaplastic ganglioglioma (X-302-AG), a high-grade 
astrocytoma (X-312-HGA) and a primary glioblastoma multiforme (X-406-GBM).  
Recapitulation of malignant glioma pathological features was observed and included 
infiltrative growth, invasion of the corpus callosum to the contralateral hemisphere and 
pleomorphic nuclei with mitotic figures.
130
  When compared to the GL26 murine cell 
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implantation, which shows a very large mass with a clearly defined brain tumor barrier 
(Figure 24A), the primary tumor xenografts show a much more infiltrative and disperse 
growth of the tumor cells throughout the entire brain.  The human transplanted cells were 
visualized by anti-human nuclear immunohistochemistry (Figure 24B).   
 
 
Figure 24: Visualization of tumor cell growth in mouse brain sections. A) A 
C57BL/6NCr mouse brain section implanted with GL26 tumor cells stained with cresyl 
violet.  There is a very large bulk tumor mass with a very definitive brain tumor barrier 
which can be seen clearly in the inset frame.  B) A NOD/SCID mouse brain section 
implanted with primary tumor AG-02 cells stained with anti-human nuclear 
immunohistochemistry.  The tumor cells show a very infiltrative and disperse growth 
pattern throughout the brain.  The inset frames show magnified sections of the brain 
where the invading tumor cells are visualized as the darker stained cells against the 
surrounding areas of the normal brain tissue.  
 
For each of the xenograft lines three mice were injected with CYC every 12 hours 
at a dose of 50 mg/kg totaling 100 mg/kg each day.  This was done for five days.  Three 
additional mice from each line were dosed in the same manner using vehicle (Veh) only 
to serve as the control.  For the X-302-AG xenograft model additional mice were dosed.  
Mice were dosed to result in some that were dosed 50 mg/kg/day (CYC 50), 
100mg/kg/day (CYC 100) or 150 mg/kg/day (CYC 150).  All mice were sacrificed five 
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hours after their final dose of CYC and the brains were excised, flash frozen in liquid 
nitrogen and stored at -80°C until further use. 
 
Drug Detection and Quantitation 
 In order to visualize the distribution and quantitate CYC in the brain 
tissue, MALDI IMS was performed on 12 µm thick brain sections spotted with CHCA 
(20 mg/ml, 50% acetonitrile).  Prior to the quantitation and imaging experiments an 
initial analysis of CYC standard (m/z 412) on the MALDI LTQ XL revealed that there 
was an extensive fragment profile with daughter ions at m/z 394, 377, 335, 321 and 213 
(Figure 25).  Various matrix/solvent combinations were tried and they all revealed 
interfering peaks with the parent m/z and also with the major fragment peak of the CYC 
at m/z 394.  Due to this matrix interference, the other fragment peaks were used to 
monitor the drug distribution in the tissue. 
 
 
Figure 25: MALDI MS/MS spectra of cyclopamine taken on a MALDI LTQ XL showing 
major fragment peaks at m/z 394, 377, 335, 321 and 213.  These peaks can be selected to 
monitor the spatial location of the compound in tissue sections.  The inset box shows the 
structure of the parent compound with a molecular weight of 411.  
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Using the MALDI small molecule quantitation protocol developed in Chapter II, 
the tissue sections from X-302-AG mouse brains were analyzed.  First, 12 µm sections 
were collected from each brain and weighed on a microbalance immediately following 
sectioning.  A 12 µm Nod/Scid mouse brain section had approximately the same weight 
as a C57Bl/6NCrl mouse brain section (Chapter III) weighing 0.68 mg with a RSD of 
4%.  Brian sections were then stained and scanned using a flatbed scanner at 3200 dpi to 
provide images for the tissue area calculation.  The images were imported into Adobe 
Photoshop and the area of the section was determined to be 62.44 mm
2
 with a RSD of 
0.2% which was approximately the same area as the C57Bl/6NCrl mouse brain sections.  
In Chapter II the area of the laser spot was found to be 0.0035 mm
2
, so the amount of 
tissue sampled within one laser position was calculated from the equation: 62.44 
mm
2
/0.68 mg = 0.0035 mm
2
/X mg.  The amount of tissue sampled was 3.81 x 10
-5 
mg.   
 A calibration curve for CYC was constructed by spiking CHCA (20 mg/ml 50% 
acetonitrile) with CYC standard to yield final concentrations of 6800, 680, 68, 6.8 and 
0.68 fg along with a blank matrix control.  All solutions were spiked with 2 µM of jervine 
(JERV), which served as the internal standard for the experiments.  Spectra were 
acquired from each of the spots, using 600 laser shots per position and 14 positions per 
matrix spot.  This totaled 140 different laser positions for each standard due to the fact 
that 10 matrix spots per calibration standard were analyzed.  For each spot the total signal 
intensity was summed for both the CYC and JERV using in-house software and the ratio 
of CYC/JERV was calculated.  The ratios for each calibration standard were plotted and a 
linear fit was calculated.  Each point on the curve had a RSD no higher than 27% and the 
curve had excellent linearity with an R
2
 value of 0.9999 (Figure 26).   
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Figure 26:  Cyclopamine Calibration Curve constructed using MALDI IMS methods 
 
From this curve the LOD of cyclopamine with this acquisition method by MALDI was 
determined to be approximately 1650 ng/g of tissue. 
 Tissue sections for the Veh, CYC 50, CYC 100 and CYC 150 X-302-AG mice 
were cut at 12 µM.  The sections were spotted with CHCA in 50% Acetonitrile spiked 
with 2 µM JERV internal standard.  Due to the infiltrative nature of the tumor cells 
within the brain, matrix spots were analyzed from various regions in the brain to get a 
representation of the amount of drug present in the tissue. A total of ten matrix spots were 
analyzed for each tissue with 14 positions per spot totaling 140 positions for each brain.  
The ratio of total CYC signal intensity over total JERV signal intensity was calculated 
and plugged into the calibration curve equation to calculate the amount of CYC present in 
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fg.  The amount of CYC was divided by the amount of tissue sampled to provide the 
CYC concentration for each tissue analyzed in ng of CYC within 1 mg of tissue.  The 
Veh and CYC 50 tissue samples were below the limits of detection and therefore the 
concentration of CYC were unable to be calculated by the MALDI method.  However, 
the CYC 100 tissues had a concentration of 2937 ng/g with a RSD of 26.7% and the  
CYC 150 tissues had a concentration of 12333 ng/g with a RSD of 15.1% (Table 7). 
  
Table 7:  Comparison of cyclopamine concentrations calculated by both LC-MS/MS and 
MALDI-IMS methods. 
 
CYC 
   
ng/g CYC 50 CYC 100 CYC 150 
LC 688 2998 8051 
LC RSD 3.2 6.2 3.7 
MALDI below LOD 2937 12333 
MALDI RSD 
 
26.7 15.1 
% difference 
 
2 35 
 
 
 
 
For comparison, traditional drug quantitation techniques involving 
homogenization and drug extraction followed by analysis on a LC-triple quadrapole 
system were performed.  The calibration curve for this experiment was constructed using 
a CYC concentration range from 0.1 -1000 ng/ml and the response curve was generated.  
A representative calibration equation, y = 0.025x + 0.006 (R
2
= 0.9917) was calculated 
using a weighted (1/x
2
) least squares linear regression model.  Samples of brain tissue 
100 
 
from the Veh, CYC 50, CYC 100 and CYC 150 X-302-AG mice were analyzed and 
using the response curve, average CYC concentrations (ng of CYC per g of tissue) were 
calculated for each dosing group (Table 7).  The Veh tissue contained no CYC, the    
CYC 50 tissue had a concentration of 688 ng/g, the CYC 100 tissue had a concentration 
of 2998 ng/g, and the CYC 150 tissue had a concentration of 8051 ng/g of cyclopamine 
as calculated by the LC-MS/MS methods. All concentration calculations had an RSD less 
than 6.5%.  Comparing the quantitation results from both the MALDI and the LC-
MS/MS methods reveals a close similarity for the CYC 100 and CYC 150 samples with 
percent differences of 2% and 35% respectively.   
 To obtain images of the CYC distribution in the X-302-AG brains, 12 µm 
sections were cut and spotted with CHCA (20 mg/.ml, 50% acetonitrile) spiked with 2 
µM JERV as an internal standard.  All images were acquired on the MALDI LTQ XL 
and visualized using ImageQuest software (Thermo Scientific Inc.).  Three transitions 
were monitored to evaluate CYC resulting in images for m/z 377, 335 and 321.  As can 
be seen in Figure 27, there is some background signal in the Veh mice and the signal in 
the CYC 50 samples is below the LOD.  However, in the CYC 100 samples some signal 
starts to become visible above the background  and in the CYC 150 samples there is 
clearly CYC signal as represented at all three m/z values monitored.  This is consistent 
with the quantitation results.  The bottom row in the figure show a representative H&E 
stained brain section for each dosing group. 
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Figure 27:  Images of cyclopamine distribution in the dosed X-302-AG brain sections at 
each dosing level.  m/z values 377, 335 and 321 were monitored.  Background signal can 
be seen in the Veh brains and the signal in the 50mg/kg/day dosed brains is below the 
LOD.  Some signal is visible above the LOD in the 100 mg/kg/day brains and there is 
distinct CYC signal in the 150 mg/kg/day samples.  The bottom row shows a 
representative H&E stained brain section for each dosing group.  
 
 
 
Responder versus Non-Responder Proteome Study 
 In a study parallel to this one, the operational status of the Hh pathway in the 
malignant glioma specimens used for the xenografts was determined.  Gliomaspheres 
(GS) were generated for two of the three specimens (GS-312-HGA and GS-406-GBM) 
under culture conditions required for eliciting a Hh pathway response in glioma primary 
cell cultures.
130
  It was found that an operational Hh pathway was present in the 312-
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HGA primary tumors but that the 406-GBM tumor lacks an operational Hh pathway.  In 
order to determine the effect of in vivo Hh pathway inhibition by cyclopamine X-312-
HGA and X-406-GBM mice were treated and assayed for survival.  It was found that 
continuous treatment with CYC (50mg/kg twice daily) showed a median survival 
difference of 11.5 days (P=0.0062, Logrank test) in X-312-HGA mice but no difference 
in survival was measured in the X-406-GBM mice receiving the same CYC treatment 
(Figure 28).
130
 
 
 
 
Figure 28:  Hedgehog pathway inhibition confers a survival advantage.  A) Treatment 
was initiated in X-312-HGA mice 50 days after xenotransplantation and continued for the 
duration of the survival study.  Cyclopamine-treated mice (50 mg/kg twice daily) had a 
median survival of 11.5 days longer than vehicle-treated mice (P =0.0062, Logrank test).  
B) Continuous cyclopamine treatment of X-406-GBM mice (50 mg/kg twice daily 
starting 100 days after xenotransplantation) did not enhance survival (P =0.56, Logrank 
test).  Solid grey bars indicate duration of treatment.  (Figure adapted from A. Sarangi 
et.al)
130
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 To further investigate the differences between the CYC responder (X-312-HGA) 
and non-responder (X-406-GBM) xenografts, protein images were taken from the brains 
using MALDI TOF IMS.  Standard MALDI imaging preparation techniques were 
employed to get the samples ready for analysis.  The CYC treated and control brains were 
cut on a cryostat and sections were thaw mounted onto target slides, dried and then 
matrix was applied using a Portrait™ 630 spotter before imaging on a Bruker Autoflex 
TOF MS.  Three sections were analyzed for each brain and sample acquisition was 
randomized to eliminate bias.  Serial sections were cut for each brain and stained with 
anti-human nuclear immunohistochemistry.  The stained sections were scanned on a 
Mirax Scanner (Carl Zeiss MicroImaging) and the images were saved.  All sections were 
evaluated by a trained neuropathologist to mark areas of tumor invaded and non-invaded 
regions.  Eight regions were marked using the Mirax software; striatum, invaded 
striatum, lateral ventricle (LV), invaded lateral ventricle, grey matter, invaded grey 
matter, corpus collosum (CC) and invaded corpus collosum (Figure 29).  The X-406-
GBM brains were so infiltrated with tumor cells that there was no non-invaded tissue to 
be marked by the pathologist and there was no invaded grey region in the X-312-HGA 
samples. 
 After acquisition of the MALDI images, it was then possible to co-register and 
overlay the marked brain images using Flex Imaging software (Bruker Daltonics).  These 
overlays allowed for the visualization of all the MALDI images and align which spectra 
came from within the specific regions of brain tissue marked by the neuropathologist.  
The spectra were then selected, choosing approximately ten spectra per region for each  
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Figure 29:  Anti-human nuclear stained brain tissue section from a primary tumor 
xenograft (X-312-HGA).  The section was scanned on a Mirax scanner and then various 
histological regions were marked by a neuropathologist.  Each color represents a different 
area of the brain:  grey matter (grey), invaded grey matter (orange), corpus collosum 
(pink), invaded corpus collosum (yellow), striatum (green), invaded striatum (red), lateral 
ventricle (purple) and invaded lateral ventricle (teal).  
 
 
brain section analyzed, and placed in separate folders for further processing and statistical 
analysis. 
 All spectra were processed using ClinPro Tools, commercially available software 
from Bruker Daltonics.  Once the spectra had undergone baseline subtraction, smoothing, 
normalization, realignment and peak picking, the data for each spectrum was exported 
collectively into a feature table, which is a list of each m/z value and its corresponding 
intensity value for each spectrum.  The mass region evaluated was from m/z 3000-30,000 
and there was an average of 240 peaks found for each brain region.  Using these feature 
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tables, various analyses and statistical tests were performed to evaluate the protein 
changes that occurred with respect to the cyclopamine treatment. 
Comparisons were made for each area of the brain, comparing CYC dosed versus 
non-dosed samples for both the X-312-HGA and X-406-GBM mouse brains.  SAM 
analysis was performed for each region and resulted in lists of m/z values that show a 
significant difference between the dosed and non-dosed brains.  The SAM used a two 
class unpaired test and significant peaks were identified that had a fold change > 1.25.  
There were a number of peaks that were changed as a result of the CYC treatment.  For 
the X-312-HGA samples, the invaded CC had 49 (21%), the invaded LV had 121 (48%) 
and the invaded striatum had 61 (25%) significant peak changes (Table 8).  For the X-
406-GBM samples, the invaded CC had 54 (23%), the invaded grey had 54 (22%), the 
invaded LV had 91 (36%) and the invaded striatum had 99 (41%) significant peak 
changes (Table 8).  
 
Table 8: Significant peak  change statistics for the X-312-HGA and X-406-GBM 
xenograft mice. 
 
NonDosed Versus Dosed       
Fold Change > 1.25 X-312-HGA X-406-GBM 
 Total # 
Peaks 
# 
Affected 
Peaks 
% of 
peaks 
changed 
FDR* # 
Affected 
Peaks 
% of 
peaks 
changed 
FDR* 
Invaded CC 234 49 21 16.5 54 23 5.2 
Invaded Grey 247 N/A N/A N/A 54 22 12.1 
Invaded LV 254 121 48 22.1 91 36 22.7 
Invaded Striatum 244 61 25 14.3 99 41 1.6 
        
CC 230 144 63 9.7 N/A N/A N/A 
Grey 257 32 12 11.7 N/A N/A N/A 
LV 229 79 34 26.5 N/A N/A N/A 
Striatum 228 51 22 8.7 N/A N/A N/A 
*FDR- False Discovery Rate 
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There are various ways to look at the significant peak changes when comparing 
the X-312-HGA (CYC responsive) and X-406-GBM (CYC non-response) xenografts.  
Appendix B shows that there are some significant features that go up in both xenografts 
and some that go down in both xenografts.  There are also some significant features that 
go up in one xenograft and down in the other and there are unique significant features to 
each xenograft. An example of this is displayed in Figure 30 which shows a graphical 
representation showing the percent change for each m/z in a signature of response found 
for the X-312-HGA responder xenograft tumors in the invaded striatum region.  The 
signals are arranged from greatest negative percent change to greatest positive percent 
change in the responder profiles.  The X-406-GBM non-responder graph displays the 
same order of features, showing that the majority of the signals do not display a 
significant change in intensity and some features display an opposite response to the 
CYC than the X-312-HGA tissues. 
Protein identifications were found for 40 of the significant features that were 
affected by cyclopamine dosing in the X-312-HGA xenografts which showed a survival 
advantage as a result of treatment.  Protein identification was achieved through protein 
separation/isolation, proteolytic digestion, sequencing of peptides by LC-MS/MS, and 
matching the peptides to genome-based protein databases.  The MALDI peaks identified 
using these strategies are shown in Table 9.  The MW and corresponding identifications 
are listed along with the percent coverage, modifications, SwissProt Identification 
number, the number of peptides identified, the intensity trend as a result of CYC dosing 
and the regions in the brain the features were found. 
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Figure 30:  SAM results displayed as bar graphs for the Invaded Striatum of the 
xenografts comparing CYC dosed versus non-dosed tissues. In the top graph each bar 
represents the percent change for each m/z in a signature of response found for the X-12-
HGG responder xenograft tumors.  The signals are arranged from greatest negative 
percent change to greatest positive percent change in the responder profiles.  The bottom 
graph displays the same order of features as the top graph, with each bar representing the 
percent change for each m/z in the X-406-GBM samples.  The majority of the signals do 
not display a significant change in intensity, however, some m/z signals display an 
opposite trend between the responder and non-responder samples. Spectra used in the 
comparison of treated to non-treated were isolated from the tumor invaded striatum of the 
brains, as determined by a neuropathologist. Before SAM analysis the spectra were 
processed (baseline-subtracted, smoothed, normalized and re-aligned).  
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Table 9: Protein Identifications for Significant Features in the X-312-HGA xenografts 
(CYC responsive) 
 
*acetylated N-terminus (+42) 
^opposite trend seen in X-406-GBM xenograft samples  
  
m/z MW (Da) Protein Name 
% Coverage 
of 
unprocessed 
precursor 
Modifications 
(amino acid 
chain) 
Swissprot 
Primary 
Accession 
Number 
Number 
of 
Peptides Trend Brain Region 
6722 6807 Purkinje cell protein 4 39 *(2-62) P63054 2 Down^ 
Invaded Striatum 
Invaded LV 
7342 7338 
Copper transport 
protein ATOX1 44 (1-68) O08997 3 Down^ 
Invaded Striatum 
Invaded LV 
7359 7446 
Cytochrome b-c1 
complex subunit 9 34 *(2-64) Q8R1I1 2 Down^ 
Invaded Striatum 
Invaded LV 
7543 7498 
Myelin basic protein 
(Isoform 3) 41 *(1-69) P04370 5 Down 
Invaded Striatum 
Invaded LV 
7960 7960 
cAMP-dependent 
protein kinase inhibitor 
alpha 48 (1-76) P63248 2 Down^ Invaded LV 
8026 7979 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) subunit 
gamma-13 13 *(1-67) Q9JMF3 2 Up Invaded CC 
8110 8236 
ATP synthase subunit 
e, mitochondrial 51 (2-71) Q06185 6 Down  
Invaded Striatum 
Invaded LV 
8675 8761 
Probable protein 
BRICK1 29 *(2-75) Q91VR8 2 Down Invaded LV 
9330 9327 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 4 43 (2-82) Q62425 4 Down^ 
Invaded Striatum 
Invaded LV 
9639 9768 
Cytochrome b-c1 
complex subunit 8 54 (2-82) Q9CQ69 3 Down^ 
Invaded Striatum 
Invaded LV 
9980 10071 
Cytochrome c oxidase 
subunit 6B1 38 *(2-86) P56391 4 Down Invaded LV 
10522 10477 
SH3 domain-binding 
glutamic acid-rich-like 
protein 3 25 *(1-93) Q91VW3 2 Up   
Invaded Striatum 
Invaded LV 
10724 10855 
LYR motif-containing 
protein 4 34 (2-91) Q8K215 3 Up Invaded CC 
10834 10963 
Heat shock protein 1 
(Chaperonin 10) 57 (2-102) Q4KL76 6 Up^ Invaded Striatum 
11086 11083 Protein S100-A11 16 (1-98) P50543 2 Down Invaded LV 
11517 11605 Cytochrome c, somatic 32 *(2-105) P62897 5 Up   
Invaded Striatum 
Invaded LV 
11652 11651 
60S acidic ribosomal 
protein P2 66 (1-115) P99027 4 Up^ 
Invaded Striatum 
Invaded LV 
11545 11675 Thioredoxin 38 *(2-105) P10639 4 Up   
Invaded Striatum 
Invaded LV 
11799 11923 
Peptidyl-prolyl cis-
trans isomerase 
FKBP1A 43 (2-108) P26883 3 Down  Invaded LV 
12137 12136 
Tumor suppressor 
candidate 2 32 (1-110) Q9WVF8 2 Down^ 
Invaded Striatum 
Invaded LV 
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Table 9 (continued): Protein Identification for Significant Features in the X-312-HGA 
xenografts (CYC responsive) 
 
*acetylated N-terminus (+42) 
^opposite trend seen in X-406-GBM xenograft samples  
 
m/z 
MW 
(Da) Protein Name 
% Coverage 
of 
unprocessed 
precursor 
Modifications 
(amino acid 
chain) 
Swissprot 
Primary 
Accession 
Number 
Number 
of 
Peptides Trend 
Brain 
Region 
12375 12504 
Macrophage migration 
inhibitory factor 39 (2-115) P34884 3 Down^ 
Invaded 
Striatum 
Invaded LV 
12437 12576 
 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 7 19 (2-113) Q9Z1P6 2 Down^ Invaded LV 
13249 13244 
UPF0366 protein 
C11orf67 homolog 21 (1-122) Q8R0P4 3 Down Invaded LV 
13281 13370 
V-type proton ATPase 
subunit F 39 *(2-119) Q9D1K2 5 Down^ Invaded LV 
13474 13480 
Endosomal adaptor 
protein p14 22 (1-125) Q9JHS3 2 Down^ Invaded LV 
13565 13527 
Cytochrome b-c1 
complex subunit 7 39 *(1-111) Q9CQB4 5 Down^ 
Invaded 
Striatum 
Invaded LV 
13641 13777 
 Histidine triad 
nucleotide-binding 
protein 1 26 (2-126) P70349 2 Down^ Invaded LV 
14208 14164 
NADH dehydrogenase 
[ubiquinone] 1 subunit 
C2 24 *(1-120) Q9CQ54 4 Down^ Invaded CC 
14053 14188 
 Iron-sulfur cluster 
assembly 1 homolog, 
mitochondrial 19 (2-129) Q9D924 2 Down^ Invaded CC 
14163 14255 Ribonuclease UK114 65 *(2-135) P52760 6 Down^ Invaded LV 
14136 14275 
Programmed cell death 
protein 5 34 (2-126) P56812 4 Down^ Invaded CC 
15345 15344 
FK506-binding protein 
2 27 (1-140) P45878 2 Up 
Invaded 
Striatum 
Invaded LV    
Invaded CC 
15836 15792 
Golgin subfamily A 
member 7 18 *(1-137) Q91W53 2 Up^ 
Invaded 
Striatum 
Invaded CC 
16230 16228 
Actin-related protein 
2/3 complex subunit 5 21 (1-151) Q3TKM9 4 Down   Invaded CC 
16299 16301 Ribosomal protein S14 26 (1-151) O70569 3 Down^ Invaded CC 
16396 16353 
Vesicle-associated 
membrane protein 4 22 *(1-141) O70480 2 Down^ 
Invaded 
Striatum 
Invaded CC 
17003 16958 
Microsomal 
glutathione S-
transferase 3 21 *(1-153) Q9CPU4 3 Down^ Invaded LV 
18418 18505 
Transmembrane 
protein 35 13 *(2-167) Q9D328 2 Down 
Invaded 
Striatum 
Invaded LV  
Invaded CC 
18654 18612 
CB1 cannabinoid 
receptor-interacting 
protein 1 45 *(1-164) Q3UFR2 5 Down Invaded LV 
19376 19462 
Translationally-
controlled tumor 
protein 21 *(2-172) P63028 3 Up^ Invaded LV 
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Discussion 
 Most previously reported methodologies for CYC quantitation involved 
the use of LC-MS/MS and was shown for concentration in plasma and cultured cells.  
This study extends on that work to include a methodology to quantify CYC in tissues 
while maintaining spatial integrity using MALDI and demonstrates for the first time the 
concentration of CYC in brain tumor xenografts (Table 7).  Comparing the concentration 
values found by the MALDI with the LC-MS/MS method developed for CYC 
quantitation from tissue shows close similarity.  The percent difference in the samples 
was approximately 35% for the CYC 150 samples and was only 2% for the CYC100 
samples.  The CYC 50 and Veh samples had CYC concentration below the LOD for the 
MALDI method and with the LC-MS/MS the CYC 50 cyclopamine concentration was 
only determined to be 688 ng/g.  The low concentration could be due to the fact that the 
half life of the CYC has been shown to be 4h and the samples were taken 5h post dose.  It 
has been shown that administration of cyclopamine by ip injection caused minimal 
toxicity at doses of 10 mg/kg and 50 mg/kg while a high dose tested (160 mg/kg) 
demonstrated toxicity.
142
  This study also showed maximum serum concentration (Cmax) 
was reached 20 min (Tmax) following injection of 10 or 50 mg/kg doses with 
corresponding Cmax values of 2.58 and 19.9μM, respectively.  The terminal elimination 
half-life of cyclopamine administered ip was 4h.
142
 
Cyclopamine has been shown to inhibit the Shh pathway in brain tumor 
xenografts and confers a survival advantage.
130
  By studying the proteomic affects of the 
CYC dosing on these xenografts, it is possible to see what affects related to the Shh 
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pathway are seen as well as point to other possible biological pathways that are affected.   
Statistical analysis found numerous protein signals that were affected by the cyclopamine 
treatment in both the responder X-312-HGA and non-responder X-406-GBM xenografts 
(Table 8).  By focusing on the signals that were altered in the responder xenograft (Table 
9), it can help shed insight into how the CYC is inhibiting tumor growth and increasing 
survival. 
Purkinje cell protein 4 was decreased in the CYC dosed X-312-HGA xenograft 
mice. Shh is produced by Purkinje cells from late embryonic stages of development 
through to adulthood.   The loss of Shh activity influences Purkinje cell development.
143
  
The inhibition of the Shh pathway would thus affect the expression of the purkinje cell 
proteins. 
Endosomal adaptor protein p14 was found to have a decreased intensity in the 
treated X-312-HGA samples as compared to the non-treated samples.  Endosomal 
adaptor protein p14 is a regulator of the mTOR pathway, a signaling cascade that 
regulates both cell growth and cell cycle progression through its ability to integrate 
signals from amino acids and energy.
144
 As part of the Ragulator complex, it recruits the 
Rag GTPases and the mTORC1 complex to lysosomes, a necessary key step in activation 
of the TOR signaling cascade by amino acids.
145
 The antiproliferative effects of mTOR 
inhibition has been observed in multiple cancerous cell lines also including inhibition of 
protein synthesis and induction of apoptosis.  The decrease in intensity of the endosomal 
adaptor protein p14 in the responder xenograft could indicate that cyclopamine serves to 
inhibit the mTOR pathway and this could be another way that cyclopamine inhibits cell 
proliferation and reduces tumor size in addition to its Hh inhibiting properties.
146
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Treatment with CYC in the X-312-HGA drug responsive xenograft shows a 
decrease in S100A11 (Calgizzarin), which is a calcium-binding protein implicated in a 
variety of biologic functions such as cytoskeleton organization, proliferation and 
differentiation.  Overexpression of S100A11 has been shown in a number of cancers such 
as prostate,
147
 colorectal,
148
 pancreatic,
149
 and breast
150
 suggesting that it may be involved 
with cancer development and progression.  It has been demonstrated that suppression of 
S100A11 by small interfering RNA (siRNA) led to apoptosis, and that the overexpression 
of S100A11 inhibited apoptosis in human uterine smooth muscle tumor cells.
151
  The 
proapoptotic effect of calgizzarin downregulation was also shown with TSA treatments 
antitumoral effect suggested by another study.
152
  This indicates that the CYC treatment 
could be inducing apoptotic pathways in the drug responsive xenografts. 
Numerous proteins involved in the electron transport chain were affected by 
cyclopamine treatment in the X-312-HGA CYC responder xenografts.  NADH 
dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 along with subcomplex 
subunits 4 and 7 are all a part of Complex I.  Cytochrome b-c1 complex subunits 7,8 and 
9 are a part of Complex III, cytochrome c oxidase subunit 6B1 is a part of Complex IV 
and ATP synthase subunit 3 is part of Complex V.  All of the above mentioned proteins 
showed a decrease in intensity in the X-312-HGA CYC treated xenografts versus the 
non-treated xenograft samples.  Cytochrome c, however, showed an increase in intensity. 
As described in Chapter III, the electron transport chain, which is embedded in 
the inner membrane of the mitochondria, consists of five multi-protein complexes. 
Complexes I and II oxidize the energy-rich molecules NADH and FADH2, respectively, 
and transfer the resulting electrons to ubiquinol, which carries it to complex III. Complex 
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III, in turn, shuttles the electrons across the inner mitochondrial membrane to cytochrome 
c, which carries them to complex IV. Complex IV uses the electrons to reduce oxygen to 
water. Each electron carrying step uses the resulting energy to pump hydrogen ions into 
the intermembrane space. This generates a proton gradient, the dissipation of which is 
used by complex V, or ATPase, to power the phosphorylation of ADP to ATP.  Along 
with carrying electrons, complexes I, II, and III generate reactive oxygen species (ROS), 
namely superoxide, at low levels.
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By inhibiting the electron transport chain, there is a greater generation of ROS 
which occurs at the tumor mitochondrial membrane.
154
  This activates apoptosis by 
facilitating the release of cytochrome c from the inner mitochondrial membrane.  Bcl-2 
proteins are layered on the surface of the mitochondria, detect damage, and activate a 
class of proteins called Bax, which punch holes in the mitochondrial membrane, causing 
cytochrome c to leak out. This cytochrome c binds to Apaf-1, or apoptotic protease 
activating factor-1, which is free-floating in the cell‟s cytoplasm.  Using energy from the 
ATPs in the mitochondrion, the Apaf-1 and cytochrome c bind together to form 
apoptosomes. The apoptosomes bind to and activate caspase-9, another free-floating 
protein. The caspase-9 then cleaves the proteins of the mitochondrial membrane, causing 
it to break down and start a chain reaction of protein denaturation and eventually 
phagocytosis of the cell.
155
 
 Numerous studies have shown that by inhibiting the complexes of the 
mitochondrial electron transport chain (most documented for Complex I and III) there is 
an increase in ROS production and subsequent cell death.
156-158
  Recently, several studies 
have also indicated that ROS may be also involved in induction of autophagy.
159, 160
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Autophagy is a self-digestion process important for cell survival
 
during starvation. It has 
also been described as a form of programmed
 
cell death. Mitochondria are important 
regulators of autophagy-induced
 
cell death and damaged mitochondria are often degraded 
by autophagosomes.  The decrease in the ETC complex proteins indicates that CYC is 
suppressing the ETC system which could be resulting in increased ROS production.  This 
ROS increase is most likely facilitating the increase in cytochrome c and subsequent 
apoptotic mechanisms. 
As is evidenced, a number of vital biological processes were affected by the 
administration of CYC in the X-312-HGA xenografts including ETC function, the mTOR 
pathway and apoptosis mechanisms.  Most of the effects were seen in multiple regions of 
the invaded brain indicating that the CYC administration has a ubiquitous effect on the 
tumor cells regardless of their location.  Further work is needed to identify all of the 
molecular features that were altered and fully elucidate what this could mean biologically 
as well as validate the proteins as viable markers of CYC efficacy.  Additional evaluation 
should also be done to investigate the molecular features that were affected solely in the 
X-406-GBM samples.  These changes could be indicative of affects that are nonspecific 
to the CYC tumor reducing activity. 
MALDI IMS has shown to be a very powerful discovery technique for 
investigating the molecular effects that cyclopamine administration has in direct human 
glioma xenografts.  The data provides not only information as to the pharmacological 
response of the CYC but also provides a means to directly correlate drug distribution with 
these molecular changes and obtain drug concentration information all while maintaining 
spatial information in the tissue samples. 
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Materials and Methods 
 
Materials 
 The MALDI matrices, sinapinic acid and 2,5-dihydroxybenzoic acid,  
hemotoxylin, cyclopamine, and jervine, normal horse serum, mouse raised anti-human 
primary antibody, horse raised anti-mouse secondary antibody, DAB solution and DAB 
buffer, and Avidin and Biotin and Avidin HRP were purchased from Sigma Chemical 
Co. (St. Louis, MO). Acetic acid, HPLC grade acetonitrile, ethanol, and methanol, 
Xylene, Para formaldehyde, Triton X100, PBS and Hydrogen Peroxide were purchased 
from Fisher Scientific (Suwanee, GA). 
 
Tissue Preparation and MALDI Imaging 
 Tissue was obtained from Dr. Michael Cooper‟s laboratory (Vanderbilt 
University, Nashville, TN).  CD133-enriched cells (10
4–105) were transplanted into the 
striatum of NOD/SCID mice according to a protocol approved by the Vanderbilt Medical 
Center IACUC. Mice were anesthetized with ketamine and xylazine, and securely placed 
on a stereotactic frame. Using aseptic surgical procedures, an incision was made in the 
scalp and a small burr hole was drilled 2.5 mm lateral to the bregma. CD133-enriched 
cells were implanted 2.5 mm into the right striatum using a Hamilton syringe. Mice were 
maintained until development of neurological symptoms or signs of distress.
130
  After 
sacrifice the brains were removed and a sagittal section at Interaural 10.6 mm, Bregma 
1.6 mm was cut and flash frozen in liquid nitrogen and stored at -80 °C until further use. 
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 Frozen brain tissues were mounted onto a cryostat chuck with OTC.  Tissue was 
trimmed until an even sagittal section was acquired.  From this position sections (12 µm) 
were collected, one for protein analysis, a serial section for CYC analysis, and another 
serial section for anti-human nuclear immunohistochemical staining.  Sections for protein 
and CYC analysis were mounted onto gold-coated MALDI targets while the sections for 
staining were thaw mounted onto glass microscope slides. 
 Slides were immediately stained, or stored at -20 °C until staining.  Slides were 
put into 4% Paraformaldehyde for 60 minutes at 4 °C before being removed and dried for 
two minutes at room temperature.  Slides were then put into 1x PBS for five minutes then 
quenched with 1% hydrogen peroxide for 20 minutes.  The slides were washed in 
phosphate buffer solution with triton X (PBST) twice for five minutes before adding a 
normal blocking horse serum (10% in 0.1% PBST) for 30 minutes.  Again the slides were 
washed in PBST twice for five minutes each wash.  An avidin biotin block was done, the 
slides were washed in PBST before the antibodies were applied.  Primary antibody 
(mouse raised, anti-human) was applied for 8-12 hours at 4 °C, slides were washed in 
PBST then secondary antibody (horse raised, anti-mouse) was added for two hours at 
room temperature.  Again the slides were washed in PBST.  Avidin/HRP was added for 
one hour, slides were washed in PBST then DAB was added in the dark for 8 minutes.  
The slides were briefly dipped in water and then Hemotoxylin counterstained before 
undergoing a series of ethanol washes to dehydrate the slides before rinsing in xylene and 
then coverslipping. 
MALDI targets were placed into a desiccator for at least an hour to dry.  To 
prepare sections for CYC analysis, a matrix solution of CHCA (20 mg/ml, 50% 
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acetonitrile) was prepared with 2 µM JERV internal standard.  Sections were spotted on 
the Portrait (Flyby 1 drop 20 passes x2) at 300 µm x 300 µm spatial resolution.  All CYC 
images were acquired on a MALDI-LTQ XL (Thermo Scientific Inc.).  The MALDI 
target with sections designated for protein analysis was reagent washed and seeded with 
finely ground SA.  Fresh SA matrix solution was made 60% acetonitrile 40% water 
0.02% TFA.  The sections were spotted using the Portrait (Flyby 1 drop 30 repeats) in a 
300 µm x 300 µm array.  Higher spatial resolution images were spotted at 150 µm x 150 
µm.  The MALDI target was scanned and sections were imaged on an Autoflex (Bruker 
Daltoniks).   
 The immunohistochemically stained sections stained were scanned on a Mirax 
Scanner and .jpeg images were exported.  Histological markings were made by a trained 
neuropathologist (Tye Able) using Mirax Software (Carl Zeiss International).  Eight 
regions were marked, striatum, invaded striatum, lateral ventricle, invaded lateral 
ventricle, grey matter, invaded grey matter, corpus collosum and invaded corpus 
collosum.  The marked images were then co-registered with the images acquired to 
extract spectra from isolated histological areas for comparisons and further statistics.  
 
Data Processing 
Spectra from each section were kept together in separate folders.  These folders 
were then input into ClinPro Tools where the imported spectra were processed with the 
following parameters; 1200 Resolution, data reduction factor of 5, Top Hat baselining 
with 10% Minimal Baseline Width, Savitsky Golay Smoothing enabled at 2 width 10 
cycles, recalibration 2000 ppm max peak shift with 20% match to calibrate peaks 
118 
 
excluded not re-calibratable spectra, from m/z range 3000-20,000, and null spectra 
exclusion. Once Spectra have been imported into ClinPro Tools and processed peak 
selection was performed (peak picking on total average spectrum, SN=2, 0% relative 
threshold to the base peak) and peak list feature tables were output. 
 
Statistical Analysis 
SAM was performed to assign a score to each feature on the basis of change in its 
spectral intensity relative to the standard deviation of repeated measurements.  For 
features with a score greater than a predetermined threshold, SAM uses permutations of 
the repeated measurements to estimate the percentage of features identified by chance, 
the false discovery rate 
91
.  Two by two comparisons were made for each brain region 
comparing dosed versus non-dosed tissue sections.  Both the X-312-HGA (responder) 
and X-406-GBM (non-responder) xenograft spectra were analyzed. 
 
Drug Quantitation Using LC-MS/MS 
The extraction and chromatographic LC-MS/MS protocols used here for were 
adapted from previous methodologies used for CYC quantitation.
142, 161-163
  Cyclopamine 
and jervine stock solutions were made in MeOH and stored at -20 °C until use.  
Calibration curves standards were made in control mouse brain homogenate to yield final 
concentrations of 1000, 100, 10, 1, 0.1, 0.01 ng/ml of CYC.  A minimum of 20 mg of 
tissue was weighed out for sample analysis.  The tissue was homogenized with PBS in a 
10:1 (ml/mg) ratio until uniform upon visual inspection.  The homogenate was sonicated 
for ten minutes and then centrifuged at 3500 g for 15 minutes and then 4000 g for 15 
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minutes.  Fifty µl of the supernatant was taken and mixed with 25 µl of internal standard 
(jervine, 1000 ng/ml).  For protein precipitation, 250 µl of acetonitrile /ethanol/acetic acid 
(90/10/0.1) was added and vortex mixed for 20 minutes.  The solution was then 
centrifuged for 15 minutes at 4000 g.  Supernatant was transferred to a glass autosampler 
tube and dried in a vacuum centrifuge (two hours, 40 °C) and then reconstituted in 50% 
methanol with 0.1% formic acid. 
Samples were analyzed on an ESI TSQ Quantum triple-quadrupole system 
(Thermo Scientific, Waltham, MA) equipped with an autosampler (set at 4 ºC) column 
oven (50 °C) and HPLC system. A Waters XTerra RP® C18 reverse phase column (2.1 x 
100 mm, 5 µm particle) was used with a fast gradient run of mobile phase A (0.1% acetic 
acid in water) to mobile phase B (0.1% acetic acid in methanol). Ten microliters of 
sample was injected onto a PEEK loop at a flow rate of 0.3 ml/min at 5% mobile phase B 
and held for one minute.  Over 5 minutes a linear gradient was run from 5%-95% mobile 
phase B and then held at 95% for one minute.  The column was then eluted from 95%-5% 
over one minute and then held at 5% mobile phase B for two minutes before injection of 
the next sample.  The total run time was ten minutes. 
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CHAPTER V 
 
CONCLUSIONS AND PERSPECTIVES 
 
The Value of MALDI Imaging in Drug Discovery and Development  
Despite the dramatic increase in drug development expenditures over the last 
decade, the number of new chemical entities has actually decreased. The industry has 
been troubled by high late-stage attrition rates and safety issues, creating a major problem 
not only for drug developers, but also for regulatory agencies, patients, and society in 
general. Current methodologies involved with drug discovery and development are 
clearly in need of assistance.  New approaches and new science are needed to transform 
drug development. 
It has been shown that MS plays a role in all aspects of the drug discovery and 
development process.  Current mass spectrometry technologies are applied in ADME 
screening for lead compound optimization, drug quantification in PK studies, drug 
metabolite identification in animals and humans, as well as PD bioanalysis in both 
clinical and toxicology studies.
164
  The technology's value spans the entire drug pipeline.   
It has been said that MS has become almost a cornerstone of modern drug discovery and 
development, from target identification and validation up to combinatorial chemistry and 
parallel synthesis chemistry. MS is seen in everything from new chemical entities to 
formula determination to target profiling and preclinical studies.  It is even seen at the far 
end, in manufacturing and many researchers are working to bring mass spectrometry into 
diagnostics.
10, 164
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Throughout the course of this research it has been demonstrated how MALDI 
IMS can extend the use of MS in drug discovery and development even further by 
introducing a new method for sample analysis.  A MALDI IMS protocol was developed 
for absolute quantitation of small molecules directly from tissue sections (Chapter II).  
This protocol allows for MALDI based imaging technologies to correlate absolute drug 
concentration with pharmacological response in tissues while still maintaining spatial 
information in rapid, high-throughput molecularly specific experiments as demonstrated 
in Chapters III and IV. 
Imaging experiments performed by MALDI were able to provide the individual, 
label-free temporal distributions of OLZ, IMAT and CYC from brain tissue sections with 
high sensitivity and reproducibility.  Highly-accurate absolute quantities of each 
compound were also obtained directly from tissue sections without the need for 
homogenization or extraction procedures.  This proves advantageous over LC-MS/MS 
techniques in that spatial information is retained, sample preparation as well as sample 
analysis is quicker and there is less chance of losing quantities of the small molecule 
being investigated during the preparation or analysis processes.  The use of this 
technology could be implemented in early phases of pre-clinical trials to assist with PK 
studies in animal models. 
  Using the calculated drug concentrations of IMAT and CYC, it was possible to 
study the proteome affects that the drug presence had on primary brain tumor xenografts 
in mice.   With the ultimate goal of PD studies being to relate the pharmacological 
response to dose-concentration or concentration-effect relationships of a therapeutic 
compound, MALDI IMS proved to be an invaluable tool to rapidly and reproducibly 
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relate the tissue distribution of the IMAT and CYC to the observed pharmacological 
response within the same tissue sample while maintaining spatial resolution. 
Altered proteins were identified that are involved in a number of different 
biological pathways, such as the ETC, apoptosis mechanisms, proliferation, cell cycle 
regulation and pre-mRNA splicing.  Future studies about the biological implications of 
the perturbation in expression of these proteins may also facilitate the discovery of 
additional molecular pathways that are altered by IMAT and CYC in primary brain 
tumors. This may contribute to an improved understanding of the IMAT and CYC 
mechanisms of action within the tumors or provide new possible drug targets for the 
development of additional therapies. Taken together, the pharmacoproteomic profiling 
could constitute a valuable tool for the identification of drug-responsive biomarkers and 
for the establishment of a molecular basis for developing novel and more effective 
approaches for therapeutic intervention.  The biological information obtained could also 
help gain a deeper understanding of the mechanisms involved in primary brain tumor 
function. 
 
Future Research Directions 
 As is important to all new technologic methods to be used in clinical research, 
issues related to quality control, standardization, specimen choice and collection, result 
interpretation and validation all need to be taken into consideration.  Publication is only 
the first step in acceptance and utilization of a new approach.  A key hurdle in this 
process is the ability to bridge the pre-clinical trials into a positive clinical trial outcome. 
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 With the push towards personalized medicine, the requirement for accurate 
molecular diagnostics for the characterization of human disease to deliver the most 
effective therapies is driving research towards developing more and novel biomarkers.
165
  
Typical approaches towards the discovery and validation of these biomarkers involve 
initial studies in vitro, followed by in vivo studies with small animal molecules before 
progressing to clinical studies in humans.
165
  MALDI IMS technologies and methods 
have become key in the discovery and utilization of biomarkers for disease diagnosis, 
prognosis and compound efficacy determination that are relevant to human disease. 
 Pairing the analysis of mouse model samples with patient samples of the same 
disease will improve the ability to find viable and accurate biomarkers.  As described in 
Chapter IV, the mouse xenografts used were developed directly from patient biopsy 
samples.  Recapitulation of the malignant glioma pathological features was observed and 
gliomaspheres generated from the tissues demonstrated active biological activity that was 
also seen in the xenograft models
130
   This shows that the xenografts are very good 
representations of the brain tumor diseases that were present in the patients. 
 MALDI IMS techniques were used to analyze sections of the patient biopsies that 
were used to develop the xenografts.  Frozen biopsy tissues were sectioned on a cryostat 
at 12 µm, mounted onto target slides, washed, dried, spotted using the Portrait with SA 
and analyzed using a MALDI TOF.  Images were visualized using Flex Imaging software 
(Bruker Daltoniks).  Significant features found in the xenografts (Chapter IV) were 
looked for in the biopsy samples.  Multiple signals were found that corresponded to both 
a CYC response in the xenograft mice and presence in the patient biopsies.  As is seen in 
Figure 31, the m/z signal 7008 is visualized in the xenograft tissue sections as well as the 
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patient biopsy that the xenografts were derived from for the 312-HGA sample.  This 
signal shows a decrease in intensity as a result of CYC treatment in the X-312-HGA 
tissues.  These preliminary results point to the usefulness of MALDI IMS in helping 
correlate potential biomarkers from preclinical mouse models to use in patient trials. 
 
 
Figure 31:  Correlation of m/z features in biopsy and xenograft tissues.  The H&E stains 
on the left correspond to the patient biopsy and CYC treated and non-treated xenograft 
brain sections of 312-HGA (CYC responder).  The right-hand MALDI images show m/z 
7008 spatial distribution.  As a result of drug treatment this signal intensity is decreased 
in the xenograft mouse models.  
 
 Future work in pursuing the validation of biomarkers discovered by 
MALDI IMS and elucidating the biological implications these biomarkers have will 
provide invaluable information for the progression of drug development and discovery 
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advances.  The MALDI IMS methodology developed in this study for the direct 
quantitation of small molecules from tissue sections and evaluation for markers of drug 
response is a significant step towards improving the productivity of pharmaceutical 
research.  With a more focused understanding of the molecular events that lead to a drug 
candidate‟s efficacy or potential side effects that can be gained by an IMS analysis, the 
pharmaceutical industry will have the capacity to deliver valuable new therapies to the 
public, extending and improving patients‟ lives safely and more effectively. 
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APPENDIX A: 
 
PROTOCOL:  QUANTITATION OF SMALL MOLECULES WITH MALDI IMS 
 
 
1.0 Scope: 
This procedure describes the steps used to achieve small molecule quantitation 
directly from tissue sections using MALDI IMS without the need for additional 
sample treatment or separation techniques.  Briefly, the protocol involves the 
preparation of a calibration curve, calculation of the amount of sampled tissue, 
robotic sample preparation combined with automated MALDI-TOF mass 
spectrometry and ultimately determination of small molecule concentration in the 
tissue.  
 
2.0 Definitions: 
 N/A 
 
3.0 Health and Safety 
Wear gloves, safety glasses, and buttoned lab coat.  Precaution should be taken 
when handling tissue, especially human, and when making solutions. The Portrait 
and MALDI LTQ have moving parts and care should be taken during sample 
loading and unloading. 
 
4.0 Equipment and Materials 
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4.1 Instruments 
4.1.1  Portrait 630™ (Labcyte Inc.) 
4.1.2  Leica CM3050s cryomicrotome (Leica Microsystems, Inc., Germany) 
4.1.3  Flatbed Scanner (Epson) 
4.1.4 Olympus BX50 microscope (Olympus Optical Co, LTD. Tokyo, Japan,) fitted 
with a Micropublisher 3.3 camera (QImaging, Canada) 
4.1.5 MALDI LTQ XL (Thermo Scientific Inc.) 
4.1.6 Microbalance 
 
4.2 Reagents 
4.2.1   Water: (H2O), Milli-Q System water (18 mega-ohm, TOC < 10 ppb) 
4.2.2 Methanol, HPLC grade 
4.2.3 2,5-dihydodroxybenzoic acid (DHB)  
 
4.3 Supplies 
4.3.1 Eppendorf tubes: Safe-Lock microcentrifuge tube, 1.5 ml 
4.3.2  Pipette and tips 
4.3.3  Vortex mixer 
4.3.4 Weigh paper 
4.3.5 Gold-coated MALDI targets 
4.3.6 Microscope slides and coverslips 
4.3.7 Dessicator 
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5.0 Procedure 
 
5.1       Calibration Standard Preparation 
5.1.1    Prepare standards as stock solutions (1mg/ml) in methanol.  Store at -20 °C. 
5.1.2  From the 1 mg/ml stock, prepare a dilution series in methanol spanning six orders 
of magnitude:  
1 ng/ml, 10 ng/ml, 100 ng/ml, 1000 ng/ml, 10,000 ng/ml, 100,000 ng/ml 
5.1.3    Prepare 10 ml of DHB matrix solution: 40 mg/ml, 50 % methanol: 50% water. 
5.1.4. Add 100 µl of the appropriate dilution series stock to 900 µl of the matrix to 
generate the following calibration curve of standard in matrix: 
 0.1 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml, 1,000 ng/ml and 10,000 ng/ml.   
5.1.5 Add the internal standard to each calibration curve solution to result in a 2 µM 
concentration. 
 
5.2 Spotting the Calibration Curve 
5.2.1 Cut control fresh frozen tissue sections at 12 µm thickness at -20 ºC using a Leica 
CM3050s cryomicrotome (Leica Microsystems, Inc., Germany). Thaw-mount the 
sections onto gold-coated MALDI target plates.  
5.2.2 Place plates into dessicator for 60 minutes to allow drying. 
5.2.3 Spot calibration curve standard matrices on an acoustic reagent multi-spotter 
(Portrait™ 630, Labcyte Inc).  Spot each standard in a in a 300 µm x 300 µm 
spatial array resulting in a 20 x 10 spot grid on the tissue.  Use the conditions 40 
passes, 1 drop/pass, 90 sec between pass wait-time, resulting in a total of 6.8 nl 
deposited per spot. 
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5.2.4 Knowing the volume of matrix standard deposited it is possible to calculate the 
amount of drug compound that was deposited onto the tissue within the matrix 
spot.  For the standard curve the amount of drug within the matrix spots is 68000, 
6800, 680, 68, 6.8 and 0.68 femtograms (fg) and a blank standard. 
 
5.3 Calibration Curve Acquisition 
5.3.1 Allow plates to dry for a minimum of 15 minutes before introducing them into a 
MALDI LTQ XL (Thermo Scientific Inc.). 
5.3.2 For each standard a minimum of 10 spots need to be analyzed.  Acquisition 
parameters for each spot use a 50 µm raster at 14 different positions across the 
matrix spot, 2 scan events per position (one for the drug, one for the internal 
standard) alternated for a total of 40 scan events per position, 3 µscans per scan 
event, 5 laser shots per µscan at a laser power of 20 µJ.  This results in a total of 
600 laser shots per position.  The intensities of the major SRM fragment for both 
the drug and the internal standard are monitored. 
5.3.3 For each matrix spot the sum of the intensities for the drug signal is divided by the 
sum of the intensities for the internal standard signal. (Spectral intensities are 
exported using in-house software developed by Surendra Dasari)   
5.3.4 Plot the calibration curve using signal ratios vs. amount of drug.  A line or curve 
is fit to the data. 
 
5.4 Tissue Area Determination 
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5.4.1 Section tissue to be analyzed at 12 µm on a cryomicrotome.  Thaw mount sections 
onto glass slides. 
5.4.2 Stain tissue sections using the Hemotoxylin and Eosin staining protocol.  
(Protocol MSRC-R-004) 
5.4.3 Using a flatbed scanner, scan an image of the slide with the stained tissue sections 
along with an object of known dimensions (for example a measurement slide with 
various shapes of known area) within the same image. 
5.4.4 Import image into Adobe Photoshop and calculate the area of the tissue section. 
5.4.4 Repeat with multiple tissue sections.  Take the average of the results. 
 
5.5 Tissue Mass Determination 
5.5.1 Obtain the mass for a piece of weigh paper on a microbalance. 
5.5.2 Cut ten sections at 12 µm thickness of the tissue to be analyzed and place onto the 
weigh paper. 
5.5.3 Immediately obtain the mass for the weigh paper with tissue sections on a 
microbalance. 
5.5.4 Subtract the mass of the weigh paper alone from the mass of the weigh paper with 
the tissue sections.  Divide this number by ten.  This results in the mass for one 12 
µm thick tissue section. 
5.5.5 Repeat this process five times.  Take the average of the results. 
 
5.6 Laser Spot Size Determination 
5.6.1 Coat a MALDI target with DHB matrix by sublimation (Protocol MSRC-R-025). 
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5.6.2 Insert plate into instrument to MALDI LTQ XL (Thermo Scientific Inc.). 
5.6.3 Using the acquisition parameters to be used for the experiment, fire the laser at 
areas of the sublimed matrix to create multiple burn patterns for laser spot size 
measurement.  (40 scan events per position, 3 µscans per scan event, 5 laser shots 
per µscan at a laser power of 20 µJ resulting in 600 laser shots per position). 
5.6.4 Take the plate to an Olympus BX50 microscope (Olympus Optical Co, LTD. 
Tokyo, Japan,) fitted with a Micropublisher 3.3 camera (QImaging, Canada) at 
10x magnification.  Acquire pictures of the laser spot burn patterns at 10x 
magnification. 
5.6.5 Use the Image Pro Plus software to measure the area of the laser spot burn 
patterns.  This represents the area of the acquisition spot during the tissue 
analysis.  
 
5.7 Calculate the Amount of Tissue Sampled 
5.7.1 To calculate the amount of tissue that is sampled within one area of acquisition, 
use the following equation: 
Area of tissue section/Mass of tissue section = Area of Acquisition spot/Mass of 
Acquisition spot  
 
5.8 Dosed Tissue Analysis 
5.8.1 Section dosed tissues at 12 µm thickness at -20 ºC using a Leica CM3050s 
cryomicrotome (Leica Microsystems, Inc., Germany) and thaw mounted onto 
gold-coated MALDI plates. 
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5.8.2 Place plates into a dessicator for an hour to dry. 
5.8.3 Spot tissue sections with DHB matrix spiked with 2 µM of internal standard using 
the acoustic reagent multi-spotter (Portrait™ 630, Labcyte Inc.) A total of 6.8 nl 
of matrix deposited per spot (40 passes, 1 drop/pass, 170 pl/drop, 90 sec between 
pass wait time) in a 300 µm x 300 µm spatial array resulting in a 20 x 10 spot 
array.  
5.8.4  Allow plates to dry for a minimum of 15 minutes before introducing them into a 
MALDI LTQ XL (Thermo Scientific Inc.). 
5.8.5 Analyze a minimum of 10 matrix spots.  Acquisition parameters for each spot use 
a 50 µm raster at 14 different positions across the matrix spot, 2 scan events per 
position (one for the drug, one for the internal standard) alternated for a total of 40 
scan events per position, 3 µscans per scan event, 5 laser shots per µscan at a laser 
power of 20 µJ resulting in 600 laser shots per position.  The intensities of the 
major SRM fragment for both the drug and the internal standard are monitored. 
5.8.6 For each matrix spot the sum of the intensities for the drug signal is divided by the 
sum of the intensities for the internal standard signal. (Spectral intensities are 
exported using in-house software developed by Surendra Dasari)   
 
5.9  Calculate the Drug Concentration in the Dosed Tissue 
5.9.1 Use the calibration curves linear equation and plug in the signal intensity ratios to 
obtain the amount of drug present at each location. 
5.9.2 Divide the amount of drug present at the location by the mass of the tissue at the 
location resulting in the concentration of drug within the tissue analyzed.  
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6.0 References: 
 Protocol MSRC-R-004 
 Protocol MSRC-R-025 
_______________________________________________________________ 
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APPENDIX B: 
 
SIGNIFICANT FEATURE CHANGES AS A RESULT OF CYCLOPAMINE 
TREATMENT IN THE X-312-HGA AND X-402-GBM XENOGRAFTS 
 
 
Up in X-312-HGA only 
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
3289 
 
3826 3271 
4620 
 
5132 3391 
4941 
 
6177 4532 
5027 
 
7655 7654 
5045 
 
7683 7683 
5065 
 
10345 9406 
5211 
 
10522 11517 
6684 
 
10630 11545 
6762 
 
10662 11733 
6802 
 
10744 15345 
7420 
 
11388 15619 
7654 
 
11472 
 7683 
 
11517 
 7797 
 
11545 
 7837 
 
11652 
 7897 
 
15618 
 7918 
   7939 
   7960 
   7984 
   8026 
   10420 
   10724 
   10744 
   15016 
   15345 
   15621 
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Down in X-312-HGA only 
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
7008 
 
4251 4180 
7134 
 
4284 7542 
9212 
 
4303 8108 
12225 
 
4418 8949 
16230 
 
4901 8986 
18417 
 
5330 13565 
  
5400 18417 
  
5598 
 
  
5694 
 
  
5899 
 
  
6225 
 
  
6278 
 
  
6291 
 
  
6650 
 
  
6683 
 
  
6783 
 
  
6800 
 
  
6826 
 
  
7342 
 
  
7359 
 
  
7418 
 
  
7542 
 
  
7859 
 
  
7937 
 
  
8108 
 
  
8605 
 
  
8659 
 
  
8675 
 
  
8774 
 
  
8791 
 
  
8949 
 
  
8986 
 
  
9193 
 
  
9980 
 
  
11086 
 
  
11794 
 
  
12514 
 
  
13249 
 
  
13443 
 
  
18417 
 
  
18654 
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Up in X-406-GBM only  
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
4964 5062   4940 
5448 9914   4964 
5484 9960   5005 
6576 10017   5756 
7008 10054   5794 
7028 10165   6050 
7342 10185   6070 
7359 10204   6254 
8383 11308   6312 
8480 12437   6651 
8494 13690   7382 
8568 13909   7755 
9914 14010   7797 
9960 14052   7835 
11195 14136   8027 
11312 14208   8298 
12137 15011   8606 
12179 15617   9914 
16794 15840   12179 
17003 16299   12437 
  16396   12602 
      12645 
      14049 
      15014 
      16794 
      17003 
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Down in X-406-GBM only  
 
Invaded CC Invaded Grey Invaded LV Invaded Striatum 
3042 3752 3238 3215 
4458 3826 3438 4052 
4771 3877 3934 4304 
5320 3898 4474 4329 
5600 5317 4767 4338 
5900 5756 5045 4388 
6444 6312 5268 4419 
6704 7654 6444 4769 
7246 7683 6951 5046 
7506 7754 7069 5062 
8647 7797 10185 5269 
8776 8026 10203 5317 
8840 8107 15012 6369 
9081 8143 15849 6443 
9781 8198   7198 
10095 8237   7506 
10844 8297   8774 
12772 8339   10055 
  8494   10163 
  8774   10185 
  8985   10203 
  9081   10299 
  9244   10375 
  10469   10469 
  10630   12772 
  12601     
  17203     
  
138 
 
Up in X-312-HGA and Down in  
X-406-GBM 
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
7668 
 
3898 7179 
10469 
 
6121 7246 
10630 
 
7506 10095 
15836 
 
7668 10132 
  
7754 10345 
  
8289 10522 
  
9914 10630 
  
10055 10744 
  
10095 10834 
  
10133 11652 
  
10163 15843 
  
12000 
 
  
12644 
 
  
13693 
 
  
13905 
 
  
14129 
 
  
14163 
 
  
15345 
 
  
17203 
 
  
19376 
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Down in X-312-HGA and Up in X-406-
GBM 
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
7071 
 
3877 5448 
13909 
 
5448 5484 
14010 
 
5484 5522 
14052 
 
5504 6542 
14136 
 
5522 6576 
14208 
 
5734 6614 
16299 
 
5756 6684 
16396 
 
5794 6702 
16611 
 
6050 6722 
  
6070 6760 
  
6254 6783 
  
6312 6800 
  
6542 6826 
  
6576 7319 
  
6614 7342 
  
6702 7359 
  
6722 7418 
  
6760 8340 
  
7319 8383 
  
7797 8398 
  
7835 8455 
  
7960 8480 
  
7980 8494 
  
8027 8527 
  
8064 8568 
  
8340 9330 
  
8383 9623 
  
8398 9639 
  
8494 12135 
  
8527 12375 
  
8568 14136 
  
9330 16396 
  
9535 
 
  
9623 
 
  
9639 
 
  
12135 
 
  
12172 
 
  
12375 
 
  
12437 
 
  
12485 
 
  
12581 
 
  
12602 
 
  
13281 
 
  
13474 
 
  
13565 
 
  
13641 
 
  
16794 
 
  
17003 
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Up in Both 
 
Invaded 
CC 
Invaded 
Grey 
Invaded 
LV 
Invaded 
Striatum 
5006 
    
Down in Both 
 
  
9081 8792 
 
 
  
141 
 
LITERATURE CITED 
 
 
1. Kennedy, T., Managing the drug discovery/development interface. Drug 
Discovery Today 1997, 2 (10), 436-444. 
 
2. Drug Discovery Handbook. John Wiley & Sons, Inc.: 2005. 
 
3. Fee, R., The Cost of Clinical Trials. Drug Discovery and Development 2007. 
 
4. Novartis www.novartis.com/research/drug-discovery.shtml. (accessed 9/17/2010). 
 
5. Canavan, N., Warning!...Warning! Drug Discovery and Development 2007. 
 
6. FDA Investigational New Drug (IND) Application. (accessed 9-17-2010). 
 
7. Health, U. S. N. I. o. ClinicalTrials.gov. (accessed 9/17/2010). 
 
8. FDA New Drug Application. (accessed 9-17-2010). 
 
9. Rieke, G. H., Detection of Light: From the Ultraviolet to the Submillimeter. 2nd 
edition ed.; NY Cambridge University Press: New York, 2003. 
http://www.netlibrary.com.proxy.library.vanderbilt.edu/Reader/. 
 
10. Gwynne, P.; Heebner, G., Mass Spectrometry in Drug Discovery and 
Development: From Physics to Pharma. Science 2006. 
 
11. Cox, K. A.; White, R. E.; Korfmacher, W. A., Rapid determination of 
pharmacokinetic properties of new chemical entities: In vivo approaches. Combinatorial 
Chemistry & High Throughput Screening 2002, 5 (1), 29-37. 
 
12. Poon, G. K.; Kwei, G.; Wang, R.; Lyons, K.; Chen, Q.; Didolkar, V.; Hop, C., 
Integrating qualitative and quantitative liquid chromatography/tandem mass 
spectrometric analysis to support drug discovery. Rapid Communications in Mass 
Spectrometry 1999, 13 (19), 1943-1950. 
 
13. Ma, S. G.; Chowdhury, S. K.; Alton, K. B., Application of mass spectrometry for 
metabolite identification. Current Drug Metabolism 2006, 7 (5), 503-523. 
 
14. Chen, Y.; Monshouwer, M.; Fitch, W. L., Analytical tools and approaches for 
metabolite identification in early drug discovery. Pharmaceutical Research 2007, 24 (2), 
248-257. 
 
15. Briggs, D.; Hearn, M. J., Sub-micron molecular imaging-A viability study by 
Time-of-Flight SIMS. Surface and Interface Analysis 1988, 13 (4), 181-&. 
142 
 
16. Levisetti, R., Recent Applications of High-Resolution Secondary-Ion-Mass-
Spectrometry Imaging Microanalysis Vacuum 1990, 41 (7-9), 1598-1600. 
 
17. Matsuo, J.; Ninomiya, S.; Yamada, H.; Ichiki, K.; Wakamatsu, Y.; Hada, M.; 
Seki, T.; Aoki, T., SIMS with highly excited primary beams for molecular depth profiling 
and imaging of organic and biological materials. Surface and Interface Analysis 42 (10-
11), 1612-1615. 
 
18. Dass, C., Principles and Practice of Biological Mass Spectrometry. 2001. 
 
19. Schwartz, S. A.; Reyzer, M. L.; Caprioli, R. M., Direct tissue analysis using 
matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample 
preparation. Journal of Mass Spectrometry 2003, 38 (7), 699-708. 
 
20. Chaurand, P.; Schwartz, S. A.; Caprioli, R. M., Profiling and imaging proteins in 
tissue sections by MS. Analytical Chemistry 2004, 76 (5), 86A-93A. 
 
21. Chaurand, P.; Schwartz, S. A.; Billheimer, D.; Xu, B. G. J.; Crecelius, A.; 
Caprioli, R. M., Integrating histology and imaging mass spectrometry. Analytical 
Chemistry 2004, 76 (4), 1145-1155. 
 
22. Aerni, H. R.; Cornett, D. S.; Caprioli, R. M., Automated acoustic matrix 
deposition for MALDI sample preparation. Analytical Chemistry 2006, 78 (3), 827-834. 
 
23. Groseclose, M. R.; Andersson, M.; Hardesty, W. M.; Caprioli, R. M., 
Identification of proteins directly from tissue: in situ tryptic digestions coupled with 
imaging mass spectrometry. Journal of Mass Spectrometry 2007, 42 (2), 254-262. 
 
24. Baluya, D. L.; Garrett, T. J.; Yost, R. A., Automated MALDI matrix deposition 
method with inkjet printing for imaging mass spectrometry. Analytical Chemistry 2007, 
79 (17), 6862-6867. 
 
25. Guo, J. In Discovery of Biomarkers for Endometria Carcinoma by Direct 
Profiling of Proteins in Tissue Sections, ASMS, San Antonio, TX, San Antonio, TX, 
2005. 
 
26. Schuerenberg, M.; Luebbert, C.; Deininger, S.-O.; Ketterlinus, R.; Detlev; 
Suckau, D., MALDI tissue imaging: mass spectrometric localization of biomarkers in 
tissue slices. Nature Methods 2007, 4 (5), iii. 
 
27. Nye, G. J.; Norris, J. L.; Nickerson, S. In Optimization of the Performance of 
Automated Matrix Spraying for MALDI Imaging Mass Spectrometry, ASMS, Seattle, 
WA, Seattle, WA, 2006. 
 
28. Mamyrin, B. A., Laser assisted reflectron time-of-flight mass spectrometry. 
International Journal of Mass Spectrometry and Ion Processes 1994, 131, 1-19. 
143 
 
29. Khatib-Shahidi, S.; Andersson, M.; Herman, J. L.; Gillespie, T. A.; Caprioli, R. 
M., Direct molecular analysis of whole-body animal tissue sections by imaging MALDI 
mass spectrometry. Analytical Chemistry 2006, 78 (18), 6448-6456. 
 
30. Li, Y.; Shrestha, B.; Vertes, A., Atmospheric pressure molecular imaging by 
infrared MALDI mass spectrometry. Analytical Chemistry 2007, 79 (2), 523-532. 
 
31. McLean, J. A.; Ridenour, W. B.; Caprioli, R. M., Profiling and imaging of tissues 
by imaging ion mobility-mass spectrometry. Journal of Mass Spectrometry 2007, 42 (8), 
1099-1105. 
 
32. Taban, I. M.; Altelaar, A. F. M.; Van der Burgt, Y. E. M.; McDonnell, L. A.; 
Heeren, R. M. A.; Fuchser, J.; Baykut, G., Imaging of peptides in the rat brain using 
MALDI-FTICR mass spectrometry. Journal of the American Society for Mass 
Spectrometry 2007, 18 (1), 145-151. 
 
33. Altelaar, A. F. M.; Taban, I. M.; McDonnell, L. A.; Verhaert, P.; de Lange, R. P. 
J.; Adan, R. A. H.; Mooi, W. J.; Heeren, R. M. A.; Piersma, S. R., High-resolution 
MALDI imaging mass spectrometry allows localization of peptide distributions at 
cellular length scales in pituitary tissue sections. International Journal of Mass 
Spectrometry 2007, 260 (2-3), 203-211. 
 
34. Verhaert, P. D.; Conaway, M. C. P.; Pekar, T. M.; Miller, K., Neuropeptide 
imaging on an LTQ with vMALDI source: The complete 'all-in-one' peptidome analysis. 
International Journal of Mass Spectrometry 2007, 260 (2-3), 177-184. 
 
35. DeKeyser, S. S.; Kutz-Naber, K. K.; Schmidt, J. J.; Barrett-Wilt, G. A.; Li, L. J., 
Imaging mass spectrometry of neuropeptides in decapod crustacean neuronal tissues. 
Journal of Proteome Research 2007, 6 (5), 1782-1791. 
 
36. Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100 (1), 57-
70. 
 
37. Stoeckli, M.; Chaurand, P.; Hallahan, D. E.; Caprioli, R. M., Imaging mass 
spectrometry: A new technology for the analysis of protein expression in mammalian 
tissues. Nature Medicine 2001, 7 (4), 493-496. 
 
38. Reyzer, M. L.; Caldwell, R. L.; Dugger, T. C.; Forbes, J. T.; Ritter, C. A.; Guix, 
M.; Arteaga, C. L.; Caprioli, R. M., Early changes in protein expression detected by mass 
spectrometry predict tumor response to molecular therapeutics. Cancer Research 2004, 
64 (24), 9093-9100. 
 
39. Chaurand, P.; Sanders, M. E.; Jensen, R. A.; Caprioli, R. M., Proteomics in 
diagnostic pathology - Profiling and imaging proteins directly in tissue sections. 
American Journal of Pathology 2004, 165 (4), 1057-1068. 
144 
 
40. Johnson, M. D.; Floyd, J. L.; Caprioli, R. M., Proteomics in Diagnostic 
Neuropathology. Journal of Neuropathology and Experimental Neurology 2006, 65 (9), 
837-845. 
 
41. Schwamborn, K.; Krieg, R. C.; Reska, M.; Jakse, G.; Knuechel, R.; Wellmann, 
A., Identifying prostate carcinoma by MALDI-Imaging. International Journal of 
Molecular Medicine 2007, 20, 155-159. 
 
42. Walgren, J. L.; Thompson, D. C., Application of proteomic technologies in the 
drug development process. Toxicology Letters 2004, 149 (1-3), 377-385. 
 
43. Lewin, D. A.; Weiner, M. P., Molecular biomarkers in drug development. Drug 
Discovery Today 2004, 9 (22), 976-983. 
 
44. Rudin, M.; Rausch, M.; Stoeckli, M., Molecular imaging in drug discovery and 
development: Potential and limitations of nonnuclear methods. Molecular Imaging and 
Biology 2005, 7 (1), 5-13. 
 
45. Hsieh, Y.; Chen, J.; Korfmacher, W. A., Mapping pharmaceuticals in tissues 
using MALDI imaging mass spectrometry. Journal of Pharmacological and 
Toxicological Methods 2007, 55 (2), 193-200. 
 
46. Meistermann, H.; Norris, J. L.; Aerni, H.-R.; Cornett, D. S.; Friedlein, A.; 
Erskine, A. R.; Augustin, A.; De Vera Mudry, M. C.; Ruepp, S.; Suter, L.; Langen, H.; 
Caprioli, R. M.; Ducret, A., Biomarker discovery by imaging mass spectrometry: 
Transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell 
Proteomics 2006, M500399-MCP200. 
 
47. Chandana, S.; Movva, S.; Arora, M.; Singh, T., Primary Brain Tumors in Adults. 
American Family Physician 2008, 77 (10), 1423-1430. 
 
48. Laerum, O. D.; Bjerkvig, R.; Steinsvag, S. K.; Ridder, L. d., Invasiveness of 
primary brain tumors. Cancer Metastasis Reviews 1984, 3, 223-236. 
 
49. Cunliffe, C. H.; Fischer, I.; Parag, Y.; Fowkes, M. E., State-of-the-Art Pathology: 
New WHO Classification, Implications, and New Developments. Neuroimaging Clinics 
of North America 20 (3), 259-271. 
 
50. Janny, P.; Cure, H.; Mohr, M.; Heldt, N.; Kwiatkowski, F.; Lemaire, J. J.; Plagne, 
R.; Rozan, R., Low grade supratentorial astrocytomas. Management and prognostic 
factors. Wiley Subscription Services, Inc., A Wiley Company: 1994; Vol. 73, pp 1937-
1945. 
 
51. Piepmeier, J.; Christopher, S.; Spencer, D.; Byrne, T.; Kim, J.; Knisel, J. P.; Lacy, 
J.; Tsukerman, L.; Makuch, R., Variations in the Natural History and Survival of Patients 
with Supratentorial Low-grade Astrocytomas. Neurosurgery 1996, 38 (5), 872-879. 
145 
 
52. Frueh, F. W., A New Approach for Clinical Trials. Drug discovery and 
Development 2010. 
 
53. Atkinson Jr, A. J.; Colburn, W. A.; DeGruttola, V. G.; DeMets, D. L.; Downing, 
G. J.; Hoth, D. F.; Oates, J. A.; Peck, C. C.; Schooley, R. T.; Spilker, B. A.; Woodcock, 
J.; Zeger, S. L., Biomarkers and surrogate endpoints: preferred definitions and conceptual 
framework. Clincial Pharmacology & Therapeutics 2001, 69, 89-95. 
 
54. Zhang, H.; Chan, D. W., Cancer biomarker discovery in plasma using a tissue-
targeted proteomic approach. Cancer Epidemiol Biomarkers Prev 2007, 16 (10), 1915-7. 
 
55. Simpson, R. J.; Bernhard, O. K.; Greening, D. W.; Moritz, R. L., Proteomics-
driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 2008, 12 
(1), 72-7. 
 
56. Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.; Radich, 
J.; Anderson, G.; Hartwell, L., The case for early detection. Nat Rev Cancer 2003, 3 (4), 
243-52. 
 
57. Nolen, B. M.; Marks, J. R.; Ta'san, S.; Rand, A.; Luong, T. M.; Wang, Y.; 
Blackwell, K.; Lokshin, A. E., Serum biomarker profiles and response to neoadjuvant 
chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10 (3), R45. 
 
58. Schuerenberg, M.; Luebbert, C.; Deininger, S. O.; Ketterlinus, R.; Suckau, D., 
MALDI tissue imaging: mass spectrometric localization of biomarkers in tissue slices. 
Nature Methods 2007, 4 (5), iii-iv. 
 
59. Zhang, H.; Wu, G.; Tu, H.; Huang, F., Discovery of serum biomarkers in 
astrocytoma by SELDI–TOF MS and proteinchip technology. Journal of Neuro-
Oncology 2007, 84 (3), 315-323. 
 
60. Ilyin, S. E.; Belkowski, S. M.; Plata-Salamán, C. R., Biomarker discovery and 
validation: technologies and integrative approaches. Trends in Biotechnology 2004, 22 
(8), 411-416. 
 
61. MALDI MS: A Practical Guide to Instrumentation, Methods and Applications. 
Weily-VCH: Munster Germany, 2007. 
 
62. ProteomeDigest The Internal Standard. 
http://www.ionsource.com/tutorial/msquan/is.htm (accessed 10/6/2010). 
 
63. MacDougall, D.; Crummett, W. B., Guidelines for data acquisition and data 
quality evaluation in environmental chemistry. Analytical Chemistry 1980, 52 (14), 2242-
2249. 
 
146 
 
64. Armbruster, D.; Tillman, M.; Hubbs, L., Limit of detection (LQD)/limit of 
quantitation (LOQ): comparison of the empirical and the statistical methods exemplified 
with GC-MS assays of abused drugs. Clin Chem 1994, 40 (7), 1233-1238. 
 
65. Aravagiri, M.; Teper, Y.; Marder, S. R., Pharmacokinetics and tissue distribution 
of olanzapine in rats. John Wiley & Sons, Ltd.: 1999; Vol. 20, pp 369-377. 
 
66. Bogusz, M. J.; Krüger, K. D.; Maier, R. D.; Erkwoh, R.; Tuchtenhagen, F., 
Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure 
chemical ionization mass spectrometry. Journal of Chromatography B: Biomedical 
Sciences and Applications 1999, 732 (2), 257-269. 
 
67. Bao, J.; Potts, B. D., Quantitative determination of olanzapine in rat brain tissue 
by high-performance liquid chromatography with electrochemical detection. Journal of 
Chromatography B: Biomedical Sciences and Applications 2001, 752 (1), 61-67. 
 
68. Central Brain Tumor Registry of the United States. Statistical report: primary 
brain tumors in the United States, 2000-2004. http://www.cbtrus.org/reports//2007-
2008/2007report.pdf (accessed September 26, 2010). 
 
69. Wen, P. Y.; Kesari, S., Malignant Gliomas in Adults. New England Journal of 
Medicine 2008, 359 (5), 492-507. 
 
70. Croom, K. F.; Perry, C. M., Imatinib Mesylate: In the Treatment of 
Gastrointestinal Stromal Tumours. Drugs 2003, 63 (5), 513-522. 
 
71. Druker, B. J., Perspectives on the development of a molecularly targeted agent. 
Cancer Cell 2002, 1 (1), 31-36. 
 
72. DiRocco, F.; Carroll, R. S.; Zhang, J.; Black, P., Platelet-derived Growth Factor 
and Its Receptor Expression in Human Oligodendrogliomas. Neurosurgery 1998, 42 (2), 
341-346. 
 
73. Deuel, T. F.; Huang, J. S., Platelet-derived growth factor. Structure, function, and 
roles in normal and transformed cells. The Journal of Clinical Investigation 1984, 74 (3), 
669-676. 
 
74. Hermanson, M.; Funa, K.; Hartman, M.; Claesson-Welsh, L.; Heldin, C.-H.; 
Westermark, B.; Nister, M., Platelet-derived Growth Factor and Its Receptors in Human 
Glioma Tissue: Expression of Messenger RNA and Protein Suggests the Presence of 
Autocrine and Paracrine Loops. Cancer Research 1992, 52 (11), 3213-3219. 
 
75. Lokker, N. A.; Sullivan, C. M.; Hollenbach, S. J.; Israel, M. A.; Giese, N. A., 
Platelet-derived Growth Factor (PDGF) Autocrine Signaling Regulates Survival and 
Mitogenic Pathways in Glioblastoma Cells. Cancer Research 2002, 62 (13), 3729-3735. 
147 
 
76. Kilic, T.; Alberta, J. A.; Zdunek, P. R.; Acar, M.; Iannarelli, P.; Oâ€™Reilly, T.; 
Buchdunger, E.; Black, P. M.; Stiles, C. D., Intracranial Inhibition of Platelet-derived 
Growth Factor-mediated Glioblastoma Cell Growth by an Orally Active Kinase Inhibitor 
of the 2-Phenylaminopyrimidine Class. Cancer Research 2000, 60 (18), 5143-5150. 
 
77. Hagerstrand, D.; Hesselager, G.; Achterberg, S.; Wickenberg Bolin, U.; 
Kowanetz, M.; Kastemar, M.; Heldin, C. H.; Isaksson, A.; Nister, M.; Ostman, A., 
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. 
Oncogene 2006, 25 (35), 4913-4922. 
 
78. Cao, R.; Rakenhielm, E.; Li, X.; Pietras, K.; Widenfalk, J.; Ostman, A.; Eriksson, 
U.; Cao, Y., Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF 
family, involves activation of PDGFR-{alpha}{alpha} and -{alpha}{beta} receptors. 
FASEB J. 2002, 16 (12), 1575-1583. 
 
79. Geng, L.; Shinohara, E. T.; Kim, D.; Tan, J.; Osusky, K.; Shyr, Y.; Hallahan, D. 
E., STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse 
models of glioblastoma. Int J Radiat Oncol Biol Phys 2006, 64 (1), 263-71. 
 
80. United States Department of Agriculture, Transportation, Sale and Handling of 
Certain Animals. . AAPHI, Ed. 2010. 
 
81. Online Ethics Center for Engineering and Research, The Ethics of Using Animals 
in Research. http://www.onlineethics.org/CMS/2963/modindex/animalres.aspx (accessed 
September 26, 2010). 
 
82. OLAW Applied Research Ethics National Association, Institutional Animal Care 
and Use Committee Guidebook. Pitts, M., Ed. 1992. 
http://grants.nih.gov/grants/olaw/GuideBook.pdf. 
 
83. Handbook of Laboratory Animal Science, Second Edition. CRC Press LLC: 2003; 
Vol. II. 
 
84. Candolfi, M.; Curtin, J.; King, G. D.; Pluhar, E.; McNiel, E.; Ohlfest, J. R.; 
Freese, A. B.; Moore, P. F.; Nichols, S. W.; Lowenstein, P. R.; Castro, M. G., 
Glioblastoma multiforme (GBM): a comparative histological analysis of gliomas in mice, 
rats, dogs and humans. AACR Meeting Abstracts 2006, 2006 (1), 642. 
 
85. Kamphorst, W.; deBoer, A. G.; Gaillard, P. J., Brain Drug Targeting: The Future 
of Brain Drug Development. University Press: Cambridge, 2001. 
 
86. Denysenko, T.; Gennero, L.; Roos, M. A.; Melcarne, A.; Juenemann, C.; Faccani, 
G.; Morra, I.; Cavallo, G.; Reguzzi, S.; Pescarmona, G.; Ponzetto, A., Glioblastoma 
cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. 
John Wiley & Sons, Ltd.: Vol. 28, pp 343-351. 
148 
 
87. Inda, M. D.; Bonavia, R.; Mukasa, A.; Narita, Y.; Sah, D. W. Y.; Vandenberg, S.; 
Brennan, C.; Johns, T. G.; Bachoo, R.; Hadwiger, P.; Tan, P.; DePinho, R. A.; Cavenee, 
W.; Furnari, F., Tumor heterogeneity is an active process maintained by a mutant EGFR-
induced cytokine circuit in glioblastoma. Genes Dev. 24 (16), 1731-1745. 
 
88. Park, D. M.; Rich, J. N., Biology of glioma cancer stem cells. Mol. Cells 2009, 28 
(1), 7-12. 
 
89. Teoh, M.; Narayanan, P.; Moo, K.; Radhakrisman, S.; Pillappan, R.; Bukhari, N.; 
Segarra, I., HPLC Determination Of Imatinib In Plasma And Tissues After 
Multiple Oral DoseAdministration To Mice. Pakistan Journal of Pharmaceutical 
Sciences 2010, 23 (1), 35-41. 
 
90. Parise, R. A.; Ramanathan, R. K.; Hayes, M. J.; Egorin, M. J., Liquid 
chromatographic-mass spectrometric assay for quantitation of imatinib and its main 
metabolite (CGP 74588) in plasma. Journal of Chromatography B 2003, 791 (1-2), 39-
44. 
 
91. Tusher, V. G.; Tibshirani, R.; Chu, G., Significance analysis of microarrays 
applied to the ionizing radiation response. Proceedings of the National Academy of 
Sciences 2001, 98 (9), 5116-5121. 
 
92. Asotra, K.; Ningaraj, N.; Black, K., The Blood-Brain Barrier: Measurement of 
Blood-Brain and Blood-Tumor Barrier Permeabilities with [14C]-Labeled Tracers. 
Methods in Molecular Medicine 2003, 89 (11), 177-190. 
 
93. Lockman, P. R.; Mittapalli, R. K.; Taskar, K. S.; Rudraraju, V.; Gril, B.; Bohn, K. 
A.; Adkins, C. E.; Roberts, A.; Thorsheim, H. R.; Gaasch, J. A.; Huang, S.; Palmieri, D.; 
Steeg, P. S.; Smith, Q. R., Heterogeneous Bloodâ€“Tumor Barrier Permeability 
Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. Clinical 
Cancer Research 16 (23), 5664-5678. 
 
94. Stewart, D. J., A critique of the role of the blood-brain barrier in the 
chemotherapy of human brain tumors. Journal of Neuro-Oncology 1994, 20 (2), 121-139. 
 
95. Holdhoff, M.; Supko, J.; Gallia, G.; Hann, C.; Bonekamp, D.; Ye, X.; Cao, B.; 
Olivi, A.; Grossman, S., Intratumoral concentrations of imatinib after oral administration 
in patients with glioblastoma multiforme. Journal of Neuro-Oncology 97 (2), 241-245. 
 
96. Gschwind, H.-P.; Pfaar, U.; Waldmeier, F.; Zollinger, M.; Sayer, C.; Zbinden, P.; 
Hayes, M.; Pokorny, R.; Seiberling, M.; Ben-Am, M.; Peng, B.; Gross, G., 
METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY 
VOLUNTEERS. Drug Metabolism and Disposition 2005, 33 (10), 1503-1512. 
 
97. Van Erp, N. P.; Gelderblom, H.; Guchelaar, H.-J., Clinical pharmacokinetics of 
tyrosine kinase inhibitors. Cancer Treatment Reviews 2009, 35 (8), 692-706. 
149 
 
98. Kramer, T., Side Effects and Therapeutic Effects: Half-life and Steady State. 
Medscape General Medicine 2003, 5 (1). 
 
99. Landriscina, M.; Maddalena, F.; Laudiero, G.; Esposito, F., Adaptation to 
Oxidative Stress, Chemoresistance, and Cell Survival. Antioxid. Redox Signal. 2009, 11 
(11), 2701-2716. 
 
100. Voet, D.; Voet, J. G., Biochemistry, Second Edition. John Wiley & Sons, Inc: 
New York, 1995. 
 
101. Chakravarti, A.; Chakladar, A.; Delaney, M. A.; Latham, D. E.; Loeffler, J. S., 
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential 
Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in 
a RAS-dependent Manner. Cancer Research 2002, 62 (15), 4307-4315. 
 
102. Servidei, T.; Riccardi, A.; Sanguinetti, M.; Dominici, C.; Riccardi, R., Increased 
sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in 
chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling 
and STI571-induced Akt inactivation. Wiley Subscription Services, Inc., A Wiley 
Company: 2006; Vol. 208, pp 220-228. 
 
103. Ziegler, D. S.; Wright, R. D.; Kesari, S.; Lemieux, M. E.; Tran, M. A.; Jain, M.; 
Zawel, L.; Kung, A. L., Resistance of human glioblastoma multiforme cells to growth 
factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. The Journal 
of Clinical Investigation 2008, 118 (9), 3109-3122. 
 
104. Oliva, C. R.; Nozell, S. E.; Diers, A.; McClugage, S. G.; Sarkaria, J. N.; Markert, 
J. M.; Darley-Usmar, V. M.; Bailey, S. M.; Gillespie, G. Y.; Landar, A.; Griguer, C. E., 
Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of 
Mitochondrial Electron Transport Chain. J. Biol. Chem. 285 (51), 39759-39767. 
 
105. Kennedy, F. G.; Jones, D. P., Oxygen Dependence of Mitochondrial-Function in 
Isolated Rat Cardiac Myocytes. American Journal of Physiology 1986, 250 (3), C374-
C383. 
 
106. Villani, G.; Greco, M.; Papa, S.; Attardi, G., Low Reserve of Cytochrome c 
Oxidase Capacity in Vivo in the Respiratory Chain of a Variety of Human Cell Types. J. 
Biol. Chem. 1998, 273 (48), 31829-31836. 
 
107. Brozzi, F.; Arcuri, C.; Giambanco, I.; Donato, R., S100B Protein Regulates 
Astrocyte Shape and Migration via Interaction with Src Kinase: Implications for 
Astrocyte Development, Activation and Tumor Growth J. Biol. Chem. 2009, 284 (13), 
8788-8802. 
 
108. Vos, M. J.; Postma, T. J.; Martens, F.; Uitdehaag, B. M. J.; Blankenstein, M. A.; 
Vandertop, W. P.; Slotman, B. J.; Heimans, J. J., Serum Levels of S-100B Protein and 
150 
 
Neuron-specific Enolase in Glioma Patients: A Pilot Study. Anticancer Research 2004, 
24 (4), 2511-2514. 
 
109. Selinfreund, R. H.; Barger, S. W.; Welsh, M. J.; Van Eldik, L. J., Antisense 
inhibition of glial S100 beta production results in alterations in cell morphology, 
cytoskeletal organization, and cell proliferation. The Journal of Cell Biology 1990, 111 
(5), 2021-2028. 
 
110. George, J. M., The synucleins. Genome Biology 2001, 3 (1). 
 
111. Liu, H.; Liu, W.; Wu, Y.; Zhou, Y.; Xue, R.; Luo, C.; Wang, L.; Zhao, W.; Jiang, 
J.-D.; Liu, J., Loss of Epigenetic Control of Synuclein-Î³ Gene as a Molecular Indicator 
of Metastasis in a Wide Range of Human Cancers. Cancer Research 2005, 65 (17), 7635-
7643. 
 
112. Crews, L.; Tsigelny, I.; Hashimoto, M.; Masliah, E., Role of Synucleins in 
Alzheimer's Disease. Neurotox. Res. 2009, 16 (3), 306-317. 
 
113. Fung, K.-M.; Rorke, L. B.; Giasson, B.; Lee, V. M. Y.; Trojanowski, J. Q., 
Expression of a-, ß-, and gamma-synuclein in glial tumors and medulloblastomas. Acta 
Neuropathologica 2003, 106 (2), 167-175. 
 
114. Surguchov, A., Focus on Molecules: The synucleins: "When friends become 
foes". Experimental Eye Research 2008, 86 (1), 1-2. 
 
115. Maniatis, T.; Reed, R., The role of small nuclear ribonucleoprotein particles in 
pre-mRNA splicing. Nature 1987, 325 (6106), 673-678. 
 
116. Cheung, H.; Baggerly, K.; Tsavachidis, S.; Bachinski, L.; Neubauer, V.; Nixon, 
T.; Aldape, K.; Cote, G.; Krahe, R., Global analysis of aberrant pre-mRNA splicing in 
glioblastoma using exon expression arrays. BMC Genomics 2008, 9 (1), 216. 
 
117. Kasai, T.; Inoue, M.; Koshiba, S.; Yabuki, T.; Aoki, M.; Nunokawa, E.; Seki, E.; 
Matsuda, T.; Matsuda, N.; Tomo, Y.; Shirouzu, M.; Terada, T.; Obayashi, N.; Hamana, 
H.; Shinya, N.; Tatsuguchi, A.; Yasuda, S.; Yoshida, M.; Hirota, H.; Matsuo, Y.; Tani, 
K.; Suzuki, H.; Arakawa, T.; Carninci, P.; Kawai, J.; Hayashizaki, Y.; Kigawa, T.; 
Yokoyama, S., Solution structure of a BolA-like protein from Mus musculus. Cold 
Spring Harbor Laboratory Press: 2004; Vol. 13, pp 545-548. 
 
118. Burton, M.; Rose, T. M.; Faergeman, N. J.; Knudsen, J., Evolution of the acyl-
CoA binding protein (ACBP). Biochem. J. 2005, 392, 299-307. 
 
119. Coté, R. J., Aseptic Technique for Cell Culture. John Wiley & Sons, Inc.: 2001. 
 
120. Norris, J. L.; Cornett, D. S.; Mobley, J. A.; Andersson, M.; Seeley, E. H.; 
Chaurand, P.; Caprioli, R. M., Processing MALDI mass spectra to improve mass spectral 
151 
 
direct tissue analysis. International Journal of Mass Spectrometry 2007, 260 (2-3), 212-
221. 
 
121. Clement, V.; Sanchez, P.; de Tribolet, N.; Radovanovic, I.; Ruiz i Altaba, A., 
HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-
Renewal, and Tumorigenicity. Current biology : CB 2007, 17 (2), 165-172. 
 
122. Ruiz i Altaba, A.; Sanchez, P.; Dahmane, N., Gli and hedgehog in cancer: 
tumours, embryos and stem cells. Nat Rev Cancer 2002, 2 (5), 361-372. 
 
123. Jessell, T. M., Neuronal specification in the spinal cord: inductive signals and 
transcriptional codes. Nat Rev Genet 2000, 1 (1), 20-29. 
 
124. Ruiz i Altaba, A.; Palma, V.; Dahmane, N., Hedgehog-GLI signaling and the 
growth of the brain. Nat Rev Neurosci 2002, 3 (1), 24-33. 
 
125. Ruiz i Altaba, A.; Stecca, B.; Sánchez, P., Hedgehog-Gli signaling in brain 
tumors: stem cells and paradevelopmental programs in cancer. Cancer Letters 2004, 204 
(2), 145-157. 
 
126. Xu, Q.; Yuan, X.; Liu, G.; Black, K. L.; Yu, J. S., Hedgehog Signaling Regulates 
Brain Tumor-Initiating Cell Proliferation and Portends Shorter Survival for Patients with 
PTEN-Coexpressing Glioblastomas. John Wiley & Sons, Ltd.: 2008; Vol. 26, pp 3018-
3026. 
 
127. Becher, O. J.; Hambardzumyan, D.; Fomchenko, E. I.; Momota, H.; Mainwaring, 
L.; Bleau, A.-M.; Katz, A. M.; Edgar, M.; Kenney, A. M.; Cordon-Cardo, C.; Blasberg, 
R. G.; Holland, E. C., Gli Activity Correlates with Tumor Grade in Platelet-Derived 
Growth Factor-Induced Gliomas. Cancer Res 2008, 68 (7), 2241-2249. 
 
128. Wang, k.; Pan, L.; Che, X.; Cui, D.; Li, C., Sonic Hedgehog/GLI1 signaling 
pathway inhibition restricts cell migration and invasion in human gliomas. Neurological 
Research 2010, 32 (9), 975-980. 
 
129. Wang, K.; Pan, L.; Che, X.; Cui, D.; Li, C., Gli1 inhibition induces cell-cycle 
arrest and enhanced apoptosis in brain glioma cell lines. Journal of Neuro-Oncology 
2010, 98 (3), 319-327. 
 
130. Sarangi, A.; Valadez, J. G.; Rush, S.; Abel, T. W.; Thompson, R. C.; Cooper, M. 
K., Targeted inhibition of the Hedgehog pathway in established malignant glioma 
xenografts enhances survival. Oncogene 2009, 28 (39), 3468-3476. 
 
131. Bar, E. E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; 
Vescovi, A. L.; DiMeco, F.; Olivi, A.; Eberhart, C. G., Cyclopamine-Mediated Hedgehog 
Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. John Wiley & 
Sons, Ltd.: 2007; Vol. 25, pp 2524-2533. 
152 
 
132. UCDavis Mouse in Science Cancer Research. 
http://www.vetmed.ucdavis.edu/Animal_alternatives/cancer.htm (accessed September 26, 
2010). 
 
133. Candolfi, M.; Curtin, J.; Nichols, W.; Muhammad, A. K. M.; King, G.; Pluhar, 
G.; McNiel, E.; Ohlfest, J.; Freese, A.; Moore, P.; Lerner, J.; Lowenstein, P.; Castro, M., 
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological 
characterization and tumor progression. Journal of Neuro-Oncology 2007, 85 (2), 133-
148. 
 
134. Zheng, X.; Cui, X.-X.; Avila, G. E.; Huang, M.-T.; Liu, Y.; Patel, J.; Kong, A. N. 
T.; Paulino, R.; Shih, W. J.; Lin, Y.; Rabson, A. B.; Reddy, B. S.; Conney, A. H., 
Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice. 
Clinical Cancer Research 2007, 13 (18), 5480-5487. 
 
135. Heikkila, J. E.; Vaha-Koskela, M. J. V.; Ruotsalainen, J. J.; Martikainen, M. W.; 
Stanford, M. M.; McCart, J. A.; Bell, J. C.; Hinkkanen, A. E., Intravenously 
Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts 
in Nude Mice. PLoS ONE 5 (1), e8603. 
 
136. Niclou, S. P.; Danzeisen, C.; Eikesdal, H. P.; Wiig, H.; Brons, N. H. C.; Poli, A. 
M. F.; Svendsen, A.; Torsvik, A.; Enger, P. O.; Terzis, J. A.; Bjerkvig, R., A novel eGFP-
expressing immunodeficient mouse model to study tumor-host interactions. FASEB J. 
2008, 22 (9), 3120-3128. 
 
137. O/'Brien, C. A.; Pollett, A.; Gallinger, S.; Dick, J. E., A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445 (7123), 
106-110. 
 
138. Charafe-Jauffret, E.; Ginestier, C.; Birnbaum, D., Breast cancer stem cells: tools 
and models to rely on. BMC Cancer 2009, 9 (1), 202. 
 
139. Yang, Z. F.; Ho, D. W.; Ng, M. N.; Lau, C. K.; Yu, W. C.; Ngai, P.; Chu, P. W. 
K.; Lam, C. T.; Poon, R. T. P.; Fan, S. T., Significance of CD90+ Cancer Stem Cells in 
Human Liver Cancer. Cancer Cell 2008, 13 (2), 153-166. 
 
140. Dong, X.; Guan, J.; English, J. C.; Flint, J.; Yee, J.; Evans, K.; Murray, N.; 
MacAulay, C.; Ng, R. T.; Gout, P. W.; Lam, W. L.; Laskin, J.; Ling, V.; Lam, S.; Wang, 
Y., Patient-Derived First Generation Xenografts of Nonâ€“Small Cell Lung Cancers: 
Promising Tools for Predicting Drug Responses for Personalized Chemotherapy. Clinical 
Cancer Research 16 (5), 1442-1451. 
 
141. Lee, J.; Kotliarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N. M.; Pastorino, S.; 
Purow, B. W.; Christopher, N.; Zhang, W.; Park, J. K.; Fine, H. A., Tumor stem cells 
derived from glioblastomas cultured in bFGF and EGF more closely mirror the 
153 
 
phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer 
Cell 2006, 9 (5), 391-403. 
 
142. Lipinski, R. J.; Hutson, P. R.; Hannam, P. W.; Nydza, R. J.; Washington, I. M.; 
Moore, R. W.; Girdaukas, G. G.; Peterson, R. E.; Bushman, W., Dose- and route-
dependent teratogenicity, toxicity, and pharmacokinetic profiles of the Hedgehog 
signaling antagonist cyclopamine in the mouse. Toxicological Sciences 2008, 104 (1), 
189-197. 
 
143. Lewis, P. M.; Gritli-Linde, A.; Smeyne, R.; Kottmann, A.; McMahon, A. P., 
Sonic hedgehog signaling is required for expansion of granule neuron precursors and 
patterning of the mouse cerebellum. Developmental Biology 2004, 270 (2), 393-410. 
 
144. Fingar, D. C.; Blenis, J., Target of rapamycin (TOR): an integrator of nutrient and 
growth factor signals and coordinator of cell growth and cell cycle progression. 
Oncogene 23 (18), 3151-3171. 
 
145. Sancak, Y.; Bar-Peled, L.; Zoncu, R.; Markhard, A. L.; Nada, S.; Sabatini, D. M., 
Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary 
for Its Activation by Amino Acids. Cell 141 (2), 290-303. 
 
146. Sanchez, P.; Ruiz i Altaba, A., In vivo inhibition of endogenous brain tumors 
through systemic interference of Hedgehog signaling in mice. Mechanisms of 
Development 2005, 122 (2), 223-230. 
 
147. Rehman, I.; Azzouzi, A. R.; Cross, S. S.; Deloulme, J. C.; Catto, J. W. F.; Wylde, 
N.; Larre, S.; Champigneuille, J.; Hamdy, F. C., Dysregulated expression of S100A11 
(Calgizzarin) in prostate cancer and precursor lesions. Hum. Pathol. 2004, 35 (11), 1385-
1391. 
 
148. Melle, C.; Ernst, G.; Schimmel, B.; Bleul, A.; Mothes, H.; Kaufmann, R.; 
Settmacher, U.; von Eggeling, F., Different expression of calgizzarin (S100A11) in 
normal colonic epithelium, adenoma and colorectal carcinoma. Int. J. Oncol. 2006, 28 
(1), 195-200. 
 
149. Ohuchida, K.; Mizumoto, K.; Ohhashi, S.; Yamaguchi, H.; Konomi, H.; Nagai, 
E.; Yamaguchi, K.; Tsuneyoshi, M.; Tanaka, M., S100A11, a putative tumor suppressor 
gene, is overexpressed in pancreatic carcinogenesis. Clinical Cancer Research 2006, 12 
(18), 5417-5422. 
 
150. Liu, X. G.; Wang, X. P.; Li, W. F.; Yang, S.; Zhou, X.; Li, S. J.; Li, X. J.; Hao, D. 
Y.; Fan, Z. M., Ca2+-binding protein S100A11: A novel diagnostic marker for breast 
carcinoma. Oncol. Rep. 23 (5), 1301-1308. 
 
151. Kanamori, T.; Takakura, K.; Mandai, M.; Kariya, M.; Fukuhara, K.; Sakaguchi, 
M.; Huh, N.-h.; Saito, K.; Sakurai, T.; Fujita, J.; Fujii, S., Increased expression of 
154 
 
calcium-binding protein S100 in human uterine smooth muscle tumours. Molecular 
Human Reproduction 2004, 10 (10), 735-742. 
 
152. Cecconi, D.; Donadelli, M.; Rinalducci, S.; Zolla, L.; Scupoli, M. T.; Scarpa, A.; 
Palmieri, M.; Righetti, P. G., Proteomic analysis of pancreatic endocrine tumor cell lines 
treated with the histone deacetylase inhibitor trichostatin A. Wiley-vch Verlag: 2007; 
Vol. 7, pp 1644-1653. 
 
153. Turrens, J. F., Mitochondrial formation of reactive oxygen species. The Journal of 
Physiology 2003, 552 (2), 335-344. 
 
154. Wang, Y.; Fang, J.; Leonard, S. S.; Krishna Rao, K. M., Cadmium inhibits the 
electron transfer chain and induces Reactive Oxygen Species. Free Radical Biology and 
Medicine 2004, 36 (11), 1434-1443. 
 
155. McClintock, D. S.; Santore, M. T.; Lee, V. Y.; Brunelle, J.; Budinger, G. R. S.; 
Zong, W.-X.; Thompson, C. B.; Hay, N.; Chandel, N. S., Bcl-2 Family Members and 
Functional Electron Transport Chain Regulate Oxygen Deprivation-Induced Cell Death. 
Mol. Cell. Biol. 2002, 22 (1), 94-104. 
 
156. Chen, Y.; McMillan-Ward, E.; Kong, J.; Israels, S. J.; Gibson, S. B., 
Mitochondrial electron-transport-chain inhibitors of complexes I and II induce 
autophagic cell death mediated by reactive oxygen species. J Cell Sci 2007, 120 (23), 
4155-4166. 
 
157. Azad, M. B.; Chen, Y.; Gibson, S. B., Regulation of autophagy by reactive 
oxygen species (ROS): implications for cancer progression and treatment. Antioxidants 
&amp; Redox Signaling 2009, 11 (4), 777(14). 
 
158. Ruy, F.; Vercesi, A.; Kowaltowski, A., Inhibition of specific electron transport 
pathways leads to oxidative stress and decreased proliferation. Journal of Bioenergetics 
and Biomembranes 2006, 38 (2), 129-135. 
 
159. Chen, Y. Q.; Gibson, S. B., Is mitochondrial generation of reactive oxygen 
species a trigger for autophagy? Autophagy 2008, 4 (2), 246-248. 
 
160. Chen, Y.; Azad, M. B.; Gibson, S. B., Superoxide is the major reactive oxygen 
species regulating autophagy. Cell Death Differ. 2009, 16 (7), 1040-1052. 
 
161. Welch, K. D.; Panter, K. E.; Lee, S. T.; Gardner, D. R.; Stegelmeier, B. L.; Cook, 
D., Cyclopamine-induced synophthalmia in sheep: defining a critical window and 
toxicokinetic evaluation. John Wiley & Sons, Ltd.: 2009; Vol. 29, pp 414-421. 
 
162. Li, H.-Y.; Xu, W.; Li, H.-L.; Zhang, W.-D.; Hu, L.-W., LC-MS-MS Method for 
the Determination of Protoveratrine A in Rat Plasma. Chromatographia 2009, 69 (5), 
523-529. 
155 
 
163. Tremblay, M. R.; Lescarbeau, A.; Grogan, M. J.; Tan, E.; Lin, G.; Austad, B. C.; 
Yu, L.-C.; Behnke, M. L.; Nair, S. J.; Hagel, M.; White, K.; Conley, J.; Manna, J. D.; 
Alvarez-Diez, T. M.; Hoyt, J.; Woodward, C. N.; Sydor, J. R.; Pink, M.; MacDougall, J.; 
Campbell, M. J.; Cushing, J.; Ferguson, J.; Curtis, M. S.; McGovern, K.; Read, M. A.; 
Palombella, V. J.; Adams, J.; Castro, A. C., Discovery of a Potent and Orally Active 
Hedgehog Pathway Antagonist (IPI-926). Journal of Medicinal Chemistry 2009, 52 (14), 
4400-4418. 
 
164. Rossi, D. T.; Sinz, M. W., Mass Spectrometry in Drug Discovery. Marcel Dekker, 
Inc.: New York, 2002. 
 
165. Contag, P. R., The Development of Biomarkers to Bridge Preclinical and Clinical 
Studies. Parma DD 2006, 1 (2). 
 
 
